



(51) Int.Cl.: **A 61 K 9/19 (2006.01)** **A 61 K 47/02 (2006.01)** **A 61 K 47/60 (2017.01)** **A 61 K 9/00 (2006.01)** **A 61 K 47/26 (2006.01)** **A 61 K 47/69 (2017.01)** **A 61 K 38/50 (2006.01)** **A 61 K 47/40 (2006.01)** **A 61 P 35/04 (2006.01)**

(45) Oversættelsen bekendtgjort den: **2022-01-31**

(80) Dato for Den Europæiske Patentmyndigheds
bekendtgørelse om meddelelse af patentet: **2021-12-01**

(86) Europæisk ansøgning nr.: **17831465.4**

(86) Europæisk indleveringsdag: **2017-06-01**

(87) Den europæiske ansøgnings publiceringsdag: **2019-04-10**

(86) International ansøgning nr.: **US2017035461**

(87) Internationalt publikationsnr.: **WO2018017190**

(30) Prioritet: **2016-06-01 US 201662344256 P** **2016-06-01 US 201662344252 P**
2016-06-01 US 201662344249 P

(84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV**
MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(73) Patenthaver: **Servier IP UK Limited, Sefton House, Sefton Park, Bells Hill, Stoke Poges, Slough SL2 4JS, Storbritannien**

(72) Opfinder: **FORNASINI, Gianfranco, 8501 Old Seven Locks Road, Bethesda, MD 20817, USA**
SOUKHAREVA, Nadejda, 7421 Mahaska Drive, Derwood, MD 20855, USA
PHILLIPS, Christopher, 5823 Ridgeview Drive, Doylestown, PA 18902, USA

(74) Fuldmægtig i Danmark: **Plougmann Vingtoft A/S, Strandvejen 70, 2900 Hellerup, Danmark**

(54) Benævnelse: **FORMULERINGER AF POLYALKYLENOXID-ASPARAGINASE OG FREMGANGSMÅDER TIL**
FREMSTILLING OG ANVENDELSE DERAF

(56) Fremdragne publikationer:
EP-B1- 0 893 439
CN-B- 102 138 909
US-A- 4 179 337
US-A1- 2010 143 324
US-A1- 2015 224 207
US-A1- 2016 060 613
Dushyant Varshney ET AL: "Part II Lyophilized Biologics and Vaccines - Modality Considerations" In: "Lyophilized Biologics and Vaccines", 1 January 2015 (2015-01-01), XP55640506, ISBN: 978-1-4939-2382-3
pages 92-100, * pages 95,100 *
NEMA SANDEEO ET AL: "Excipients: Their Role in Parenteral Dosage Forms", 1 January 2000 (2000-01-01),
ENCYCLOPEDIA OF PHARMACEUTICAL TECHNOLOGY,, PAGE(S) 137 - 172, XP009105976, ISBN: 978-0-8247-2818-2 * the whole document *

DK/EP 3463308 T3

DESCRIPTION

INTRODUCTION

[0001] L-asparaginase is an enzyme that hydrolyzes the amino acid L-asparagine via a deamination reaction to produce L-aspartate and ammonia. *E. coli* contain two asparaginase isoenzymes: L-asparaginase I and L-asparaginase II. L-asparaginase I is located in the cytosol and has a low affinity for asparagine. However, L-asparaginase II is located in the periplasm and has a high affinity for L-asparagine. *E. coli* L-asparaginase II is a tetramer of identical subunits. *E. coli* L-asparaginase II is also known as L-asparagine amidohydrolase, type EC-2, EC 3.5.1.1. L-asparaginase is known to have therapeutic value in the treatment of leukemia. L-asparaginase is an amidohydrolase which catalyzes L-asparagine into L-aspartic acid and ammonia. It plays a major role in the metabolism of L-asparagine in plants, animals and microorganisms. It is now well established that the therapeutic activity of the enzyme is caused by the depletion/removal of circulatory L-asparagine, an essential nutrient for the proliferation and survival of tumor (leukemic) cells which are compromised in L-asparagine synthesis ability, but not for the normal cells. The administration of L-asparaginase to leukemic patients induces the selective death of the tumor cells by hydrolyzing L-asparagine, resulting in the treatment of malignant tumors.

[0002] In some cases, L-asparaginase, by itself, suffers from typical disadvantages of protein therapeutics, such as a high rate of clearance of a protein foreign to the patient, and the potential for inducing an immune response in a patient treated with this enzyme. In order to address these shortcomings, a polyethylene glycol-conjugated derivative of L-asparaginase (PEG- asparaginase) can be used. PEG-asparaginase can be produced using L-asparaginase II extracted from *E. coli* and can be substantially non-antigenic and can exhibit a reduced rate of clearance from the circulation of a patient.

[0003] A PEG-asparaginase liquid injection formulation (Oncaspar®) has been previously approved for commercial marketing by the U.S. Food and Drug Administration. Oncaspar® was approved as a first-line treatment of patients with acute lymphoblastic leukemia (ALL) as a component of a multi-agent chemotherapy regimen. In addition, Oncaspar® was approved for the treatment of patients with ALL and hypersensitivity to asparaginase (e.g., native forms of L- asparaginase).

[0004] CN102138909B describes an asparaginase freeze-dried powder injection and preparation method thereof. Varshney *et al.* describes modality considerations in lyophilized biologics and vaccines. Sandeep *et al.* describes the role of excipients in parenteral dosage forms. US20160060613A1 describes PEGylated L-asparaginase. EP0893439B 1 describes a process for forming a modified polypeptide comprising a polypeptide and a polyalkylene oxide. US4179337A describes non-immunogenic polypeptides. US20150224207A1 describes thiol-selective water-soluble polymer derivatives. US20100143324A1 describes a method for treatment of cancers or inflammatory diseases.

SUMMARY

[0005] Aspects of the invention include polyalkylene oxide-asparaginase compositions. In some instances, the compositions include one or more of a buffer and a salt. In other aspects, the composition is a lyophilized storage stable composition. In some instances, the lyophilized compositions include one or more of a buffer, a salt, and a sugar. Aspects of the invention further include methods of making the compositions. The compositions find use in a variety of applications, e.g., in the treatment of a neoplastic condition in a subject.

[0006] The invention provides a reconstituted lyophilized composition comprising: a polyalkylene oxide-asparaginase at a concentration of 100 to 5,000 IU per ml of said composition; dibasic sodium phosphate at a

concentration of 0.1 to 0.8 wt. %; monobasic sodium phosphate at a concentration of 0.01 to 0.5 wt. %.; a salt at a concentration of 0.05 to 1 wt. %; and a sugar at a concentration of 0.1 to 25 wt. %, wherein the polyalkylene oxide-asparaginase comprises an asparaginase covalently linked to a polyalkylene oxide group.

[0007] The invention also provides a lyophilized storage stable composition comprising: a polyalkylene oxide-asparaginase; a buffer which comprises dibasic sodium phosphate and monobasic sodium phosphate; a salt; and a sugar, wherein the lyophilized storage stable composition is capable of forming the composition described in the previous paragraph by reconstituting the lyophilized storage stable composition with water for injection (WFI).

[0008] The invention further provides a method of making a lyophilized polyalkylene oxide-asparaginase composition wherein the method comprises lyophilizing an aqueous concentrate composition comprising: (i) a polyalkylene oxide-asparaginase comprising a polyalkylene oxide group covalently linked by a linker to an asparaginase; (ii) a buffer, which comprises dibasic sodium phosphate and monobasic sodium phosphate; (iii) a salt; and (iv) a sugar in a manner sufficient to produce a lyophilized storage stable polyalkylene oxide asparaginase composition according to the invention, optionally wherein the method further comprises introducing an aqueous concentrate composition into a unit dosage container and lyophilizing the aqueous concentrate composition in the unit dosage container, optionally wherein the unit dosage container is a vial, such as a sealed glass vial.

[0009] The invention also provides a composition according to the invention for use in a method of treating a subject for a neoplastic condition.

[0010] The invention also further provides a kit comprising one or more unit dosage containers each containing a lyophilized storage stable composition according to the invention.

BRIEF DESCRIPTION OF THE FIGURES

[0011]

FIG. 1 shows a process flow diagram for a method of making a lyophilized storage stable composition according to embodiments of the present disclosure.

FIG. 2 shows a graph of purity (%) vs. time (weeks) at 40 °C for a lyophilized storage stable composition according to embodiments of the present disclosure.

FIG. 3 shows a graph of potency (IU/mL) vs. time (weeks) at 40 °C for a lyophilized storage stable composition according to embodiments of the present disclosure.

FIG. 4 shows a graph of purity (%) vs. time (weeks) at 25 °C for a lyophilized storage stable composition according to embodiments of the present disclosure.

FIG. 5 shows a graph of potency (IU/mL) vs. time (weeks) at 25 °C for a lyophilized storage stable composition according to embodiments of the present disclosure.

FIG. 6 shows a process flow diagram of a method of making a lyophilized storage stable composition, according to embodiments of the present disclosure. The final formulation and filtration steps are shown.

FIG. 7 shows a process flow diagram of a method of making a lyophilized storage stable composition, according to embodiments of the present disclosure. The aseptic filling and lyophilization steps are shown.

FIG. 8 shows a graph of purity by GF-HPLC (%) vs. time (months) for a lyophilized composition stored at 2-8 °C (e.g., 5°C), according to embodiments of the present disclosure.

FIG. 9 shows a graph of potency (activity) (IU/mL) vs. time (months) for a lyophilized composition stored at 2-8 °C (e.g., 5°C), according to embodiments of the present disclosure.

FIG. 10 shows a graph of total aggregates by GF-HPLC vs. time (months) for a lyophilized composition stored at 2-8 °C (e.g., 5°C), according to embodiments of the present disclosure.

FIG. 11 shows a graph of purity by GF-HPLC (%) vs. time (months) for a lyophilized composition stored under accelerated conditions (25 ± 3°C; 60% ± 5% RH), according to embodiments of the present disclosure.

FIG. 12 shows a graph of potency (activity) (IU/mL) vs. time (months) for a lyophilized composition stored under accelerated conditions (25 ± 3°C; 60% ± 5% RH), according to embodiments of the present disclosure.

FIG. 13 shows a graph of total aggregates by GF-HPLC vs. time (months) for a lyophilized composition stored under accelerated conditions (25 ± 3°C; 60% ± 5% RH), according to embodiments of the present disclosure.

FIG. 14 shows a graph of purity by GF-HPLC (%) vs. time (months) for a lyophilized composition stored under heat stress conditions (40 ± 2°C; 75% ± 5% RH), according to embodiments of the present disclosure.

FIG. 15 shows a graph of potency (activity) (IU/mL) vs. time (months) for a lyophilized composition stored under heat stress conditions (40 ± 2°C; 75% ± 5% RH), according to embodiments of the present disclosure.

FIG. 16 shows a graph of total aggregates by GF-HPLC vs. time (months) for a lyophilized composition stored under heat stress conditions (40 ± 2°C; 75% ± 5% RH), according to embodiments of the present disclosure.

DEFINITIONS

[0012] In describing the embodiments of the present disclosure, the following terms may be employed, and are intended to be defined as indicated below.

[0013] By "substantially purified" is meant the isolation of a substance such that the substance includes the majority of the sample in which it resides. For example, a sample that is substantially purified contains 50% or more of the substance of interest, such as 60% or more of the substance of interest, such as 75% or more of the substance of interest, such as 90% or more of the substance of interest, such as 95% or more of the substance of interest, including 99% or more of the substance of interest. Any convenient protocol may be employed for purifying the substance of interest and includes filtration (e.g., diafiltration, ultrafiltration, etc.), selective precipitation, crystallization, ion-exchange chromatography, affinity chromatography and sedimentation according to density.

[0014] By "isolated" is meant to describe a compound of interest that is in an environment different from that in which the compound naturally occurs. "Isolated" is meant to include compounds that are within samples that are substantially enriched for the compound of interest and/or in which the compound of interest is partially or substantially purified.

[0015] The terms "patient" and "subject" are used interchangeably and are used in their conventional sense to refer to a living organism suffering from or prone to a condition that can be prevented or treated by administration of a composition of the present disclosure, and includes both humans and non-human animals. Examples of subjects include humans, chimpanzees and other apes and monkey species; farm animals such as cattle, sheep, pigs, goats and horses; domestic mammals such as dogs and cats; laboratory animals including rodents such as mice, rats and guinea pigs; birds, including domestic, wild and game birds such as chickens, turkeys and other gallinaceous birds, ducks and geese. The term does not denote a particular age.

Thus, adult, juvenile and newborn individuals are of interest.

[0016] "Pharmaceutically effective amount" and "therapeutically effective amount" refer to an amount of a compound or composition sufficient to treat a specified disorder or disease or one or more of its symptoms and/or to prevent the occurrence of the disease or disorder. In reference to neoplastic conditions, a pharmaceutically or therapeutically effective amount includes an amount sufficient to, among other things, cause the amount and/or occurrence of the cancer in a subject to decrease, and/or decrease the growth rate of the cancer.

[0017] The term "treating" or "treatment" as used herein means the treating or treatment of a disease or medical condition in a patient, such as a mammal (e.g., a human) that includes: (a) preventing the disease or medical condition from occurring, such as, prophylactic treatment of a subject; (b) ameliorating the disease or medical condition, such as, eliminating or causing regression of the disease or medical condition in a patient; (c) suppressing the disease or medical condition, for example by, slowing or arresting the development of the disease or medical condition in a patient; or (d) alleviating a symptom of the disease or medical condition in a patient.

[0018] The term "physiological conditions" is meant to encompass those conditions compatible with living cells, e.g., predominantly aqueous conditions of a temperature, pH, salinity, etc. that are compatible with living cells.

[0019] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the embodiments of the present disclosure. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges and are also encompassed within the embodiments of the present disclosure, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included. Certain ranges are presented herein with numerical values being preceded by the term "about." The term "about" is used herein to provide literal support for the exact number that it precedes, as well as a number that is near to or approximately the number that the term precedes. In determining whether a number is near to or approximately a specifically recited number, the near or approximating unrecited number may be a number, which, in the context in which it is presented, provides the substantial equivalent of the specifically recited number.

DETAILED DESCRIPTION

[0020] Aspects of the invention include polyalkylene oxide-asparaginase compositions. The compositions include one or more of a buffer and a salt. Aspects of the invention further include methods of making the compositions. The compositions find use in a variety of applications, e.g., in the treatment of a neoplastic condition in a subject.

[0021] Aspects of the invention include lyophilized storage stable polyalkylene oxide-asparaginase compositions. In the claimed invention, the lyophilized compositions include one or more of a buffer, a salt, and a sugar. Aspects of the invention further include methods of making the compositions. The compositions find use in a variety of applications, e.g., in the treatment of a neoplastic condition (e.g., acute myeloid leukemia (AML)) in a subject.

[0022] Aspects of the invention include compositions of the invention for use in a method of treating a subject for AML. The methods include administering to the subject a dosage of a polyalkylene oxide-asparaginase


effective to treat the subject for AML. Aspects of the invention further include polyalkylene oxide- asparaginase containing compositions and kits that can be used in the subject methods.

[0023] In further describing the embodiments of the present disclosure, compositions (e.g., liquid and lyophilized) are described first in greater detail. Next, methods of making, methods of using and kits that include the subject composition are also described.


COMPOSITIONS

[0024] Aspects of the present disclosure include a composition of a polyalkylene oxide-asparaginase that includes a polyalkylene oxide group covalently linked by a linker to an asparaginase. The composition also includes one or more of a buffer and a salt. In certain embodiments, the composition is a lyophilized storage stable composition. The lyophilized storage stable composition also includes one or more of a buffer, a salt and a sugar.

[0025] As described herein, compositions of the present disclosure include a polyalkylene oxide-asparaginase. A polyalkylene oxide-asparaginase includes an asparaginase covalently linked by a linker to one or more polyalkylene oxide groups. Asparaginase is an enzyme that may be composed of four identical subunits with one active site per tetramer. For example, the asparaginase enzyme can be L-asparaginase (e.g., L-asparaginase II), which hydrolyzes the amino acid L-asparagine (also known as (S)-2,4-diamino-4-oxobutanoic acid, or asparaginine, or abbreviated as Asn or N) to produce L-aspartate (also known as (S)-2-aminosuccinic acid) and ammonia according to the following reaction:



[0026] In some cases, asparaginase can hydrolyze the amino acid L-glutamine (also known as (S)-2,5-diamino-5-oxopentanoic acid, or abbreviated as Gln or Q) to produce L-glutamate (also known as (S)-2-aminopentanedioic acid) and ammonia according to the following reaction:



[0027] The above reactions that are mediated by L-asparaginase may also be referred to as a deamination reaction. In some instances, the L-asparaginase in the composition is derived from a prokaryotic source, such as a bacteria, including the bacteria *Escherichia coli* (E. coli). As such, the asparaginase in the subject composition may be an E. coli asparaginase. In some cases, the asparaginase is expressed by E. coli. The asparaginase can be recovered and purified from a culture medium containing the E. coli that expresses the asparaginase. In addition to wild type asparaginases, the asparaginase may also be one that is a non-naturally occurring asparaginase and/or synthetically produced asparaginase and/or an active fragment of a naturally occurring and/or synthetic asparaginase. Examples of asparaginases that may be employed in embodiments of the invention include those described in: 9,322,008; 9,127,266; 9,051,561; 8,617,868; 7,807,436; 6,991,788; 6,537,547; 6,436,396; 6,368,845; 6,274,367; 6,251,388; 6,165,735; 6,140,101; 6,087,151; 6,042,825; 5,854,051; 5,310,670; 4,729,957 and 4,617,271.

[0028] As described above, the asparaginase in the polyalkylene oxide-asparaginase composition is an asparaginase covalently linked to one or more polyalkylene oxide groups. For instance, the asparaginase may include one or more polyalkylene oxide groups covalently linked to the asparaginase via a post-translational modification process. The polyalkylene oxide-asparaginase may include one or more polyalkylene oxide


groups covalently linked to the asparaginase at one or more positions on the asparaginase. For example, a polyalkylene oxide group may be covalently linked to an amino acid residue of the asparaginase. In some cases, the polyalkylene oxide group is covalently linked to an amino group of an amino acid residue of the asparaginase. In some embodiments, the polyalkylene oxide group is covalently linked to an amino acid side chain of an N-terminal amino acid in the asparaginase. In some embodiments, the polyalkylene oxide group is covalently linked to an epsilon-amino group of lysine (K) in the asparaginase. In some embodiments, the polyalkylene oxide group is covalently linked to an amino acid side chain of the N-terminal amino acid and an epsilon-amino group of lysine (K) in the asparaginase.

[0029] In some cases, the polyalkylene oxide-asparaginase is substantially non-antigenic. By "non-antigenic" or "substantially non-antigenic" is meant a composition that does not elicit a significant immune response in a subject when the composition is administered to the subject. In some instances, the polyalkylene oxide-asparaginase has a reduced rate of clearance from the circulation of a subject as compared to an unmodified asparaginase. For example, the elimination half-life of a polyalkylene oxide-asparaginase may be 1 day or more, such as 2 days or more, or 3 days or more, or 4 days or more, or 5 days or more, or 6 days or more, or 7 days or more, or 8 days or more, or 9 days or more, or 10 days or more, or 11 days or more, or 12 days or more, or 13 days or more, or 14 days or more, or 15 days or more, or 16 days or more, or 17 days or more, or 18 days or more, or 19 days or more, or 20 days or more. In some embodiments, the elimination half-life of a polyalkylene oxide-asparaginase is 3 days or more. In some embodiments, the elimination half-life of a polyalkylene oxide-asparaginase is 5 days or more.

[0030] The polyalkylene oxide group that is linked to the asparaginase can be any physiologically compatible polyalkylene oxide group. Poly(alkylene oxide)s (PAO), which are also known as polyoxyalkylenes (POA), are made by the polymerization of alkylene oxides (e.g., ethylene oxide, propylene oxide, butylene oxide). A homopolymer is formed only from one type of alkylene oxide while a copolymer is formed from two or more different alkylene oxides, known as alkylene oxide copolymers (AOC). Examples of the former are poly(ethylene oxide) (PEO), which is a polymer of ethylene oxide (EO), and poly(propylene oxide) (PPO), which is a polymer of propylene oxide (PO). Poly(ethylene oxide) is also commonly known as polyethylene glycol (PEG) or polyoxyethylene (POE). The molecular weight of such polymers is generally characterized as the average of a distribution of lengths (or repeat units). In addition to the standard linear forms, branched or star forms of poly(alkylene oxide)s are produced by initiating the polymerization reaction with a polyfunctional initiator with multiple hydroxyl-, amino-, or thiol-groups each of which can serve as a starting point for polymer chain growth. For example, the use of glycerol (three hydroxyl groups) as an initiator results in a three-armed branched polymer, while pentaerythritol results in a four-armed polymer. Conventionally, polymers of this type with 3 to 10 arms are termed "branched" while those with more than 10 arms are termed "star" polymers. "Comb" copolymers are similar to branched and star forms, but the initiator for comb copolymers is a polyfunctional polymer with multiple hydroxyl-, amino-, or thiol-groups spaced along the initiator backbone, each of which can serve as a starting point for polymer chain growth. "Graft" copolymers are made by the addition of pendant polymer chains along a polymer backbone that possesses unsaturated C=C bonds or pendant functional groups (e.g., hydroxyl) from which pendant chains can be added by using a reactive monofunctional polymer chain. All poly(alkylene oxide)s contain, in addition to multiple alkylene oxide-derived repeat units, a single residue corresponding to the molecule used to initiate the polymer synthesis. For linear polymers, this may be an alkylene glycol corresponding to the alkylene oxide used for the synthesis (e.g., ethylene glycol and ethylene oxide, respectively) and thus the initiator-derived residue will be indistinguishable from the other repeat units in the polymer chain. But small molecules other than alkylene glycols are often used as initiators, examples include methanol or N-butanol (for linear polymers) and trimethylol propane, glycerol, and pentaerythritol (for branched polymers) or ethylene diamine. The mass of initiator relative to the mass of the final polymer chain is generally very small and can usually be neglected. Thus, the term poly(alkylene oxide) is used here in its customary sense, and includes both poly(alkylene oxide)s initiated with an alkylene glycol molecule and poly(alkylene oxide)s initiated with another small molecule.

[0031] In certain embodiments, a physiologically compatible polyalkylene oxide group is substantially stable in

conditions compatible with living cells, e.g., predominantly aqueous conditions of a temperature, pH, salinity, etc. that are compatible with living cells. In certain embodiments, a polyalkylene oxide group is water-soluble. The term "water-soluble polymer" refers to a polyalkylene oxide group that is substantially soluble in water, such as in aqueous conditions found in the body of a subject. Polyalkylene oxide groups of interest include straight chain polyalkylene glycols. Straight chain polyalkylene glycols employed in certain embodiments of the invention are of the following structural formula:




wherein R is selected from the group consisting of hydrogen, lower alkyl and mixtures thereof, R1 is selected from the group consisting of hydrogen and lower alkyl, and n is a positive integer. By "lower alkyl" is meant an alkyl group having from one to four carbon atoms, i.e., methyl, ethyl, propyl, butyl, and isomers of the foregoing. R may be selected from the group consisting of hydrogen, methyl, and mixtures thereof, R1 may be selected from the group consisting of hydrogen and methyl, and n may be a positive integer selected to provide for the desired polymeric size. In some instances, the poly(alkylene glycols) employed in embodiments of the invention are poly(ethylene glycol), poly(propylene glycol), mixtures thereof, and copolymers of poly(ethylene glycol) and poly(propylene glycol), wherein one of the terminal hydroxyl groups of the polymer may be substituted with a lower alkyl group.

[0032] In some embodiments, the polyalkylene oxide is a polyethylene glycol (PEG). In certain embodiments, the polyethylene glycol (PEG) has a molecular weight of 1,000 to 20,000 daltons. In certain embodiments, the PEG has a molecular weight of 1,000 to 20,000 daltons, or 1,000 to 19,000 daltons, or 1,000 to 18,000 daltons, or 1,000 to 17,000 daltons, or 1,000 to 16,000 daltons, or 1,000 to 15,000 daltons, or 1,000 to 14,000 daltons, or 1,000 to 13,000 daltons, or 1,000 to 12,000 daltons, or 1,000 to 11,000, or 1,000 to 10,000, or 1,500 to 10,000 daltons, or 2,000 to 10,000 daltons, or 2,000 to 9,000 daltons, or 2,000 to 8,000 daltons, or 2,000 to 7,000 daltons, or 2,000 to 6,000 daltons, or 3,000 to 6,000 daltons or 4,000 to 6,000 daltons, or 4,500 to 5,500 daltons. In certain embodiments, the PEG has a molecular weight of 2,000 to 10,000 daltons. In certain embodiments, the PEG has a molecular weight of 4,000 to 6,000 daltons. In certain embodiments, the PEG has a molecular weight of 5,000 daltons. In some instances, the polyethylene glycol is a methoxypolyethylene glycol (e.g., monomethoxypolyethylene glycol, or "mPEG").

[0033] As described above, the polyalkylene oxide group may be covalently attached to the asparaginase. In some cases, the polyalkylene oxide group is covalently linked by a linker to the asparaginase. As such, the polyalkylene oxide group may be covalently attached to the asparaginase through the linker. The linker may be any convenient functional group that allow for attachment of the polyalkylene oxide group to the asparaginase. For example, the linker may include a reactive functional group that provides for a covalent bond between the polyethylene oxide group and the asparaginase. In some cases, the linker includes a reactive functional group that provides for a covalent bond between the polyethylene oxide group and an amino acid residue of the asparaginase. For instance, the linker may include a reactive functional group that provides for a covalent bond between the polyalkylene oxide group and an amino group of an amino acid residue of the asparaginase. Examples of such reactive functional groups include p-nitrophenoxy, thiazolidinyl thione, N-hydroxysuccinimidyl, or other suitable reactive functional groups such as N-hydroxybenzotriazolyl, halogen, N- hydroxyphthalimidyl, imidazolyl, O-acyl ureas, pentafluorophenol or 2,4,6-trichlorophenol. In some cases, the reactive functional group of the linker is N-hydroxysuccinimidyl. Accordingly, following covalent attachment of the polyalkylene oxide group to the asparaginase, the linker may include functional groups, such as a urethane linker (also known as a carbamate linker), a succinate linker.


[0034] In certain embodiments, the linker includes a urethane linker (also known as a carbamate linker). For example, a reaction for the attachment of methoxypolyethylene glycol (mPEG) to an amino group of an amino acid of a polypeptide (e.g., asparaginase) through a urethane (carbamate) linker is shown below.





[0035] In the reaction shown above, methoxypolyethylene glycol succinimidyl carbonate (also referred to as SC-PEG) is reacted with an amino group of an amino acid of a polypeptide (e.g., asparaginase) to produce a polyethylene glycol-asparaginase with a urethane (carbamate) linker. SC-PEG-asparaginase is also described in Angiolillo, AL., et al., "Pharmacokinetic (PK) and pharmacodynamics (PD) properties of SC-PEG E. coli 1-asparaginase (EZN-2285) in the treatment of patients with acute lymphoblastic leukemia (ALL): Results from Children's Oncology Group (COG) study AALL07P4", 2012 American Society of Clinical Oncology (ASCO) Annual Meeting, Poster 9543; and Angiolillo, AL., et al., "Pharmacokinetic and Pharmacodynamic Properties of Calaspargase Pegol Escherichia coli L-Asparaginase in the Treatment of Patients With Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Study AALL07P4", J Clin. Oncology, 32(34), 2014, 3874-3882.

[0036] In certain embodiments, the linker includes a succinate linker (also referred to as a succinyl linker). For example, a reaction for the attachment of methoxypolyethylene glycol (mPEG) to an amino group of an amino acid of a polypeptide (e.g., asparaginase) through a succinate linker is shown below.



[0037] In the reaction shown above, methoxypolyethylene glycol succinimidyl succinate (also referred to as SS-PEG) is reacted with an amino group of an amino acid of a polypeptide (e.g. asparaginase) to produce a polyethylene glycol-asparaginase with a succinate linker. SS-PEG- asparaginase is also described in U.S. Patent Nos. 5,122,614; 5,324,844; and 5,612,460.

[0038] In certain instances, the composition that contains the polyalkylene oxide-asparaginase is a dehydrated composition. As used herein, a dehydrated composition is a composition that includes water in a low amount, such as 25% or less, or 20% or less, or 15% or less, or 10% or less, or 9% or less, or 8% or less, or 7% or less, or 6% or less, or 5% or less, or 4% or less, or 3% or less, or 2% or less, or 1% or less water as measured by Karl Fischer (KF) titration. In some cases, a dehydrated composition has 3% or less water as measured by Karl Fischer titration. In some cases, a dehydrated composition has 1% or less water as measured by Karl Fischer titration. In some cases, a dehydrated composition has 0.5% or less water as measured by Karl Fischer titration. Any convenient protocol may be used to produce a dehydrated composition, such as increasing the temperature of the composition (e.g., heating), reducing the pressure, lyophilization (also known as freeze-drying), and combinations thereof.

[0039] In the claimed invention, lyophilization is used to produce a dehydrated composition, and thus the composition (e.g., the composition that contains the polyalkylene oxide-asparaginase) is a lyophilized composition. In some instances, a lyophilized composition is a composition where water has been removed from the composition by sublimation, where the water in the composition undergoes a phase transition from a solid to a gas. For example, a lyophilized composition may be a composition where water has been removed from the composition by freezing the composition (e.g., freezing the water in the composition) and then reducing the pressure surrounding the composition such that the water in the composition undergoes sublimation. As described above, a lyophilized composition may include water in a low amount, such as 25% or less, or 20% or less, or 15% or less, or 10% or less, or 9% or less, or 8% or less, or 7% or less, or 6% or less, or 5% or less, or 4% or less, or 3% or less, or 2% or less, or 1% or less, or 0.5% or less, or 0.25% or less, or 0.1% or less water as measured by Karl Fischer (KF) titration. In certain embodiments, the lyophilized composition may include water in a low amount, such as between about 0.1% to about 25%, or about 0.25% to about 20%, or about 0.5 % to about 15%, or about 1% to about 10%, or about 2% to about 9%, or about 3% to

about 8%, or about 4% to about 7%, or about 5% to about 6% as measured by Karl Fischer (KF) titration. In certain embodiments, the lyophilized composition may include water in a low amount, such as between about 0.1% to about 5%, or about 0.25% to about 4%, or about 0.5% to about 3%, or about 1% to about 2% as measured by Karl Fischer (KF) titration. In some cases, a lyophilized composition has 3% or less water as measured by Karl Fischer titration. In some cases, a lyophilized composition has 1% or less water as measured by Karl Fischer titration. In some cases, a lyophilized composition has 0.5% or less water as measured by Karl Fischer titration.

[0040] Due to the low water content of a lyophilized composition as described above, the lyophilized composition may be in the form of a solid. In some cases, the solid lyophilized composition is a powder. In some cases, a lyophilized composition may facilitate storage of the composition for an extended period of time (e.g., as compared to a liquid formulation of the same composition). For instance, a lyophilized composition may be a storage stable composition (e.g., a lyophilized storage stable composition), where the composition is substantially stable for an extended period of time. By "stable" or "storage stable" or "substantially stable" is meant a composition that does not significantly degrade and/or lose activity over an extended period of time. For example, a storage stable composition may not have significant impurities due to degradation of the composition over an extended period of time, such as 10% or less impurities, or 9% or less, or 8% or less, or 7% or less, or 6% or less, or 5% or less, or 4% or less, or 3% or less, or 2% or less, or 1% or less degradation products over an extended period of time. In certain embodiments, a storage stable composition may have between about 1% to about 10%, or about 2% to about 9%, or about 3% to about 8%, or about 4% to about 7%, or about 6% to about 5% less degradation products over an extended period of time. In certain instances, a storage stable composition has 5% or less impurities over an extended period of time. In some cases, a storage stable composition substantially retains its activity over an extended period of time, such as retains 100% of its activity, or 99% or more, or 98% or more, or 97% or more, or 96% or more, or 95% or more, or 94% or more, or 93% or more, or 92% or more, or 91% or more, or 90% or more, or 85% or more, or 80% or more, or 75% or more of its activity over an extended period of time. In some embodiments, a storage stable composition substantially retains its activity over an extended period of time, such as between about 75% to about 100%, or about 80% to about 99%, or about 85% to about 98%, or about 90% to about 97%, or about 91% to about 96%, or about 92% to about 95%, or about 93% to about 94% more of its activity over an extended period of time. For example, a storage stable composition may retain 90% or more of its activity over an extended period of time. In some cases, a storage stable composition retains 95% or more of its activity over an extended period of time. An extended period of time is a period of time such as 1 week or more, or 2 weeks or more, or 3 weeks or more, or 1 month or more, or 2 months or more, or 3 months or more, or 4 months or more, or 6 months or more, or 9 months or more, or 1 year or more, or 1.5 years (e.g., 18 months) or more, or 2 years or more, or 2.5 years (e.g., 30 months) or more, or 3 years or more, or 3.5 years (e.g., 42 months) or more, or 4 years or more, or 4.5 years (e.g., 54 months) or more, or 5 years or more. For instance, an extended period of time may be 6 months or more. In some cases, an extended period of time is 9 months or more. In some cases, an extended period of time is 1 year (e.g., 12 months) or more. In some cases, an extended period of time is 1.5 years (e.g., 18 months) or more. In some cases, an extended period of time is 2 years (e.g., 24 months) or more. In some embodiments, an extended period of time can be between about 1 week to about 3 weeks, or about 1 month to about 6 months, or about 6 months to about 9 months, or about 1 year to about 1.5 years, or about 1 year to about 2 years, or about 1 year to about 3 years, or about 1 year to about 4 years, or about 1 year to about 5 years. In some embodiments, a storage stable composition is substantially stable for an extended period of time at ambient temperature, such as a temperature of 20 to 40 °C, or 25 to 35 °C, or 25 to 30 °C. In some instances, a storage stable composition is substantially stable for an extended period of time at a temperature less than ambient temperature, such as a temperature of 0 to 20 °C, or 0 to 15 °C, or 0 to 10 °C, or 2 to 8 °C.

[0041] In some cases, the composition includes a therapeutically effective amount of the polyalkylene oxide-asparaginase. The enzymatic activity of the polyalkylene oxide-asparaginase can be measured in International Units (IU), which corresponds to the amount of enzyme required to generate 1 µmol of ammonia per minute at a pH of 7.3 and temperature of 37 °C. In some cases, the polyalkylene oxide-asparaginase may be present in

the composition in an amount (e.g., the polyalkylene oxide-asparaginase may have a potency (activity)) ranging from 100 to 5,000 IU/g, such as 500 to 4,500 IU/g, or 500 to 4,000 IU/g, or 500 to 3,500 IU/g, or 500 to 3,000 IU/g, or 500 to 2,500 IU/g, or 500 to 2,000 IU/g, or 500 to 1,500 IU/g, or 500 to 1,000 IU/g, or 600 to 900 IU/g, or, or 700 to 800 IU/g. In certain instances, the polyalkylene oxide-asparaginase may be present in the composition in an amount ranging from 500 to 1,000 IU/g. For example, the polyalkylene oxide-asparaginase may have a potency (activity) ranging from 500 to 1,000 IU/g. In certain instances, the polyalkylene oxide-asparaginase is present in the composition in an amount ranging from 700 to 800 IU/g. For example, the polyalkylene oxide-asparaginase may have a potency (activity) ranging from 700 to 800 IU/g. In certain instances, the polyalkylene oxide-asparaginase is present in the composition in an amount of 750 IU/g. For example, the polyalkylene oxide-asparaginase may have a potency (activity) of 750 IU/g

[0042] In some cases, the polyalkylene oxide-asparaginase in the composition is present in a therapeutically effective amount, where the polyalkylene oxide-asparaginase has a specific activity of 50 IU/mg protein or more, such as 55 IU/mg protein or more, or 60 IU/mg protein or more, or 65 IU/mg protein or more, or 70 IU/mg protein or more, or 75 IU/mg protein or more, or 80 IU/mg protein or more, or 85 IU/mg protein or more, or 90 IU/mg protein or more, or 95 IU/mg protein or more, or 100 IU/mg protein or more, or 105 IU/mg protein or more, or 110 IU/mg protein or more, or 115 IU/mg protein or more, or 120 IU/mg protein or more, or 125 IU/mg protein or more, or 130 IU/mg protein or more, or 135 IU/mg protein or more, or 140 IU/mg protein or more, or 145 IU/mg protein or more, or 150 IU/mg protein or more. For instance, the polyalkylene oxide-asparaginase in the composition may have a specific activity of 85 IU/mg protein or more. In some embodiments, the polyalkylene oxide-asparaginase in the composition has a specific activity ranging from 50 to 150 IU/mg protein, or 55 to 145 IU/mg protein, or 60 to 140 IU/mg protein, or 65 to 135 IU/mg protein, or 70 to 130 IU/mg protein, or 75 to 125 IU/mg protein, or 80 to 120 IU/mg protein, or 85 to 115 IU/mg protein, or 90 to 110 IU/mg protein, or 95 to 105 IU/mg protein. In some cases, the polyalkylene oxide-asparaginase in the composition has a specific activity ranging from 50 to 150 IU/mg protein, such as 65 to 140 IU/mg protein, or 70 to 135 IU/mg protein, or 75 to 130 IU/mg protein, or 75 to 125 IU/mg protein. For instance, the polyalkylene oxide-asparaginase in the composition may have a specific activity ranging from 75 to 125 IU/mg protein.

[0043] In certain embodiments, the polyalkylene oxide-asparaginase in the composition is present in a therapeutically effective amount, where the polyalkylene oxide-asparaginase in the composition is present in an amount ranging from 1 mg/mL to 15 mg/mL, such as 1.5 mg/mL to 14.5 mg/mL, or 2 mg/mL to 14 mg/mL, or 2.5 mg/mL to 13.5 mg/mL, or 3 mg/mL to 13 mg/mL, or 3.5 mg/mL to 12.5 mg/mL, or 4 mg/mL to 12 mg/mL, or 4.5 mg/mL to 11.5 mg/mL, or 4.5 mg/mL to 11 mg/mL, or 4.5 mg/mL to 10.5 mg/mL, or 4.5 mg/mL to 10 mg/mL, or 4.5 mg/mL to 9.5 mg/mL, or 4.5 mg/mL to 9 mg/mL, or 4.5 mg/mL to 8.5 mg/mL, or 5 mg/mL to 8 mg/mL. In some cases, the polyalkylene oxide-asparaginase in the composition is present in an amount ranging from 4.5 mg/mL to 8.5 mg/mL.

[0044] When administered to a subject, the composition may include an amount of the polyalkylene oxide-asparaginase sufficient to deliver from 100 to 5,000 IU/m² of the polyalkylene oxide-asparaginase to the subject, such as from 500 to 5,000 IU/m² or 500 to 4,500 IU/m², or 500 to 4,000 IU/m², or 500 to 3,500 IU/m² or 500 to 3,000 IU/m², or 1,000 to 3,000 IU/m², or 1,500 to 3,000 IU/m², or 1,750 to 3,000 IU/m², or 2,000 to 3,000 IU/m², or 2,000 to 2,750 IU/m² or 2,250 to 2,750 IU/m² of the polyalkylene oxide-asparaginase to the subject. For example, the composition may include an amount of the polyalkylene oxide-asparaginase sufficient to deliver from 1,500 to 3,000 IU/m² of the polyalkylene oxide-asparaginase to the subject. In certain instances, the composition includes an amount of the polyalkylene oxide-asparaginase sufficient to deliver from 2,000 to 2,750 IU/m² of the polyalkylene oxide-asparaginase to the subject. In certain instances, the composition includes an amount of the polyalkylene oxide-asparaginase sufficient to deliver from 2,250 to 2,750 IU/m² of the polyalkylene oxide-asparaginase to the subject. For instance, the composition may include an amount of the polyalkylene oxide-asparaginase sufficient to deliver 2,500 IU/m² of the polyalkylene oxide-asparaginase to the subject.

[0045] In certain embodiments, the dosage administered to the subject is a liquid dosage, for example, an aqueous dosage. In some embodiments, in addition to the polyalkylene oxide-asparaginase, the dosage includes a buffer and a salt.

[0046] The compositions of the present disclosure, in addition to the polyalkylene oxide-asparaginase, may include additional components. For instance, the composition may include a buffer. Buffers suitable for use in the compositions of the present disclosure include buffers that are compatible with the polyalkylene oxide-asparaginase and suitable for administration to a subject, e.g., by injection or intravenous administration. Examples of suitable buffers include phosphate buffers (e.g., phosphate buffered saline (PBS)), Dulbecco's phosphate buffered saline (DPBS), Hank's balanced salt solution (HBSS), Earle's balanced salt solution (EBSS), Tris buffer, Ringer's lactate buffer, and combinations thereof. The buffer included in the composition may be a buffer that maintains the pH of the composition at a physiologically compatible pH, such as a pH ranging from 6 to 8, or a pH of about 7, for example 7.2, 7.3 or 7.4. In the claimed invention, the buffer is a phosphate buffer. The phosphate buffer includes dibasic sodium phosphate (also known as disodium phosphate or sodium hydrogen phosphate; Na₂HPO₄) and monobasic sodium phosphate (also known as monosodium phosphate; NaH₂PO₄).

[0047] In some cases, the amount of dibasic sodium phosphate in the composition ranges from 0.1 to 0.8 wt.%, or 0.1 to 0.7 wt.%, or 0.1 to 0.6 wt.%, or 0.2 to 0.6 wt.%, or 0.3 to 0.6 wt.%, or 0.4 to 0.6 wt.%, or 0.5 to 0.6 wt.%. In certain instances, the dibasic sodium phosphate may be present in the composition in an amount ranging from 0.2 to 0.8 wt.%. In certain instances, the dibasic sodium phosphate may be present in the composition in an amount ranging from 0.3 to 0.6 wt.%. In certain instances, the dibasic sodium phosphate may be present in the composition in an amount ranging from 0.5 to 0.6 wt.%. For instance, the dibasic sodium phosphate may be present in the composition in an amount of about 0.6 wt.%, such as 0.56 wt.%(or 0.558 wt.%). In certain embodiments, the amount of monobasic sodium phosphate in the composition ranges from 0.01 to 0.4 wt.%, or 0.01 to 0.2 wt.%, or 0.02 to 0.18 wt.%, or 0.03 to 0.16 wt.%, or 0.04 to 0.16 wt.%, or 0.045 to 0.15 wt.%, or 0.04 to 0.14 wt.%, or 0.05 to 0.14 wt.%, or 0.1 to 0.2 wt.%, or 0.1 to 0.15 wt.%. For instance, the monobasic sodium phosphate may be present in the composition in an amount ranging from 0.05 to 0.2 wt.%. In certain instances, the monobasic sodium phosphate may be present in the composition in an amount ranging from 0.01 to 0.2 wt.%. In certain instances, the monobasic sodium phosphate may be present in the composition in an amount ranging from 0.09 to 0.15 wt.%. In certain instances, the monobasic sodium phosphate may be present in the composition in an amount ranging from 0.1 to 0.2 wt.%. In certain instances, the monobasic sodium phosphate may be present in the composition in an amount ranging from 0.1 to 0.15 wt.%. For instance, the monobasic sodium phosphate may be present in the composition in an amount of 0.12 wt.%(or 0.129 wt.%).

[0048] Another additional component included in the compositions of the present disclosure is a salt. Salts suitable for use in the compositions of the present disclosure include salts that are compatible with the polyalkylene oxide-asparaginase and suitable for administration to a subject, e.g., by injection or intravenous administration. Examples of suitable salts include sodium chloride, potassium chloride, calcium chloride, magnesium chloride and combinations thereof. In certain instances, the salt is sodium chloride.

[0049] In some cases, the amount of salt (e.g., sodium chloride) in the composition ranges from 0.1 to 1 wt.%, or 0.2 to 1 wt.%, or 0.3 to 1 wt.%, or 0.4 to 1 wt.%, or 0.5 to 1 wt.%, or 0.6 to 1 wt.%, or 0.7 to 1 wt.%, or 0.8 to 1 wt.%, or 0.8 to 0.9 wt.%. For instance, the salt (e.g., sodium chloride) may be present in the composition in an amount ranging from 0.5 to 1 wt.%. In certain instances, the salt (e.g., sodium chloride) may be present in the composition in an amount ranging from 0.7 to 1 wt.%. In certain instances, the salt (e.g., sodium chloride) may be present in the composition in an amount ranging from 0.8 to 0.9 wt.%. For instance, the salt (e.g., sodium chloride) may be present in the composition in an amount of 0.85 wt. %.

[0050] In certain embodiments, the polyalkylene oxide-asparaginase containing composition is a lyophilized composition. Lyophilized compositions of the present disclosure, in addition to the polyalkylene oxide-

asparaginase, also include a buffer, a salt, and a sugar. For example, aspects of the present disclosure include a lyophilized storage stable composition of a polyalkylene oxide-asparaginase that includes a polyalkylene oxide group covalently linked by a linker to an asparaginase, a buffer, a salt, and a sugar.

[0051] Buffers suitable for use in the lyophilized compositions of the present disclosure include buffers that are compatible with the polyalkylene oxide-asparaginase and suitable for administration to a subject, e.g., by injection or intravenous administration. Examples of suitable buffers include those described above. In the claimed invention, the buffer is a phosphate buffer. In the claimed invention, the phosphate buffer includes dibasic sodium phosphate and monobasic sodium phosphate. In some cases, the amount of dibasic sodium phosphate in the composition ranges from 0.1 to 0.8 wt. %, or 0.1 to 0.7 wt. %, or 0.1 to 0.6 wt. %, or 0.1 to 0.5 wt. %, or 0.1 to 0.4 wt. %, or 0.2 to 0.4 wt. %, or 0.2 to 0.3 wt. %, or 0.25 to 0.3 wt. %. For instance, the dibasic sodium phosphate may be present in the composition in an amount ranging from 0.1 to 0.5 wt. %. In certain instances, the dibasic sodium phosphate may be present in the composition in an amount ranging from 0.2 to 0.4 wt. %. In certain instances, the dibasic sodium phosphate may be present in the composition in an amount ranging from 0.25 to 0.3 wt. %. For instance, the dibasic sodium phosphate may be present in the composition in an amount of about 0.3 wt. %, such as 0.28 wt. % (or 0.279 wt. %). In certain embodiments, the amount of monobasic sodium phosphate in the composition ranges from 0.01 to 0.5 wt. %, or 0.01 to 0.4 wt. %, or 0.01 to 0.3 wt. %, or 0.01 to 0.2 wt. %, or 0.01 to 0.1 wt. %, or 0.02 to 0.09 wt. %, or 0.03 to 0.08 wt. %, or 0.04 to 0.08 wt. %, or 0.045 to 0.075 wt. %, or 0.04 to 0.07 wt. %, or 0.05 to 0.07 wt. %. For instance, the monobasic sodium phosphate may be present in the composition in an amount ranging from 0.01 to 0.1 wt. %. In certain instances, the monobasic sodium phosphate may be present in the composition in an amount ranging from 0.05 to 0.07 wt. %. In certain instances, the monobasic sodium phosphate may be present in the composition in an amount ranging from 0.045 to 0.075 wt. %. For instance, the monobasic sodium phosphate may be present in the composition in an amount of 0.06 wt. %.

[0052] Lyophilized compositions of the present disclosure include a salt. Salts suitable for use in the compositions of the present disclosure include salts that are compatible with the polyalkylene oxide-asparaginase and suitable for administration to a subject, e.g., by injection or intravenous administration. Examples of suitable salts include those described above. In certain instances, the salt is sodium chloride.

[0053] The amount of salt (e.g., sodium chloride) in the composition ranges from 0.05 to 1 wt. %, such as 0.1 to 0.9 wt. %, or 0.1 to 0.8 wt. %, or 0.1 to 0.7 wt. %, or 0.1 to 0.6 wt. %, or 0.1 to 0.5 wt. %, or 0.2 to 0.5 wt. %, or 0.3 to 0.5 wt. %, or 0.4 to 0.5 wt. %, or 0.4 to 0.45 wt. %. For instance, the salt (e.g., sodium chloride) may be present in the composition in an amount ranging from 0.1 to 1 wt. %. In certain instances, the salt (e.g., sodium chloride) may be present in the composition in an amount ranging from 0.3 to 0.5 wt. %. In certain instances, the salt (e.g., sodium chloride) may be present in the composition in an amount ranging from 0.4 to 0.45 wt. %. For instance, the salt (e.g., sodium chloride) may be present in the composition in an amount of about 0.4 wt. %, such as 0.425 wt. %. Another component included in the compositions of the present disclosure is a sugar. Sugars suitable for use in the compositions of the present disclosure include sugars that are compatible with the polyalkylene oxide-asparaginase and suitable for administration to a subject, e.g., by injection or intravenous administration. Examples of suitable sugars include sucrose, mannitol, maltose, trehalose, 2-hydroxypropyl-beta-cyclodextrin (β -HPCD), lactose, glucose, fructose, galactose, glucosamine and combinations thereof. In certain instances, the sugar is a disaccharide. For example, the disaccharide may be sucrose.

[0054] The amount of sugar (e.g., sucrose) in the composition ranges from 0.1 to 25 wt. %, such as 0.5 to 20 wt. %, or 1 to 15 wt. %, or 1 to 10 wt. %, or 1 to 9 wt. %, or 1 to 8 wt. %, or 2 to 7 wt. %, or 2 to 6 wt. %, or 3 to 5 wt. %, or 4 to 5 wt. %. For instance, the sugar (e.g., sucrose) may be present in the composition in an amount ranging from 1 to 10 wt. %. In certain instances, the sugar (e.g., sucrose) may be present in the composition in an amount ranging from 3 to 5 wt. %. In certain instances, the sugar (e.g., sucrose) may be present in the composition in an amount ranging from 4 to 5 wt. %. For instance, the sugar (e.g., sucrose) may

be present in the composition in an amount of 4.5 wt. %.

[0055] In some embodiments, the composition comprises a polyalkylene oxide-asparaginase having a potency (activity) ranging from 500 to 1,000 IU/g, , monobasic sodium phosphate in an amount ranging from 0.01 to 0.2 wt.%, a salt (e.g., sodium chloride) in an amount ranging from 0.2 to 2 wt.%, and water.

[0056] In some embodiments, the composition comprises a polyalkylene oxide-asparaginase having a potency (activity) ranging from 700 to 800 IU/g, dibasic sodium phosphate in an amount ranging from 0.2 to 0.8 wt. %, monobasic sodium phosphate in an amount ranging from 0.1 to 0.14 wt. %, a salt (e.g., sodium chloride) in an amount ranging from 0.6 to 1.0 wt.%, and water.

[0057] In some embodiments, the composition comprises a polyalkylene oxide-asparaginase having a potency (activity) ranging from 700 to 800 IU/g, dibasic sodium phosphate in an amount ranging from 0.5 to 0.6 wt. %, monobasic sodium phosphate in an amount ranging from 0.09 to 0.15 wt.%, a salt (e.g., sodium chloride) in an amount ranging from 0.8 to 0.9 wt.%, and water.

[0058] In some embodiments, the composition comprises, polyalkylene oxide-asparaginase having a potency (activity) of 750 IU/g, dibasic sodium phosphate in an amount of about 0.6 wt. %, monobasic sodium phosphate in an amount of about 0.1 wt. %, a salt (e.g., sodium chloride) in an amount of about 0.9 wt. %, and water.

[0059] In some embodiments, the composition comprises, polyalkylene oxide-asparaginase having a potency (activity) of 750 IU/g, dibasic sodium phosphate in an amount of 0.56 wt. % (or 0.558 wt. %), monobasic sodium phosphate in an amount of 0.13 wt. % (or 0.129 wt. %), a salt (e.g., sodium chloride) in an amount of 0.85 wt. %, and water.

[0060] In some embodiments, the composition comprises a polyalkylene oxide-asparaginase, dibasic sodium phosphate, monobasic sodium phosphate, salt (e.g., sodium chloride), and water. In other embodiments, the composition comprises, consists essentially of, or consists of a polyalkylene oxide-asparaginase, dibasic sodium phosphate, monobasic sodium phosphate, salt (e.g., sodium chloride), sugar (e.g., sucrose), and water.

[0061] In some embodiments, the composition comprises, consists essentially of, or consists of a polyalkylene oxide-asparaginase having a potency (activity) ranging from 500 to 1,000 IU/g, dibasic sodium phosphate in an amount ranging from 0.1 to 0.5 wt. %, monobasic sodium phosphate in an amount ranging from 0.01 to 0.1 wt. %, a salt (e.g., sodium chloride) in an amount ranging from 0.1 to 1 wt. %, a sugar (e.g., sucrose) in an amount ranging from 1 to 10 wt. %, and water.

[0062] In some embodiments, the composition comprises, consists essentially of, or consists of a polyalkylene oxide-asparaginase having a potency (activity) ranging from 700 to 800 IU/g, dibasic sodium phosphate in an amount ranging from 0.2 to 0.4 wt. %, monobasic sodium phosphate in an amount ranging from 0.05 to 0.07 wt. %, a salt (e.g., sodium chloride) in an amount ranging from 0.3 to 0.5 wt. %, a sugar (e.g., sucrose) in an amount ranging from 3 to 5 wt. %, and water.

[0063] In some embodiments, the composition comprises, consists essentially of, or consists of a polyalkylene oxide-asparaginase having a potency (activity) ranging from 700 to 800 IU/g, dibasic sodium phosphate in an amount ranging from 0.25 to 0.3 wt. %, monobasic sodium phosphate in an amount ranging from 0.045 to 0.075 wt. %, a salt (e.g., sodium chloride) in an amount ranging from 0.4 to 0.45 wt. %, a sugar (e.g., sucrose) in an amount ranging from 4 to 5 wt. %, and water.

[0064] In some embodiments, the composition comprises, consists essentially of, or consists of a polyalkylene oxide-asparaginase having a potency (activity) of 750 IU/g, dibasic sodium phosphate in an amount of about 0.3 wt. %, monobasic sodium phosphate in an amount of about 0.06 wt. %, a salt (e.g., sodium chloride) in an

amount of about 0.4 wt. %, a sugar (e.g., sucrose) in an amount of about 4.5 wt. %, and water.

[0065] In some embodiments, the composition comprises, consists essentially of, or consists of a polyalkylene oxide-asparaginase having a potency (activity) of 750 IU/g, dibasic sodium phosphate in an amount of 0.28 wt.% (or 0.279 wt.%), monobasic sodium phosphate in an amount of 0.06 wt. %, a salt (e.g., sodium chloride) in an amount of 0.43 wt. % (or 0.425 wt. %), a sugar (e.g., sucrose) in an amount of 4.5 wt. %, and water.

[0066] In certain instances, the composition (e.g., liquid or lyophilized composition) is a sterile composition. By "sterile" is meant that there are substantially no immunogenic components in the composition, such as for example substantially no microbes (e.g., fungi, bacteria, viruses, spore forms, etc.). In some cases, the composition is present in a container. Providing the composition in a container may facilitate maintaining the composition as a sterile composition. For instance, the container may be configured to maintain the composition enclosed in the container in a sterile environment. As such, the container may be a sealed container, for example the container may include a seal, such as a water-tight and/or an air-tight seal. The seal may be removable from the container to allow a user access to the contents of the container. In some instances, the seal may be a frangible seal, or in other instances, the seal may be configured to allow insertion of a needle, cannula or syringe into the interior of the container without removing the seal from the container. In some cases, a seal configured to allow access to the interior of the container without removing the seal from the container may facilitate maintaining the contents of the container (e.g., the composition in the container) in a sterile environment prior to administration of the composition to a subject. Suitable materials for the seal include, for example, rubber or polymer seals, such as silicone rubber, natural rubber, styrene butadiene rubber, ethylene-propylene copolymers, polychloroprene, polyacrylate, polybutadiene, polyurethane, styrene butadiene and combinations thereof. For example, in certain embodiments, the seal is a septum pierceable by a needle, syringe, or cannula. The seal may also provide convenient access to a sample in the container, as well as a protective barrier that overlies the opening of the container. In some instances, the seal is a removable seal, such as a threaded or snap-on cap or other suitable sealing element that can be applied to the opening of the container. For instance, a threaded cap can be screwed over the opening before or after a sample has been added to the container.

[0067] In some cases, the container is a unit dosage container. A unit dosage container refers to a container that contains one or more unitary dosages for administration to a subject. In some embodiments, a unit dosage container includes a predetermined quantity of a subject composition calculated in an amount sufficient to produce a desired effect in a subject. Certain embodiments of the compositions may be provided in a unit dosage container suitable for individual administration of precise dosages. The amount of active composition administered to a subject may depend on the subject being treated, the severity of the affliction, and the manner of administration. For example, the unit dosage container may contain a quantity of the composition to be administered as disclosed herein in an amount effective to achieve the desired effect in the subject being treated. In certain instances, a unit dosage container includes a composition having a polyalkylene oxide-asparagine in a therapeutically effective amount. Therapeutically effective amounts of the polyalkylene oxide-asparagine are described above. In certain embodiments, the unit dosage container is a vial. In some cases, the vial is a sealed vial (e.g., as described above regarding a sealed container).

[0068] The container may be composed of any convenient material that is compatible with the polyalkylene oxide-asparaginase and other components of the composition. For example, the container can be a solid-compatible container configured to contain a solid (e.g., a lyophilized composition). In some instances, the container is a liquid-compatible container configured to contain a liquid. Containers may also be solid and liquid compatible, where the container is configured to contain solids and liquids. In some cases, a liquid in the container may be an aqueous liquid, and in these cases, the container may be compatible with aqueous compositions. By "compatible" is meant that the container is substantially inert (e.g., does not significantly react with) the liquid and/or compositions or other components in contact with the container. Examples of suitable container materials include glass and plastic. For example, the container may be composed of glass, such as

silicate glass,

borosilicate glass, sodium borosilicate glass (e.g., PYREX™), fused quartz glass, fused silica glass. Other examples of suitable container materials for the container include plastics, such as polypropylene, polymethylpentene, polytetrafluoroethylene (PTFE), perfluoroethers (PFE), fluorinated ethylene propylene (FEP), perfluoroalkoxy alkanes (PFA), polyethylene terephthalate (PET), polyethylene (PE), polyetheretherketone (PEEK), polystyrene. In certain instances, as described above, the container is a vial, and as such may be a glass vial. As described above, the container may be a sealed container, and as such may be a sealed glass vial.

[0069] As described in more detail below, liquid or reconstituted compositions of the present disclosure may be administered to a subject, for example by injection or intravenously. In certain embodiments, prior to administration of the reconstituted composition to a subject, a solid composition, e.g., as described above, may be combined with a liquid to provide a liquid composition suitable for administration, for example by injection or intravenously. In some cases, prior to administration of the composition to a subject, a solid composition may be combined with water (e.g., water for injection, WFI) to provide an aqueous composition suitable for administration, for example by injection or intravenously. For instance, a lyophilized composition may be reconstituted with water (e.g., water for injection, WFI) to produce a reconstituted dosage unit suitable for administration to a subject, for example by injection or intravenously.

[0070] As set forth herein, aspects of the present disclosure include a composition that includes: a polyalkylene oxide-asparaginase that includes a polyalkylene oxide group covalently linked by a linker to an asparaginase; a buffer and a salt. In certain embodiments, as described above, the polyalkylene oxide is a polyethylene glycol. In certain embodiments, as described above, the linker is a urethane (carbamate) linker. In certain embodiments, as described above, the asparaginase is an *E. coli* asparaginase. In the claimed invention, as described above, the buffer is a phosphate buffer. In certain embodiments, as described above, the salt is sodium chloride. Accordingly, certain embodiments of the composition include a polyethylene glycol-asparaginase that includes a polyethylene glycol group covalently linked by a urethane linker to an *E. coli* asparaginase; a phosphate buffer and a salt. Each of the components of these compositions (e.g., molecular weight of polyethylene glycol, amount of polyethylene glycol-asparaginase, amount and type of phosphate buffer, amount and type of salt) is as described in detail above.

[0071] As set forth herein, aspects of the present disclosure include a lyophilized storage stable composition that includes: a polyalkylene oxide-asparaginase that includes a polyalkylene oxide group covalently linked by a linker to an asparaginase; a buffer, a salt and a sugar. In certain embodiments, as described above, the polyalkylene oxide is a polyethylene glycol. In certain embodiments, as described above, the linker is a urethane (carbamate) linker. In certain embodiments, as described above, the asparaginase is an *E. coli* asparaginase. In certain embodiments, as described above, the buffer is a phosphate buffer. In certain embodiments, as described above, the salt is sodium chloride. In certain embodiments, as described above, the sugar is a disaccharide (e.g., sucrose). Accordingly, certain embodiments of the lyophilized storage stable composition include a polyethylene glycol-asparaginase that includes a polyethylene glycol group covalently linked by a urethane linker to an *E. coli* asparaginase; a phosphate buffer, a salt and a disaccharide. Each of the components of these compositions (e.g., molecular weight of polyethylene glycol, amount of polyethylene glycol-asparaginase, amount and type of phosphate buffer, amount and type of salt, amount and type of disaccharide, etc.) is as described in detail above.

[0072] Compositions of the present disclosure may also include other components, such as additional pharmaceutically acceptable excipients or a dosage delivery vehicle as part of the composition. Excipients may include, carbohydrates, inorganic salts, organic salts, antimicrobial agents, antioxidants, surfactants, water (e.g., water for injection (WFI)), alcohols, polyols, glycerine, vegetable oils, phospholipids, buffers, acids, bases, and any combinations thereof. A carbohydrate such as a sugar, a derivatized sugar such as an alditol, aldonic acid, an esterified sugar, and/or a sugar polymer may also be employed. Some

carbohydrate excipients of interest include, for example, monosaccharides, such as fructose, maltose, galactose, glucose, D-mannose, sorbose; disaccharides, such as lactose, sucrose, trehalose, cellobiose; polysaccharides, such as raffinose, melezitose, maltodextrins, dextrans, starches; and alditols, such as mannitol, xylitol, maltitol, lactitol, xylitol, sorbitol (glucitol), pyranosyl sorbitol, myoinositol. Inorganic and organic salts may include, citric acid, sodium chloride, potassium chloride,

sodium sulfate, potassium nitrate, monobasic sodium phosphate, dibasic sodium phosphate, and any combinations thereof.

[0073] In certain embodiments, compositions of the present disclosure may also include an antimicrobial agent for preventing or deterring microbial growth, such as for example benzalkonium chloride, benzethonium chloride, benzyl alcohol, cetylpyridinium chloride, chlorobutanol, phenol, phenylethyl alcohol, phenylmercuric nitrate, thimersol, and any combinations thereof.

[0074] One or more antioxidants may also be included in the composition. Antioxidants, which can reduce or prevent oxidation and thus deterioration of the composition, may include, for example, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, hypophosphorous acid, monothioglycerol, propyl gallate, sodium bisulfite, sodium formaldehyde sulfoxylate, sodium metabisulfite, and any combinations thereof.


[0075] One or more surfactants may also be included in compositions of the present disclosure. For example, suitable surfactants may include, polysorbates, such as "Tween 20" and "Tween 80," and pluronics such as F68 and F88 (BASF, Mount Olive, New Jersey); sorbitan esters; lipids, such as phospholipids such as lecithin and other phosphatidylcholines, phosphatidylethanolamines, fatty acids and fatty esters; steroids, such as cholesterol; chelating agents, such as EDTA; and zinc and other cations.

[0076] Acids or bases may also be present in compositions of the present disclosure. For example, acids may include hydrochloric acid, acetic acid, phosphoric acid, citric acid, malic acid, lactic acid, formic acid, trichloroacetic acid, nitric acid, perchloric acid, phosphoric acid, sulfuric acid, fumaric acid, and any combinations thereof. Examples of bases include, sodium hydroxide, sodium acetate, ammonium hydroxide, potassium hydroxide, ammonium acetate, potassium acetate, sodium phosphate, potassium phosphate, sodium citrate, sodium formate, sodium sulfate, potassium sulfate, potassium fumerate, and any combinations thereof.

[0077] The amount of any individual excipient in the composition may vary depending on the nature and function of the excipient, dosage delivery vehicle and particular needs of the composition. In some instances, the optimal amount of any individual excipient is determined through routine experimentation, i.e., by preparing compositions containing varying amounts of the excipient (ranging from low to high), examining the stability and other parameters, and then determining the range at which optimal performance is attained with no significant adverse effects. Generally, however, the excipient(s) will be present in the composition in an amount of 1% to 99% by weight, such as from 5% to 98% by weight, such as from 15% to 95% by weight of the excipient, including 30% or less by weight, or 20 % or less by weight, or 10% or less by weight. Pharmaceutical excipients along with other excipients that may be employed in the compositions are described in "Remington: The Science & Practice of Pharmacy", 22nd ed., Williams & Williams, (2012), the "Physician's Desk Reference", 70th ed., PDR Network, Montvale, NJ (2015), and Rowe, RC., Handbook of Pharmaceutical Excipients, 7th ed., Pharmaceutical Press, New York, NY, (2012).

METHODS OF USE (not claimed)

[0078] Aspects of the present disclosure, which is not claimed, also include methods of using the compositions (e.g., liquid and lyophilized) described herein. In certain embodiments, the method of use is a method of deaminating asparagine in a subject. As described above, the asparaginase enzyme can mediate a deamination reaction where the amino acid asparagine is hydrolyzed to produce aspartate and ammonia, e.g., according to the following reaction:



[0079] In some cases, the activity of asparaginase reduces the concentration of asparagine in a subject, such as reduces the plasma concentration of asparagine in the subject. A depletion of asparagine in a subject may adversely affect cells in the subject that depend on the presence of asparagine for protein synthesis. For example, protein synthesis in cells that lack the ability to synthesize their own asparagine (e.g., cells that lack the enzyme asparagine synthetase) may be adversely affected by a lack of exogenous asparagine, which in turn may lead to apoptosis of the cells. In some instances, cells in a subject that depend on the presence of asparagine for protein synthesis may be associated with a neoplastic condition, such as a cancer. Accordingly, methods of the present disclosure include methods for treating a subject for a neoplastic condition, such as methods of treating a subject for a cancer. Accordingly, compositions of the present disclosure that include a polyalkylene oxide-asparaginase may be therapeutically effective for the treatment of neoplastic conditions, such as a cancer. In certain embodiments, non-neoplastic cells in the subject are not significantly affected by the polyalkylene oxide-asparaginase compositions of the present disclosure. For instance, non-neoplastic cells in the subject may have the enzyme asparagine synthetase, and thus retain the ability to synthesize asparagine.

[0080] In certain embodiments, the neoplastic condition to be treated in the subject includes neoplastic conditions that are amenable to treatment by administration of a polyalkylene oxide-asparaginase to the subject, e.g., neoplastic conditions that depend on exogenous asparagine. For example, neoplastic conditions that may be treated by administering a polyalkylene oxide-asparaginase to a subject include cancers, such as solid tumors or liquid tumors.

[0081] In certain cases, the neoplastic condition is characterized by the presence of a solid tumor. Accordingly, in some embodiments, a method of the present disclosure, which is not claimed, is a method of treating a subject for a solid tumor using a polyalkylene oxide-asparaginase (e.g., liquid or a reconstituted lyophilized polyalkylene oxide-asparaginase composition of the present disclosure). Methods of treating a subject for a neoplastic condition are useful for treating a wide variety of solid tumors, including carcinomas and sarcomas. Types of solid tumors may include pancreatic cancer, melanoma, squamous cell cancer, non- squamous cell lung cancer (NSCLC), colon cancer, breast cancer, ovarian cancer, cervical cancer, prostate cancer. For example, carcinomas that can be treated using a subject method include, esophageal carcinoma, hepatocellular carcinoma, basal cell carcinoma (a form of skin cancer), squamous cell carcinoma (various tissues), bladder carcinoma, including transitional cell carcinoma (a malignant neoplasm of the bladder), bronchogenic carcinoma, colon carcinoma, colorectal carcinoma, gastric carcinoma, lung carcinoma, including small cell carcinoma and non-small cell carcinoma of the lung, adrenocortical carcinoma, thyroid carcinoma, pancreatic carcinoma, breast carcinoma, ovarian carcinoma, prostate carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, cystadenocarcinoma, medullary carcinoma, renal cell carcinoma, ductal carcinoma in situ or bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical carcinoma, uterine carcinoma, testicular carcinoma, osteogenic carcinoma, epithelial carcinoma, and nasopharyngeal carcinoma, etc.

[0082] Sarcomas that can be treated using a subject method include, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, chordoma, osteogenic sarcoma, osteosarcoma, angiosarcoma,

endothelioma, lymphangiosarcoma, lymphangioendothelioma, synovioma, mesothelioma, Ewing's sarcoma, leiomyosarcoma, rhabdomyosarcoma, and other soft tissue sarcomas.

[0083] Other solid tumors that can be treated using a subject method include, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendrolioma, menangioma, melanoma, neuroblastoma, and retinoblastoma.

[0084] In certain cases, the neoplastic condition is characterized by the presence of a liquid tumor. For instance, a liquid tumor may include metastatic cancer cells (e.g., circulating tumor cells (CTC)), blood cancers and combinations thereof. Examples of blood cancers include, leukemia, lymphoma and myeloma. In some instances, the cancer is leukemia. Accordingly, in some embodiments, which are not claimed, the method is a method of treating a subject for leukemia using a polyalkylene oxide-asparaginase (e.g., liquid or a reconstituted lyophilized polyalkylene oxide-asparaginase composition of the present disclosure).

[0085] Various types of leukemia may be amenable to treatment using the subject methods. For example, the leukemia may be an acute leukemia. An acute leukemia may be characterized by a rapid increase in the number of immature blood cells. A rapid increase in immature blood cells may result in crowding, which in turn may cause the bone marrow to produce significantly less healthy blood cells. Thus, methods of the present disclosure include methods for treating a subject for acute leukemia, e.g., by administering to the subject a dosage of a polyalkylene oxide-asparaginase (e.g., liquid or a reconstituted lyophilized polyalkylene oxide-asparaginase composition of the present disclosure) effective to treat the subject for acute leukemia.

[0086] In other instances, the leukemia is a chronic leukemia. In some cases, chronic leukemia may be characterized by an increase in the number of relatively mature, but abnormal, white blood cells. Chronic leukemia may take an extended period of time to develop (e.g., months or years), where the abnormal white blood cells are produced at a significantly higher rate than normal. Thus, methods of the present disclosure, which are not claimed, include methods for treating a subject for chronic leukemia, e.g., by administering to the subject a dosage of a polyalkylene oxide-asparaginase (e.g., liquid or a reconstituted lyophilized polyalkylene oxide-asparaginase composition of the present disclosure) effective to treat the subject for chronic leukemia.

[0087] In certain embodiments, the leukemia is a lymphoblastic leukemia (also referred to as lymphocytic leukemia). A lymphoblastic leukemia may be characterized by the type of blood cell affected by the leukemia. In lymphoblastic leukemia the abnormal change in the blood cells takes place in bone marrow cells that normally develop into lymphocytes. For example, lymphoblastic leukemia may be B-cell leukemia. Thus, methods of the present disclosure, which are not claimed, include methods for treating a subject for lymphoblastic leukemia (lymphocytic leukemia), e.g., by administering to the subject a dosage of a polyalkylene oxide-asparaginase (e.g., liquid or a reconstituted lyophilized polyalkylene oxide-asparaginase composition of the present disclosure) effective to treat the subject for lymphoblastic leukemia (lymphocytic leukemia). For example, a specific type of lymphoblastic leukemia that may be treated using the subject methods includes acute lymphoblastic leukemia (ALL). In these embodiments, methods of the present disclosure, which are not claimed, include methods for treating a subject for acute lymphoblastic leukemia (ALL), e.g., by administering to the subject a dosage of a polyalkylene oxide-asparaginase (e.g., liquid or a reconstituted lyophilized polyalkylene oxide-asparaginase composition of the present disclosure) effective to treat the subject for ALL. Other types of lymphoblastic leukemia that may be treated using the subject methods include, chronic lymphocytic leukemia (CLL). In these embodiments, methods of the present disclosure include methods for treating a subject for chronic lymphocytic leukemia (CLL), e.g., by administering to the subject a dosage of a polyalkylene oxide-asparaginase (e.g., liquid or a reconstituted lyophilized polyalkylene oxide- asparaginase composition of the present disclosure) effective to treat the subject for CLL.

[0088] In other embodiments, the leukemia is a myeloid leukemia (also referred to as myelogenous leukemia). A myeloid leukemia may be characterized by the type of blood cell affected by the leukemia. In myeloid

leukemia the abnormal change in the blood cells takes place in bone marrow cells that normally develop into red blood cells and/or platelets. Thus, methods of the present disclosure, which are not claimed, include methods for treating a subject for myeloid leukemia (myelogenous leukemia), e.g., by administering to the subject a dosage of a polyalkylene oxide- asparaginase (e.g., liquid or a reconstituted lyophilized polyalkylene oxide-asparaginase composition of the present disclosure) effective to treat the subject for myeloid leukemia (myelogenous leukemia). For example, a specific type of myeloid leukemia that may be treated using the subject methods includes acute myeloid leukemia (AML). In these embodiments, methods of the present disclosure, which are not claimed, include methods for treating a subject for acute myeloid leukemia (AML), e.g., by administering to the subject a dosage of a polyalkylene oxide-asparaginase (e.g., liquid or a reconstituted lyophilized polyalkylene oxide-asparaginase composition of the present disclosure) effective to treat the subject for AML.

[0089] Examples of AML include, AMLs with recurrent cytogenetic translocations, AML with multilineage dysplasia, and other AMLs. For instance, AMLs with recurrent cytogenetic translocations include, among others, AML with t(8;21)(q22;q22), AML(CBF-alpha)/ETO, Acute promyelocytic leukemia (AML with t(15; 17) (q22;q11-12) and variants, PML/RAR-alpha), AML with abnormal bone marrow eosinophils (inv(16)(p13q22) or t(16;16)(p13;q11), CBFb/MYH11 IX), and AML with 11q23 (MLL) abnormalities. Examples of AML with multilineage dysplasia may include those that are associated with or without prior myelodysplastic syndrome. Other types of acute myeloid leukemia include, for example, AML minimally differentiated, AML without maturation, AML with maturation, acute myelomonocytic leukemia, acute monocytic leukemia, acute erythroid leukemia, acute megakaryocytic leukemia, acute basophilic leukemia, and acute panmyelosis with myelofibrosis.

[0090] Other types of myeloid leukemia that may be treated using the subject methods include, chronic myelogenous leukemia (CML). In these embodiments, methods of the present disclosure include methods for treating a subject for chronic myelogenous leukemia (CML), e.g., by administering to the subject a dosage of a polyalkylene oxide-asparaginase (e.g., liquid or a reconstituted lyophilized polyalkylene oxide-asparaginase composition of the present disclosure) effective to treat the subject for CML.

[0091] In certain cases, asparaginase can mediate the deamination of glutamine, where the amino acid glutamine is hydrolyzed to produce glutamate and ammonia, e.g., according to the following reaction:



[0092] In some cases, the activity of asparaginase reduces the concentration of glutamine in a subject, such as reduces the plasma concentration of glutamine in the subject. Similar to the discussion above, a depletion of glutamine in a subject may adversely affect cells in the subject that depend on the presence of glutamine for protein synthesis. For example, protein synthesis in cells that lack the ability to synthesize their own glutamine (e.g., cells that lack the enzyme glutamine synthetase) may be adversely affected by a lack of exogenous glutamine, which in turn may lead to apoptosis of the cells. In some instances, cells in a subject that depend on the presence of glutamine for protein synthesis may be associated with a neoplastic condition, such as a cancer. Accordingly, methods of the present disclosure, which are not claimed, include methods for treating a subject for a neoplastic condition, such as methods of treating a subject for a cancer, where the neoplastic condition may depend on exogenous glutamine. For example, embodiments of the subject methods, which are not claimed, include methods of deaminating glutamine in a subject. In certain embodiments, non-neoplastic cells in the subject are not significantly affected by the polyalkylene oxide-asparaginase administered to the subject. For instance, non-neoplastic cells in the subject may have the enzyme glutamine synthetase, and thus retain the ability to synthesize glutamine.

[0093] As described above, compositions of the present disclosure include lyophilized storage stable

compositions. Prior to administration of the composition to a subject, a lyophilized composition may be combined with a liquid to provide a liquid composition suitable for administration, for example by injection or intravenously. In some cases, prior to administration of the composition to a subject, a lyophilized composition is combined with water (e.g., water for injection, WFI) to provide an aqueous composition suitable for administration, for example by injection or intravenously. For instance, methods of the present disclosure may include reconstituting a lyophilized composition (e.g., a lyophilized storage stable composition) of the present disclosure. Reconstituting a lyophilized composition may produce a reconstituted dosage unit. In some cases, the reconstituted dosage unit is suitable for administration to the subject, for example by injection or intravenously. In certain embodiments, reconstituting the lyophilized composition includes combining the lyophilized composition (e.g., the lyophilized storage stable composition) with water (e.g., water for injection, WFI).

[0094] The liquid or reconstituted dosage unit may include a predetermined quantity of the composition of the present disclosure calculated in an amount sufficient to produce a desired therapeutic effect in a subject. The amount of the composition in a dosage unit (e.g., liquid or reconstituted) that is administered to a subject may depend on the subject being treated, the severity of the affliction, and the manner of administration. For example, the dosage unit may include a quantity of the composition to be administered as disclosed herein in a therapeutically effective amount.

[0095] Certain embodiments of the dosage unit may include an amount of the polyalkylene oxide-asparaginase ranging from 100 to 5,000 IU/mL, such as 500 to 4,500 IU/mL, or 500 to 4,000 IU/mL, or 500 to 3,500 IU/mL, or 500 to 3,000 IU/mL, or 500 to 2,500 IU/mL, or 500 to 2,000 IU/mL, or 500 to 1,500 IU/mL, or 500 to 1,000 IU/mL, or 600 to 900 IU/mL, or, or 700 to 800 IU/mL. In certain instances, the dosage unit includes an amount of the polyalkylene oxide-asparaginase ranging from 500 to 1,000 IU/mL. In certain instances, the dosage unit includes an amount of the polyalkylene oxide-asparaginase ranging from 700 to 800 IU/mL. For example, the dosage unit may include 750 IU/mL of the polyalkylene oxide-asparaginase.

[0096] In certain embodiments, the dosage unit includes a therapeutically effective amount (e.g., specific activity) of the polyalkylene oxide-asparaginase, such as 50 IU/mg protein or more, such as 55 IU/mg protein or more, or 60 IU/mg protein or more, or 65 IU/mg protein or more, or 70 IU/mg protein or more, or 75 IU/mg protein or more, or 80 IU/mg protein or more, or 85 IU/mg protein or more, or 90 IU/mg protein or more, or 95 IU/mg protein or more, or 100 IU/mg protein or more, or 105 IU/mg protein or more, or 110 IU/mg protein or more, or 115 IU/mg protein or more, or 120 IU/mg protein or more, or 125 IU/mg protein or more, or 130 IU/mg protein or more, or 135 IU/mg protein or more, or 140 IU/mg protein or more, or 145 IU/mg protein or more, or 150 IU/mg protein or more. For instance, the dosage unit may have a specific activity of 85 IU/mg protein or more. In some embodiments, the dosage unit has a specific activity ranging from 50 to 150 IU/mg protein, or 55 to 145 IU/mg protein, or 60 to 140 IU/mg protein, or 65 to 135 IU/mg protein, or 70 to 130 IU/mg protein, or 75 to 125 IU/mg protein, or 80 to 120 IU/mg protein, or 85 to 115 IU/mg protein, or 90 to 110 IU/mg protein, or 95 to 105 IU/mg protein. In some cases, the dosage unit has a specific activity ranging from 50 to 150 IU/mg protein, such as 65 to 140 IU/mg protein, or 70 to 135 IU/mg protein, or 75 to 130 IU/mg protein, or 75 to 125 IU/mg protein. For instance, the dosage unit may have a specific activity ranging from 75 to 125 IU/mg protein.

[0097] In certain embodiments, the dosage unit includes a therapeutically effective amount (e.g., protein concentration) of the polyalkylene oxide-asparaginase in an amount ranging from 1 mg/mL to 15 mg/mL, such as 1.5 mg/mL to 14.5 mg/mL, or 2 mg/mL to 14 mg/mL, or 2.5 mg/mL to 13.5 mg/mL, or 3 mg/mL to 13 mg/mL, or 3.5 mg/mL to 12.5 mg/mL, or 4 mg/mL to 12 mg/mL, or 4.5 mg/mL to 11.5 mg/mL, or 4.5 mg/mL to 11 mg/mL, or 4.5 mg/mL to 10.5 mg/mL, or 4.5 mg/mL to 10 mg/mL, or 4.5 mg/mL to 9.5 mg/mL, or 4.5 mg/mL to 9 mg/mL, or 4.5 mg/mL to 8.5 mg/mL, or 5 mg/mL to 8 mg/mL. In some cases, the dosage unit includes the polyalkylene oxide-asparaginase in an amount ranging from 4.5 mg/mL to 8.5 mg/mL.

[0098] When administered to a subject, the dosage unit may include a therapeutically effective amount of the

polyalkylene oxide-asparaginase such that the dosage unit delivers from 100 to 5,000 IU/m² of the polyalkylene oxide-asparaginase to the subject, such as from 500 to 5,000 IU/m², or 500 to 4,500 IU/m², or 500 to 4,000 IU/m², or 500 to 3,500 IU/m², or 500 to 3,000 IU/m², or 1,000 to 3,000 IU/m², or 1,500 to 3,000 IU/m², or 1,750 to 3,000 IU/m², or 2,000 to 3,000 IU/m², or 2,000 to 2,750 IU/m², or 2,250 to 2,750 IU/m² of the polyalkylene oxide-asparaginase to the subject. For example, the dosage unit may deliver from 1,500 to 3,000 IU/m² of the polyalkylene oxide-asparaginase to the subject. In certain instances, the dosage unit delivers from 2,000 to 2,750 IU/m² of the polyalkylene oxide-asparaginase to the subject. In certain instances, the dosage unit delivers from 2,250 to 2,750 IU/m² of the polyalkylene oxide-asparaginase to the subject. For instance, the dosage unit may deliver 2,500 IU/m² of the polyalkylene oxide-asparaginase to the subject.

[0099] In certain embodiments, the dosage unit includes a buffer, such as a buffer described in detail above. For instance, the dosage unit may include a phosphate buffer, and as such may include dibasic sodium phosphate and monobasic sodium phosphate.

[0100] In some cases, the dosage unit includes a phosphate buffer, and as such may include dibasic sodium phosphate and monobasic sodium phosphate. In certain instances, the dosage unit includes dibasic sodium phosphate in an amount ranging from 0.5 to 10 mg/g, such as 1 to 9 mg/g, or 1 to 8 mg/g, or 1 to 7 mg/g, or 2 to 7 mg/g, or 3 to 6 mg/g, or 4 to 6 mg/g, or 5 to 6 mg/g. For instance, the dosage unit may include dibasic sodium phosphate in an amount ranging from 4 to 6 mg/g. In certain instances, the dosage unit includes dibasic sodium phosphate in an amount ranging from 5 to 6 mg/g. For example, the dosage unit may include dibasic sodium phosphate in an amount of about 5.5 mg/g, such as 5.6 mg/g (or 5,58 mg/g). In certain embodiments, the dosage unit includes monobasic sodium phosphate in an amount ranging from 0.05 to 5 mg/g, such as 0.1 to 4.5 mg/g, or 0.1 to 4 mg/g, or 0.1 to 3.5 mg/g, or 0.1 to 3 mg/g, or 0.1 to 2.5 mg/g, or 0.1 to 2 mg/g, or 0.5 to 2 mg/g, or 1 to 2 mg/g, or 1 to 1.5 mg/g. For instance, the dosage unit may include monobasic sodium phosphate in an amount ranging from 1 to 2 mg/g. In certain instances, the dosage unit includes monobasic sodium phosphate in an amount ranging from 1 to 1.5 mg/g. For instance, the dosage unit may include monobasic sodium phosphate in an amount of 1.2 mg/g (or 1.29 mg/g).

[0101] In certain embodiments, the dosage unit includes a salt. Salts suitable for use in the dosage unit include salts that are compatible with the polyalkylene oxide-asparaginase and suitable for administration to a subject, e.g., by injection or intravenous administration. Examples of suitable salts include, sodium chloride, potassium chloride, calcium chloride, magnesium chloride, and combinations thereof.

[0102] In certain instances, the dosage unit includes a salt, such as sodium chloride. In some cases, the dosage unit includes a salt (e.g., sodium chloride) in an amount ranging from 1 to 20 mg/g, such as 1 to 19 mg/g, or 1 to 18 mg/g, or 1 to 17 mg/g, or 1 to 16 mg/g, or 1 to 15 mg/g, or 2 to 15 mg/g, or 3 to 15 mg/g, or 4 to 15 mg/g, or 5 to 14 mg/g, or 5 to 13 mg/g, or 5 to 12 mg/g, or 5 to 11 mg/g, or 5 to 10 mg/g, or 5 to 9 mg/g, or 6 to 9 mg/g, or 7 to 9 mg/g, or 8 to 9 mg/g.

[0103] For instance, the dosage unit may include a salt (e.g., sodium chloride) in an amount ranging from 1 to 10 mg/g. In certain instances, the dosage unit includes a salt (e.g., sodium chloride) in an amount ranging from 5 to 10 mg/g. In certain instances, the dosage unit includes a salt (e.g., sodium chloride) in an amount ranging from 6 to 9 mg/g. In certain instances, the dosage unit includes a salt (e.g., sodium chloride) in an amount ranging from 8 to 9 mg/g. For instance, the dosage unit may include a salt (e.g., sodium chloride) in an amount of 8.5 mg/g.

[0104] In some instances, the formulation that is administered to a subject is the PEG-asparaginase liquid injection formulation known commercially as Oncaspar® which is approved for commercial marketing by the U.S. Food and Drug Administration. Oncaspar® (pegasparase) is L-asparaginase (L-asparagine amidohydrolase) that is covalently conjugated to monomethyoxypolyethylene glycol (mPEG), which is present

in a clear, colorless, preservative-free, isotonic sterile solution in phosphate-buffered saline, pH 7.3. Each milliliter contains 750± 150 International Units of pegaspargase, dibasic sodium phosphate, USP (5.58 mg), monobasic sodium phosphate, USP (1.20 mg) and sodium chloride, USP (9.5 mg) in water for injection, USP.

[0105] In certain embodiments, the dosage unit administered to the subject is a dosage unit prepared from a lyophilized composition, for example a lyophilized storage stable composition as described herein. The dosage unit prepared from the lyophilized composition may be a liquid dosage. In addition to the polyalkylene oxide-asparaginase, embodiments of the dosage unit (e.g., a dosage reconstituted from a lyophilized composition) may include a buffer, a salt and a sugar.

[0106] In certain embodiments, the reconstituted dosage unit includes a buffer, such as a buffer described in detail above. In some cases, the reconstituted dosage unit includes dibasic sodium phosphate in an amount ranging from 0.5 to 10 mg/g, such as 1 to 9 mg/g, or 1 to 8 mg/g, or 1 to 7 mg/g, or 1 to 6 mg/g, or 1 to 5 mg/g, or 1 to 4 mg/g, or 2 to 4 mg/g, or 2 to 3 mg/g, or 2.5 to 3 mg/g. For instance, the reconstituted dosage unit may include dibasic sodium phosphate in an amount ranging from 1 to 5 mg/g. In certain instances, the reconstituted dosage unit may include dibasic sodium phosphate in an amount ranging from 2 to 4 mg/g. In certain instances, the reconstituted dosage unit may include dibasic sodium phosphate in an amount ranging from 2.5 to 3 mg/g. For instance, the reconstituted dosage unit may include dibasic sodium phosphate in an amount of about 3 mg/g, such as 2.8 mg/g (or 2.79 mg/g). In certain embodiments, the reconstituted dosage unit includes monobasic sodium phosphate in an amount ranging from 0.05 to 1 mg/g, such as 0.1 to 0.9 mg/g, or 0.1 to 0.8 mg/g, or 0.2 to 0.8 mg/g, or 0.3 to 0.8 mg/g, or 0.4 to 0.8 mg/g, or 0.45 to 0.75 mg/g, or 0.5 to 0.7 mg/g. For instance, the reconstituted dosage unit may include monobasic sodium phosphate in an amount ranging from 0.45 to 0.75 mg/g. In certain instances, the reconstituted dosage unit includes monobasic sodium phosphate in an amount ranging from 0.5 to 0.7 mg/g. For instance, the reconstituted dosage unit may include monobasic sodium phosphate in an amount of 0.6 mg/g.

[0107] In certain embodiments, the reconstituted dosage unit includes a salt, such as a salt described in detail above. In certain instances, the reconstituted dosage unit includes a salt, such as sodium chloride. In some cases, the reconstituted dosage unit includes a salt (e.g., sodium chloride) in an amount ranging from 0.5 to 10 mg/g, such as 1 to 9 mg/g, or 1 to 8 mg/g, or 1 to 7 mg/g, or 1 to 6 mg/g, or 1 to 5 mg/g, or 2 to 5 mg/g, or 3 to 5 mg/g, or 4 to 5 mg/g, or 4 to 4.5 mg/g. For instance, the reconstituted dosage unit may include a salt (e.g., sodium chloride) in an amount ranging from 1 to 10 mg/g. In certain instances, the reconstituted dosage unit includes a salt (e.g., sodium chloride) in an amount ranging from 3 to 5 mg/g. In certain instances, the reconstituted dosage unit includes a salt (e.g., sodium chloride) in an amount ranging from 4 to 4.55 mg/g. For instance, the reconstituted dosage unit may include a salt (e.g., sodium chloride) in an amount of about 4 mg/g, such as 4.25 mg/g.

[0108] In certain embodiments, the reconstituted dosage unit includes a sugar, such as a sugar described in detail above. In certain instances, the reconstituted dosage unit includes a sugar, such as a disaccharide. In some cases, the reconstituted dosage unit includes a sugar, such as sucrose. In some cases, the reconstituted dosage unit includes an amount of sugar (e.g., sucrose) ranging from 1 to 250 mg/g, such as 5 to 200 mg/g, or 10 to 150 mg/g, or 10 to 100 mg/g, or 10 to 90 mg/g, or 10 to 80 mg/g, or 20 to 70 mg/g, or 20 to 60 mg/g, or 30 to 50 mg/g, or 40 to 50 mg/g. For instance, the reconstituted dosage unit may include a sugar (e.g., sucrose) in an amount ranging from 10 to 100 mg/g. In certain instances, the reconstituted dosage unit may include a sugar (e.g., sucrose) in an amount ranging from 30 to 50 mg/g. In certain instances, the reconstituted dosage unit may include a sugar (e.g., sucrose) in an amount ranging from 40 to 50 mg/g. For instance, the reconstituted dosage unit may include a sugar (e.g., sucrose) in an amount of 45 mg/g.

[0109] In certain embodiments, the dosage unit (e.g., liquid or reconstituted) has a pH compatible with physiological conditions. In some cases, the pH of the dosage unit ranges from 6 to 8. In some cases, the pH of the dosage unit ranges from 7 to 8. For example, the pH of the dosage unit may range from 7 to 7.5. In some cases, the pH of the dosage unit is 7.2. In some cases, the pH of the dosage unit is 7.3. In some cases,

the pH of the dosage unit is 7.4.

[0110] In certain embodiments, which are not claimed, the method may include administering the dosage unit to the subject to deaminate asparagines in the subject. The route of administration may be selected according to a variety of factors including the condition to be treated, the type of composition and/or device used, the patient to be treated. Routes of administration useful in the disclosed methods include, oral and parenteral routes, such as intravenous (iv), intraperitoneal (ip), intramuscular (im), rectal, topical, ophthalmic, nasal, and transdermal. For example, compositions suitable for injection can be administered by an intravenous, intramuscular, intradermal, subcutaneous, sublingual, intraosseous, or other route of administration.

[0111] In some instances, administering the dosage unit to the subject includes intravenously administering the dosage unit to the subject. In some cases, administering the dosage unit to the subject includes intramuscularly administering the dosage unit to the subject.

[0112] In some instances, administering the reconstituted dosage unit to the subject includes intravenously administering the reconstituted dosage unit to the subject. In some cases, administering the reconstituted dosage unit to the subject includes intramuscularly administering the reconstituted dosage unit to the subject.

[0113] In certain embodiments, which are not claimed, the method includes administering the dosage unit to the subject according to a treatment regimen. For example, in some cases, a subject to be treated may have been prescribed a treatment regimen from a health care provider. In some cases, a treatment regimen includes, administration five times per day, four times per day, three times per day, twice per day, once per day, three times per week, twice per week, once per week, once every two weeks, once every three weeks, once per month, once every 5 weeks, once every 6 weeks, once every 7 weeks, once every other month, and any combination thereof.

[0114] In some embodiments, the treatment regimen includes administering one or more doses over an extended period of time. In certain cases, a single dose (e.g., a single dosage unit) is administered to the subject, and the initial dose may be followed by one or more doses administered to the subject at a subsequent time. In some instances, more than one dose (e.g., more than one dosage unit) is administered to the subject, and the initial doses may be followed by one or more doses administered to the subject at a subsequent time. For example, a single dose (e.g., a single dosage unit) may be administered to the subject, and the single dose may be followed by a single dose administered to the subject at a subsequent time. Additional single doses may be administered at subsequent points in time. In other cases, a single dose (e.g., a single dosage unit) may be administered to the subject, and the single dose may be followed by two doses administered to the subject at a subsequent time. Additional single or multiple doses may be administered at subsequent points in time.

[0115] In certain instances, the treatment regimen includes multiple phases. The treatment regimen may include multiple phases where the dosage schedule is different in each phase of the treatment regimen. In some cases, a subject is prescribed a treatment regimen with two phases; an induction phase and a consolidation phase. In certain instances, a subject is prescribed a treatment regimen with two phases where the dosage schedule of the first phase is different than the dosage schedule in the second phase. For example, a subject may be prescribed a treatment regimen with two phases including an induction phase and a consolidation phase, where the

[0116] dosage schedule of the induction phase is different than the dosage schedule of the consolidation phase. In other embodiments, a subject may be prescribed a treatment regimen with three phases; an induction phase, a consolidation phase, and a maintenance phase. In some instances, a subject is prescribed a treatment regimen with three phases including an induction phase, a consolidation phase, and a maintenance phase, where the dosage schedule of each phase is different from the other phases. For

instance, a subject may be prescribed a treatment regimen with three phases including an induction phase, a consolidation phase, and a maintenance phase, where the dosage schedules of the induction phase, the consolidation phase, and the maintenance phase are each different from each other.

[0117] In certain embodiments, the length of the treatment time during each phase of the treatment regimen is the same, or in other cases may be different. For example, the length of time during the induction phase may be 1 week or more, such as 2 weeks or more, or 3 weeks or more, or 4 weeks or more, or 5 weeks or more, or 6 weeks or more, or 7 weeks or more, or 8 weeks or more, or 9 weeks or more, or 10 weeks or more, or 11 weeks or more, or 12 weeks or more, or 13 weeks or more, or 14 weeks or more, or 15 weeks or more, or 16 weeks or more, or 17 weeks or more, or 18 weeks or more, or 19 weeks or more, or 20 weeks or more, or 21 weeks or more, or 22 weeks or more, or 23 weeks or more, or 24 weeks or more, or 25 weeks or more, or 26 weeks or more, or 27 weeks or more, or 28 weeks or more, or 29 weeks or more, or 30 weeks or more, or 31 weeks or more, or 32 weeks or more. In some cases, the length of time during the induction phase is 4 weeks. In some cases, the length of time during the induction phase is 5 weeks.

[0118] In certain embodiments, the length of time during the consolidation phase is 1 week or more, such as 2 weeks or more, or 3 weeks or more, or 4 weeks or more, or 5 weeks or more, or 6 weeks or more, or 7 weeks or more, or 8 weeks or more, or 9 weeks or more, or 10 weeks or more, or 11 weeks or more, or 12 weeks or more, or 13 weeks or more, or 14 weeks or more, or 15 weeks or more, or 16 weeks or more, or 17 weeks or more, or 18 weeks or more, or 19 weeks or more, or 20 weeks or more, or 21 weeks or more, or 22 weeks or more, or 23 weeks or more, or 24 weeks or more, or 25 weeks or more, or 26 weeks or more, or 27 weeks or more, or 28 weeks or more, or 29 weeks or more, or 30 weeks or more, or 31 weeks or more, or 32 weeks or more. In some cases, the length of time during the consolidation phase is 8 weeks. In some cases, the length of time during the consolidation phase is 27 weeks. In some cases, the length of time during the consolidation phase is 30 weeks.

[0119] In certain embodiments, the length of time during the maintenance phase is 1 week or more, such as 2 weeks or more, or 3 weeks or more, or 4 weeks or more, or 5 weeks or more, or 6 weeks or more, or 7 weeks or more, or 8 weeks or more, or 9 weeks or more, or 10 weeks or more, or 12 weeks or more, or 16 weeks or more, or 20 weeks or more, or 24 weeks or more, or 28 weeks or more, or 32 weeks or more, or 36 weeks or more, or 40 weeks or more, or 44 weeks or more, or 48 weeks or more, or 52 weeks or more, or 56 weeks or more, or 60 weeks or more, or 64 weeks or more, or 68 weeks or more, or 72 weeks or more, or 76 weeks or more, or 80 weeks or more, or 84 weeks or more, or 88 weeks or more, or 92 weeks or more, or 96 weeks or more, or 100 weeks or more, or 104 weeks or more, or 108 weeks or more, or 112 weeks or more, or 116 weeks or more, or 120 weeks or more, or 124 weeks or more, or 128 weeks or more, or 132 weeks or more, or 136 weeks or more, or 140 weeks or more, or 144 weeks or more, or 148 weeks or more, or 152 weeks or more, or 156 weeks or more, or 160 weeks or more, or 164 weeks or more, or 168 weeks or more, or 172 weeks or more, or 176 weeks or more, or 180 weeks or more. In some cases, the length of time during the maintenance phase is 8 weeks. In some cases, the length of time during the maintenance phase is 88 weeks. In some cases, the length of time during the maintenance phase is 104 weeks. In some cases, the length of time during the consolidation phase is 140 weeks. In some cases, the length of time during the maintenance phase is 156 weeks. In some cases, the length of time during the maintenance phase ranges from 88 to 104 weeks. In some cases, the length of time during the maintenance phase ranges from 88 to 140 weeks. In some cases, the length of time during the maintenance phase ranges from 88 to 156 weeks.

[0120] Examples of the treatment regimens that may be administered to a subject include, those described here. In certain embodiments, the treatment regimen includes administering a single dosage unit to a subject in an induction phase and multiple dosage units during a maintenance phase. In certain embodiments, the treatment regimen includes administering a single dosage unit to a subject in an induction phase and multiple dosage units during a consolidation phase. For example, the multiple dosage units may be administered to the subject by administering a dosage unit to the subject every 3 weeks (e.g., during the consolidation phase). In some cases, a single dosage unit is administered to the subject once every 3 weeks. As described above, the consolidation phase may be 30 weeks, and thus a total of 10 dosage units may be administered to the subject (e.g., a single dosage unit may be administered to the subject once every 3 weeks for 30 weeks). Additional (or fewer) dosage units may be administered to the subject in between the induction phase and the consolidation phase, or after the consolidation phase, as desired or prescribed by a health care provider.

[0121] In other examples, the treatment regimen may include administering a single dosage unit to a subject in an induction phase and multiple dosage units during a consolidation phase, where the multiple dosage units may be administered to the subject by administering a dosage unit to the subject every 2 weeks. In some cases, a single dosage unit is administered to the subject once every 2 weeks. As described above, the consolidation phase may be 30 weeks, and thus a total of 15 dosage units may be administered to the subject (e.g., a single dosage unit may be administered to the subject once every 2 weeks for 30 weeks). Additional (or fewer) dosage units may be administered to the subject in between the induction phase and the consolidation phase, or after the consolidation phase, as desired or prescribed by a health care provider.

[0122] In other embodiments, the treatment regimen includes administering a single dosage unit to a subject in an induction phase, multiple dosage units during a consolidation phase, and multiple dosage units during a maintenance phase. For example, the multiple dosage units during the consolidation phase may be administered to the subject on certain days following initiation of the consolidation phase. In some instances, the multiple dosage units during the consolidation phase may be administered to the subject by administering more than one dosage unit to the subject at the same time. For example, the multiple dosage units during the consolidation phase may be administered to the subject by administering more than one dosage unit to the subject on a particular day following initiation of the consolidation phase and more than one dosage unit to the subject on a subsequent day during the consolidation phase. An example of this type of treatment regimen may include administering 2 dosage units to the subject on day 15 following initiation of the consolidation phase and 2 dosage units on day 43 following initiation of the consolidation phase. Additional (or fewer) dosage units may be administered to the subject in between the induction phase and the consolidation phase, or after the consolidation phase but before the maintenance phase, as desired or prescribed by a health care provider.

[0123] In certain embodiments, the multiple dosage units during the maintenance phase may be administered to the subject on certain days following initiation of the maintenance phase. In some instances, the multiple dosage units during the maintenance phase may be administered to the subject by administering more than one dosage unit to the subject at the same time. For example, the multiple units during the maintenance phase may be administered to the subject by administering more than one dosage unit to the subject on a particular day following initiation of the maintenance phase and more than one dosage unit to the subject on a subsequent day during the maintenance phase. An example of this type of treatment regimen may include administering 2 dosage units to the subject on day 2 following initiation of the maintenance phase and 2 dosage units on day 22 following initiation of the maintenance phase. Another example of a treatment regimen during the maintenance phase may include administering 2 dosage units to the subject on day 4 following initiation of the maintenance phase and 2 dosage units on day 43 following initiation of the maintenance phase. In some cases, a treatment regimen may include multiple maintenance phases. In certain instances, the dosage schedule during each maintenance phase may be the same, or in other instances the dosage schedule during each maintenance phase may be different. Additional (or fewer) dosage units may be administered to the subject in between the consolidation phase and the maintenance phase, or after the maintenance phase, or in between different maintenance phases, as desired or prescribed by a health care provider.

[0124] In certain embodiments, dosage units of the present disclosure can be administered prior to, concurrent with, or subsequent to other active agents for treating related or unrelated conditions, e.g., in combination therapy. Examples of such additional therapies include radiation therapies, surgical therapies and chemotherapeutic therapies. If provided at the same time as other active agents, dosage units of the present disclosure can be provided in the same or in a different formulation. For example, concurrent therapy may be achieved by administering a dosage unit and a pharmaceutical composition having at least one other active agent, such as a chemotherapeutic agent, which in combination provide a therapeutically effective dose, according to a particular treatment regimen. Administration of separate pharmaceutical compositions can be performed simultaneously or at different times (e.g., sequentially, in either order, on the same day, or on different days), as long as a therapeutically effective effect of the combination of these substances is caused in the subject undergoing therapy.

[0125] Accordingly, aspects of the present disclosure further include combination therapies. In certain embodiments, the subject method includes administering a therapeutically effective amount of one or more additional active agents. By combination therapy is meant that a polyalkylene oxide asparaginase (e.g., as described herein) can be used in a combination with another therapeutic agent to treat a single disease or condition. In certain embodiments, a compound of the present disclosure is administered concurrently with the administration of another therapeutic agent, which can be administered as a component of a composition including the compound of the present disclosure or as a component of a different composition. In certain embodiments, a composition including a compound of the present disclosure is administered prior or subsequent to administration of another therapeutic agent.

[0126] The subject compounds can be used jointly with any agent useful in the treatment of a neoplastic condition, such as anti-cancer agents and anti-tumor agents. One class of anti-cancer agents of interest includes chemotherapeutic agents. "Chemotherapy" means the administration of one or more chemotherapeutic drugs and/or other agents to a cancer patient by various methods, including intravenous, oral, intramuscular, intraperitoneal, intravesical, subcutaneous, transdermal, buccal, or inhalation. Agents of interest which can be used in jointly with the subject compounds include, Cancer chemotherapeutic agents, Agents that act to reduce cellular proliferation, Antimetabolite agents , Microtubule affecting agents, Hormone modulators and steroids, natural products and Biological response modifiers, e.g., as described in greater detail below.

[0127] Cancer chemotherapeutic agents include non-peptidic (i.e., non-proteinaceous) compounds that reduce proliferation of cancer cells, and encompass cytotoxic agents and cytostatic agents. Non-limiting examples of chemotherapeutic agents include alkylating agents, nitrosoureas, antimetabolites, antitumor antibiotics, plant (vinca) alkaloids, and steroid hormones. Peptidic compounds can also be used. Suitable cancer chemotherapeutic agents include dolastatin and active analogs and derivatives thereof; and auristatin and active analogs and derivatives thereof (e.g., Monomethyl auristatin D (MMAD), monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF)). See, e.g., WO 96/33212, WO 96/14856, and U.S. 6,323,315. For example, dolastatin 10 or auristatin PE can be included in an antibody-drug conjugate of the present disclosure. Suitable cancer chemotherapeutic agents also include maytansinoids and active analogs and derivatives thereof (see, e.g., EP 1391213; and Liu et al (1996) Proc. Natl. Acad. Sci. USA 93:8618-8623); duocarmycins and active analogs and derivatives thereof (e.g., including the synthetic analogues, KW-2189 and CB 1-TM); and benzodiazepines and active analogs and derivatives thereof (e.g., pyrrolobenzodiazepine (PBD)).

[0128] Agents that act to reduce cellular proliferation are known in the art and widely used. Such agents include alkylating agents, such as nitrogen mustards, nitrosoureas, ethylenimine derivatives, alkyl sulfonates, and triazenes, including mechlorethamine, cyclophosphamide (Cytoxan™), melphalan (L-sarcolysin), carmustine (BCNU), lomustine (CCNU), semustine (methyl-CCNU), streptozocin, chlorozotocin, uracil mustard, chlormethine, ifosfamide, chlorambucil, pipobroman, triethylenemelamine, triethylenethiophosphoramide, busulfan, dacarbazine, and temozolomide.

[0129] Antimetabolite agents include folic acid analogs, pyrimidine analogs, purine analogs, and adenosine deaminase inhibitors, including cytarabine (CYTOSAR-U), cytosine arabinoside, fluorouracil (5-FU), flouxuridine (FudR), 6-thioguanine, 6-mercaptopurine (6-MP), pentostatin, 5-fluorouracil (5-FU), methotrexate, 10-propargyl-5,8-dideazafolate (PDDF, CB3717), 5,8-dideazatetrahydrofolic acid (DDATHF), leucovorin, fludarabine phosphate, pentostatine, and gemcitabine.

[0130] Suitable natural products and their derivatives, (e.g., vinca alkaloids, antitumor antibiotics, enzymes, lymphokines, and epipodophyllotoxins), include, Ara-C, paclitaxel (Taxol®), docetaxel (Taxotere®), deoxycoformycin, mitomycin-C, azathioprine; brequinar; alkaloids, e.g. vincristine, vinblastine, vinorelbine, vindesine, etc.; podophyllotoxins, e.g. etoposide, teniposide, etc.; antibiotics, e.g. anthracycline, daunorubicin

hydrochloride (daunomycin, rubidomycin, cerubidine), idarubicin, doxorubicin, epirubicin and morpholino derivatives, etc.; phenoxizone biscyclopeptides, e.g. dactinomycin; basic glycopeptides, e.g. bleomycin; anthraquinone glycosides, e.g. plicamycin (mithramycin); anthracenediones, e.g. mitoxantrone; azirinopyrrolo indolediones, e.g. mitomycin; macrocyclic immunosuppressants, e.g. cyclosporine, FK-506 (tacrolimus, prograf), rapamycin, etc..

[0131] Other anti-proliferative cytotoxic agents are navelbene, CPT-11, anastrazole, letrozole, capecitabine, relaxafine, cyclophosphamide, ifosamide, and droloxafine. Microtubule affecting agents that have antiproliferative activity are also suitable for use and include, allocolchicine (NSC 406042), Halichondrin B (NSC 609395), colchicine (NSC 757), colchicine derivatives (e.g., NSC 33410), dolstatin 10 (NSC 376128), maytansine (NSC 153858), rhizoxin (NSC 332598), paclitaxel (Taxol®), Taxol® derivatives, docetaxel (Taxotere®), thiocolchicine (NSC 361792), trityl cysterin, vinblastine sulfate, vincristine sulfate, natural and synthetic epothilones including eophthilone A, eophthilone B, discodermolide; estramustine, nocodazole.

[0132] Hormone modulators and steroids (including synthetic analogs) that are suitable for use include, adrenocorticosteroids, e.g. prednisone, dexamethasone, etc.; estrogens and pregestins, e.g. hydroxyprogesterone caproate, medroxyprogesterone acetate, megestrol acetate, estradiol, clomiphene, tamoxifen; etc.; and adrenocortical suppressants, e.g. aminoglutethimide; 1 7a-ethinylestradiol; diethylstilbestrol, testosterone, fluoxymesterone, dromostanolone propionate, testolactone, methylprednisolone, methyl-testosterone, prednisolone, triamcinolone, chlorotrianisene, hydroxyprogesterone, aminoglutethimide, estramustine, medroxyprogesterone acetate, leuprolide, Flutamide (Drogenil), Toremifene (Fareston), and Zoladex®. Estrogens stimulate proliferation and differentiation; therefore compounds that bind to the estrogen receptor are used to block this activity. Corticosteroids may inhibit T cell proliferation.

[0133] Other suitable chemotherapeutic agents include metal complexes, e.g. cisplatin (cis-DDP), carboplatin, etc.; ureas, e.g. hydroxyurea; and hydrazines, e.g. N-methylhydrazine; epidophyllotoxin; a topoisomerase inhibitor; procarbazine; mitoxantrone; leucovorin; tegafur; etc. Other anti-proliferative agents of interest include immunosuppressants, e.g. mycophenolic acid, thalidomide, desoxyspergualin, azasporine, leflunomide, mizoribine, azaspirane (SKF 105685); Iressa® (ZD 1839, 4-(3-chloro-4-fluorophenylamino)-7-methoxy-6-(3-(4-morpholiny)propoxy)quinazoline); etc.

[0134] Taxanes are suitable for use. "Taxanes" include paclitaxel, as well as any active taxane derivative or pro-drug. "Paclitaxel" (which should be understood herein to include analogues, formulations, and derivatives such as, for example, docetaxel, TAXOL™, TAXOTERE™ (a formulation of docetaxel), 10-desacetyl analogs of paclitaxel and 3'N-desbenzoyl-3'N-t-butoxycarbonyl analogs of paclitaxel) may be readily prepared utilizing techniques known to those skilled in the art (see also WO 94/07882, WO 94/07881, WO 94/07880, WO 94/07876, WO 93/23555, WO 93/10076; U.S. Pat. Nos. 5,294,637; 5,283,253; 5,279,949; 5,274,137; 5,202,448; 5,200,534; 5,229,529; and EP 590,267), or obtained from a variety of commercial sources, including for example, Sigma Chemical Co., St. Louis, Mo. (T7402 from *Taxus brevifolia*; or T-1912 from *Taxus yunnanensis*). Paclitaxel should be understood to refer to not only the common chemically available form of paclitaxel, but analogs and derivatives (e.g., Taxotere™ docetaxel, as noted above) and paclitaxel conjugates (e.g., paclitaxel-PEG, paclitaxel-dextran, or paclitaxel-xylose). Also included within the term "taxane" are a variety of known derivatives, including both hydrophilic derivatives, and hydrophobic derivatives. Taxane derivatives include galactose and mannose derivatives described in International Patent Application No. WO 99/18113; piperazino and other derivatives described in WO 99/14209; taxane derivatives described in WO 99/09021, WO 98/22451, and U.S. Patent No. 5,869,680; 6-thio derivatives described in WO 98/28288; sulfonamide derivatives described in U.S. Patent No. 5,821,263; and taxol derivative described in U.S. Patent No. 5,415,869. It further includes prodrugs of paclitaxel including those described in WO 98/58927; WO 98/13059; and U.S. Patent No. 5,824,701.

[0135] Biological response modifiers suitable for use include, (1) inhibitors of tyrosine kinase (RTK) activity; (2)

inhibitors of serine/threonine kinase activity; (3) tumor-associated antigen antagonists, such as antibodies that bind specifically to a tumor antigen; (4) apoptosis receptor agonists; (5) interleukin-2; (6) IFN- α ; (7) IFN- γ ; (8) colony stimulating factors; and (9) inhibitors of angiogenesis.

[0136] Subjects that may be treated using the methods and compositions of the present disclosure include subjects of any age. In some cases, the subject may be an adult. For example a human adult subject may be 18 years or older. Subjects that may be treated using the methods and compositions of the present disclosure also include juvenile subjects. For example a human juvenile subject may be less than 18 years old. In some instances, the subjects range in agent from 1 month to 18 years, such as 1 year to 18 years, including 2 years to 18 years, e.g., 5 years to 16 years.

[0137] In some instances, the methods include diagnosing a subject as having AML. A subject may be diagnosed as having AML using any convenient protocol. In some instances, the French, American, and British (FAB) classification system is employed to diagnose and classify acute myeloid leukemia. The diagnosis of acute myeloid leukemia requires that myeloblasts constitute 30% (or 20% based on a recent World Health Organization (WHO) classification system) or more of bone marrow cells or circulating white blood cells. The hematologic properties of the disease, defines the various subtypes described below. The FAB nomenclature (M1 through M7) classifies the subtypes of acute myeloid leukemia according to the normal marrow elements that the blasts most closely resemble. In some instances, the methods include determining suitability of a subject diagnosed as having AML for treatment using a polyalkylene oxide asparaginase composition, e.g., as described herein. In some instances, the methods include monitoring the effectiveness of treatment. Effectiveness of treatment may be monitored using any convenient protocol.

METHODS OF MAKING

[0138] Aspects of the present disclosure include methods of making the polyalkylene oxide-asparaginase compositions described herein. In certain cases, the method is a method of making a liquid polyalkylene oxide-asparaginase composition as described herein. The method may include producing an aqueous composition that includes a polyalkylene oxide-asparaginase having a polyalkylene oxide group covalently linked by a linker to an asparaginase, a buffer, and a salt.

[0139] Embodiments of the methods of making the polyalkylene oxide-asparaginase composition may include producing an aqueous concentrate composition. For example, the method for producing the aqueous concentrate composition may include one or more of the steps of: preparing a solution of asparaginase (e.g., L-asparaginase); attaching a polyalkylene oxide (e.g., polyethylene glycol) to the asparaginase; clarifying the polyalkylene oxide-asparaginase; filtering and concentrating the solution of the polyalkylene oxide-asparaginase; diluting the solution of the polyalkylene oxide-asparaginase; filtering the solution of the polyalkylene oxide-asparaginase and filling the solution of the polyalkylene oxide-asparaginase into a sterile container; and storing the solution of the polyalkylene oxide-asparaginase.

[0140] In the method for producing the aqueous concentrate composition, a solution of asparaginase (e.g., L-asparaginase) may be prepared. The asparaginase may be mixed with a solution, such as an aqueous solution (e.g., a buffered aqueous solution). Examples of suitable buffers include, a phosphate buffer, phosphate buffered saline (PBS), Dulbecco's phosphate buffered saline (DPBS), Hank's balanced salt solution (HBSS), Earle's balanced salt solution (EBSS), Tris buffer, Ringer's lactate buffer, borate buffer and combinations thereof. In the claimed invention, the asparaginase is mixed with a phosphate buffer.

[0141] The phosphate buffer includes dibasic sodium phosphate and monobasic sodium phosphate. In some cases, the amount of dibasic sodium phosphate in the aqueous concentrate composition ranges from 0.1 to 0.8 wt.%, or 0.1 to 0.7 wt.%, or 0.1 to 0.6 wt.%, or 0.2 to 0.6 wt.%, or 0.3 to 0.6 wt.%, or 0.4 to 0.6 wt.%, or 0.5

to 0.6 wt.%. In certain instances, the dibasic sodium phosphate may be present in the composition in an amount ranging from 0.2 to 0.8 wt. %. In certain instances, the dibasic sodium phosphate may be present in the composition in an amount ranging from 0.3 to 0.6 wt. %. In certain instances, the dibasic sodium phosphate may be present in the composition in an amount ranging from 0.5 to 0.6 wt. %. For instance, the dibasic sodium phosphate may be present in the composition in an amount of about 0.6 wt. %, such as 0.56 wt. % (or 0.558 wt. %). In certain embodiments, the amount of monobasic sodium phosphate in the aqueous concentrate composition ranges 0.01 to 0.4 wt.%, or 0.01 to 0.2 wt.%, or 0.02 to 0.18 wt. %, or 0.03 to 0.16 wt. %, or 0.04 to 0.16 wt. %, or 0.045 to 0.15 wt. %, or 0.04 to 0.14 wt. %, or 0.05 to 0.14 wt. %, or 0.1 to 0.2 wt. %, or 0.1 to 0.15 wt. %. For instance, the monobasic sodium phosphate may be present in the aqueous concentrate composition in an amount ranging from 0.05 to 0.2 wt. In certain instances, the monobasic sodium phosphate may be present in the composition in an amount ranging from 0.01 to 0.2 wt. %. In certain instances, the monobasic sodium phosphate may be present in the composition in an amount ranging from 0.09 to 0.15 wt. %. In certain instances, the monobasic sodium phosphate may be present in the composition in an amount ranging from 0.1 to 0.2 wt. %. In certain instances, the monobasic sodium phosphate may be present in the composition in an amount ranging from 0.1 to 0.15 wt.

[0142] %. For instance, the monobasic sodium phosphate may be present in the composition in an amount of 0.12wt. %(or 0.129 wt. %).

[0143] Additional components included in the aqueous concentrate composition include a salt. Examples of suitable salts include sodium chloride, potassium chloride, calcium chloride, magnesium chloride and combinations thereof. In certain instances, the salt is sodium chloride. In some cases, the amount of salt (e.g., sodium chloride) in the aqueous concentrate composition ranges from 0.1 to 1 wt. %, or 0.2 to 1 wt. %, or 0.3 to 1 wt. %, or 0.4 to 1 wt. %, or 0.5 to 1 wt. %, or 0.6 to 1 wt. %, or 0.7 to 1 wt. %, or 0.8 to 1 wt. %, or 0.8 to 0.9 wt. %. For instance, the salt (e.g., sodium chloride) may be present in the composition in an amount ranging from 0.5 to 1 wt. %. In certain instances, the salt (e.g., sodium chloride) may be present in the composition in an amount ranging from 0.7 to 1 wt. %. In certain instances, the salt (e.g., sodium chloride) may be present in the composition in an amount ranging from 0.8 to 0.9 wt. %. For instance, the salt (e.g., sodium chloride) may be present in the composition in an amount of 0.85 wt. %.

[0144] Other aspects of the present disclosure include methods of making the lyophilized storage stable compositions described herein. In certain cases, the method is a method of making a lyophilized polyalkylene oxide-asparaginase composition as described herein. The method may include lyophilizing an aqueous composition that includes a polyalkylene oxide-asparaginase having a polyalkylene oxide group covalently linked by a linker to an asparaginase, a buffer, a salt, and a sugar in a manner sufficient to produce a lyophilized storage stable polyalkylene oxide-asparaginase composition.

[0145] In certain embodiments, lyophilizing is used to dehydrate the aqueous concentrate composition. In some instances, lyophilizing includes removing water from the aqueous concentrate composition. The water may be removed by sublimating the water in the composition. For instance, the water in the composition may undergo a phase transition from a solid to a gas. In certain cases, lyophilizing includes freezing the composition (e.g., freezing the water in the composition) and then reducing the pressure surrounding the composition such that the water in the composition undergoes sublimation. During lyophilization, the temperature of the composition may be reduced, for example to a temperature below the freezing point of water in the composition. For example, the temperature of the composition may be reduced to 0 °C or less, or -5 °C or less, or -10 °C or less, or -15 °C or less, or -20 °C or less, or -25 °C or less, or -30 °C or less, or -35 °C or less, or -40 °C or less, or -45 °C or less, or -50 °C or less, or -55 °C or less, or -60 °C or less, or -65 °C or less, or -75 °C or less. In some cases, the temperature of the composition is reduced to -45 °C. In some cases, the temperature of the composition is reduced to -30 °C.

[0146] In certain embodiments, the pressure surrounding the composition is reduced below standard

atmospheric pressure. The SI unit for pressure is Pascal, which can be converted as 1 Torr = 133,322 Pa. For example, the pressure surrounding the composition may be reduced to 500 T or less, such as 250 T or less, or 100 T or less, or 50 T or less, or 10 T or less, or 1 T or less, or 500 mT or less, or 400 mT or less, or 300 mT or less, or 200 mT or less, or 100 mT or less, or 90 mT or less, or 80 mT or less, or 70 mT or less, or 60 mT or less, or 50 mT or less, or 40 mT or less, or 30 mT or less, or 20 mT or less, or 10 mT or less. In some cases, the pressure surrounding the composition is reduced to 60 mT or less, such as 50 mT.

[0147] In some embodiments, lyophilizing may also include increasing the temperature of the composition while the pressure surrounding the composition is reduced. For example, the temperature of the composition may be increased from a minimum temperature as described above to a temperature greater than the minimum temperature. In some cases, the temperature is increased to facilitate sublimation of the water in the composition at the reduced surrounding pressure.

[0148] Embodiments of the method of making the lyophilized polyalkylene oxide-asparaginase composition may also include producing the aqueous concentrate composition, which is subsequently lyophilized. A process flow diagram of a method for producing the aqueous concentrate composition is shown in FIG. 1. As shown in FIG. 1, the method for producing the aqueous concentrate composition may include one or more of the steps of: preparing a solution of asparaginase (e.g., L-asparaginase) (10); attaching a polyalkylene oxide (e.g., polyethylene glycol) to the asparaginase (20); clarifying the polyalkylene oxide-asparaginase (30); filtering and concentrating the solution of the polyalkylene oxide-asparaginase (40); diluting the solution of the polyalkylene oxide-asparaginase (50); filtering the solution of the polyalkylene oxide-asparaginase and filling the solution of the polyalkylene oxide-asparaginase into a sterile container (60); and storing the solution of the polyalkylene oxide-asparaginase (70).

[0149] In the method for producing the aqueous concentrate composition, a solution of asparaginase (e.g., L-asparaginase) may be prepared. The asparaginase may be mixed with a solution, such as an aqueous solution (e.g., a buffered aqueous solution). Examples of suitable buffers include a phosphate buffer, phosphate buffered saline (PBS), Dulbecco's phosphate buffered saline (DPBS), Hank's balanced salt solution (HBSS), Earle's balanced salt solution (EBSS), Tris buffer, Ringer's lactate buffer, borate buffer, and combinations thereof. In the claimed invention, the asparaginase is mixed with a phosphate buffer.

[0150] In the claimed invention, the phosphate buffer includes dibasic sodium phosphate and monobasic sodium phosphate. In some cases, the amount of dibasic sodium phosphate in the aqueous concentrate composition ranges from 0.1 to 0.8 wt.%, or 0.1 to 0.7 wt.%, or 0.1 to 0.6 wt.%, or 0.1 to 0.5 wt.%, or 0.1 to 0.4 wt.%, or 0.2 to 0.4 wt.%, or 0.2 to 0.3 wt.%, or 0.25 to 0.3 wt.%. For instance, the dibasic sodium

phosphate may be present in the aqueous concentrate composition in an amount ranging from 0.1 to 0.5 wt.%. The amount of monobasic sodium phosphate in the aqueous concentrate composition ranges from 0.01 to 0.5 wt.%, or 0.01 to 0.4 wt.%, or 0.01 to 0.3 wt.%, or 0.01 to 0.2 wt.%, or 0.01 to 0.1 wt.%, or 0.02 to 0.09 wt.%, or

0.03 to 0.08 wt.%, or 0.04 to 0.08 wt.%, or 0.045 to 0.075 wt.%, or 0.04 to 0.07 wt.%, or 0.05 to 0.07 wt.%. For instance, the monobasic sodium phosphate may be present in the aqueous concentrate composition in an amount ranging from 0.01 to 0.1 wt.

[0151] Additional components included in the aqueous concentrate composition include a salt. Examples of suitable salts include sodium chloride, potassium chloride, calcium chloride, magnesium chloride and combinations thereof. In certain instances, the salt is sodium chloride.

[0152] The amount of salt (e.g., sodium chloride) in the aqueous concentrate composition ranges from 0.05 to

1 wt. %, such as 0.1 to 0.9 wt. %, or 0.1 to 0.8 wt. %, or 0.1 to 0.7 wt. %, or 0.1 to 0.6 wt. %, or 0.1 to 0.5 wt. %, or 0.2 to 0.5 wt. %, or 0.3 to 0.5 wt. %, or 0.4 to 0.5 wt. %, or 0.4 to 0.45 wt. %. For instance, the salt (e.g., sodium chloride) may be present in the aqueous concentrate composition in an amount ranging from 0.1 to 1 wt. %.

[0153] Another component included in the aqueous concentrate composition is a sugar. Examples of suitable sugars include, sucrose, mannitol, maltose, trehalose, 2-hydroxypropyl-beta-cyclodextrin (β -HPCD), lactose, glucose, fructose, galactose, glucosamine and combinations thereof. In certain instances, the sugar is a disaccharide. For example, the disaccharide may be sucrose.

[0154] The amount of sugar (e.g., sucrose) in the aqueous concentrate composition ranges from 0.1 to 25 wt. %, such as 0.5 to 20 wt. %, or 1 to 15 wt. %, or 1 to 10 wt. %, or 1 to 9 wt. %, or 1 to 8 wt. %, or 2 to 7 wt. %, or 2 to 6 wt. %, or 3 to 5 wt. %, or 4 to 5 wt. %. For instance, the sugar (e.g., sucrose) may be present in the aqueous concentrate composition in an amount ranging from 1 to 10 wt. %.

[0155] After preparation of the asparaginase solution, the asparaginase may be attached to a polyalkylene oxide (e.g., polyethylene glycol), such that the polyalkylene oxide is covalently bonded to the asparaginase to produce a polyalkylene oxide-asparaginase conjugate. After preparation of the polyalkylene oxide-asparaginase, the solution may undergo clarification. In some cases, clarification includes filtering the solution through a filter to remove particulate matter from the solution. The filtering step may produce a substantially purified polyalkylene oxide-asparaginase.

[0156] In some instances, the filtered polyalkylene oxide-asparaginase solution is then subjected to a diafiltration and concentration step. The polyalkylene oxide-asparaginase solution may be diafiltered using an ultrafiltration membrane and a resulting concentrate of the polyalkylene oxide-asparaginase may be obtained. The concentrate from the diafiltration step may then be diluted such that the solution contains a desired concentration of the polyalkylene oxide-asparaginase. Suitable buffers useful for the dilution step include those described above. In some cases, a phosphate buffer is used to dilute the polyalkylene oxide-asparaginase solution, thus producing the desired aqueous concentrate composition. For example, the concentrate from the diafiltration step may be diluted such that the resulting aqueous concentrate composition includes an amount of polyalkylene oxide-asparaginase having a potency (activity) ranging from 100 to 5,000 IU/mL, such as 500 to 4,500 IU/mL, or 500 to 4,000 IU/mL, or 500 to 3,500 IU/mL, or 500 to 3,000 IU/mL, or 1,000 to 3,000 IU/mL, or 1,500 to 3,000 IU/mL. In certain instances, the aqueous concentrate composition includes the polyalkylene oxide-asparaginase in an amount ranging from 1,500 to 3,000 IU/mL. In some cases, the amount of polyalkylene oxide-asparaginase in the aqueous concentrate composition is greater than the amount of polyalkylene oxide-asparaginase in the reconstituted lyophilized composition described herein. In some cases, the diafiltration produces a substantially purified polyalkylene oxide- asparagmase.

[0157] The aqueous concentrate composition may then be filtered and filled into a sterile container. Examples of suitable container materials for the container include polymers, such as polypropylene, polymethylpentene, polytetrafluoroethylene (PTFE), perfluoroethers (PFE), fluorinated ethylene propylene (FEP), perfluoroalkoxy alkanes (PFA), polyethylene terephthalate (PET), polyethylene (PE), polyetheretherketone (PEEK), polystyrene. For example, the container may be a sterile polymer bag. The aqueous concentrate composition may be stored in the container for a period of time, and may be processed into the lyophilized storage stable composition of the present disclosure.

[0158] Embodiments of the method may further include shipping the aqueous concentrate composition to a remote location. A "remote location," is a location other than the location at which the aqueous concentrate composition is produced. For example, a remote location could be another location (e.g., office, lab, etc.) in the same city, another location in a different city, another location in a different state, another location in a different country, etc. As such, when one item is indicated as being "remote" from another, what is meant is that the two items can be in the same room but separated, or at least in different rooms or different buildings, and can be at

least one mile, ten miles, or one hundred miles or more apart.

[0159] In certain embodiments, as described above, the method includes lyophilizing the aqueous concentrate composition in a manner sufficient to produce a lyophilized storage stable polyalkylene oxide-asparaginase composition. In some instances, the lyophilization may be performed in a unit dosage container. Lyophilizing the aqueous concentrate composition to produce the lyophilized storage stable polyalkylene oxide-asparaginase composition in the unit dosage container may facilitate production of the lyophilized composition in the unit dosage container, for example, by eliminating the need to lyophilize the aqueous concentrate composition in a separate container and then transfer the lyophilized composition from the separate container to the unit dosage container. As such, in some embodiments, the method includes introducing the aqueous concentrate composition into a unit dosage container and lyophilizing the aqueous concentrate composition in the unit dosage container. As described above, the unit dosage container may be a vial, such as a glass vial.

[0160] After lyophilization, the method may further include sealing the lyophilized composition in the unit dosage container. For example, a seal or cap may be applied to the opening of the unit dosage container, thus sealing the unit dosage container. The sealed containers may be stored for an extended period of time, such as 1 week or more, or 2 weeks or more, or 3 weeks or more, or 1 month or more, or 2 months or more, or 3 months or more, or 4 months or more, or 6 months or more, or 9 months or more, or 1 year or more, or 1.5 years (e.g., 18 months) or more, or 2 years or more, or 2.5 years (e.g., 30 months) or more, or 3 years or more, or 3.5 years (e.g., 42 months) or more, or 4 years or more, or 4.5 years (e.g., 54 months) or more, or 5 years or more. For instance, an extended period of time may be 6 months or more. In some cases, the sealed containers may be stored for 9 months or more. In some cases, the sealed containers may be stored for 1 year (e.g., 12 months) or more. In some cases, the sealed containers may be stored for 1.5 years (e.g., 18 months) or more. In some cases, the sealed containers may be stored for 2 years (e.g., 24 months) or more.

KIT

[0161] Also provided are kits for use in practicing the subject methods, where the kits may include one or more of the above liquid and/or lyophilized compositions. For example, the kit may include a unit dosage container that contains a liquid composition as described herein. Or, for example, the kit may include a unit dosage container that contains a lyophilized composition as described herein. In some instances, the kit includes two or more unit dosage containers each containing a liquid composition as described herein. In some instances, the kit includes two or more unit dosage containers each containing a lyophilized composition as described herein. In some instances, the kit includes two or more unit dosage containers, where one or more of the unit dosage containers contains a liquid composition as described herein and one or more of the unit dosage containers contains a lyophilized composition as described herein. In certain embodiments, the kit includes a packaging configured to contain the unit dosage container(s). The packaging may be a sealed packaging, such as a sterile sealed packaging. A sterile packaging may be configured to be sealed from the outside environment, such that there are substantially no microbes (such as fungi, bacteria, viruses, spore forms, etc.) inside the packaging. In some instances, the packaging is sealed, such as a water vapor-resistant packaging, optionally under an air-tight and/or vacuum seal.

[0162] In certain embodiments, the kit includes a buffer. For instance, the kit may include a dilution liquid, e.g., a dilution buffer, which may be suitable for administration to a subject. The kit may further include other components, e.g., administration devices, liquid sources, etc., which may find use in practicing the subject methods. The various components in the kits may be packaged as desired, e.g., together or separately. Components of the subject kits may be present in separate containers, or multiple components may be present in a single container, where the containers and/or packaging (or a portion thereof) of the kit may be sterile, as desired.

[0163] In addition to above mentioned components, the subject kits may further include instructions for using the components of the kit to practice the subject methods. The instructions for practicing the subject methods are generally recorded on a suitable recording medium. For example, the instructions may be printed, such as on paper or plastic, etc. As such, the instructions may be present in the kits as a package insert, in the labeling of the container of the kit or components thereof (i.e., associated with the packaging or subpackaging) etc. In other embodiments, the instructions are present as an electronic storage data file present on a suitable computer readable storage medium, e.g. portable flash drive, CD-ROM, DVD-ROM, Blu-ray, etc. In yet other embodiments, the actual instructions are not present in the kit, but directions for obtaining the instructions from a remote source, e.g. via the Internet, are provided. An example of this embodiment is a kit that includes a web address where the instructions can be viewed and/or from which the instructions can be downloaded. As with the instructions, this embodiment for obtaining the instructions is recorded on a suitable substrate.

UTILITY

[0164] The subject compositions (e.g., liquid or lyophilized storage stable compositions) and methods find use in applications where there is a desire to treat a subject for a disease or condition amenable to treatment by administration of a polyalkylene oxide-asparaginase. For example, the subject compositions (e.g., liquid or lyophilized storage stable compositions) and methods find use in the treatment of a neoplastic condition in a subject. In some cases, the subject compositions (e.g., liquid or lyophilized storage stable compositions) and methods find use in the treatment of a cancer in the subject. Examples of types of cancers amenable to treatment using the subject compositions (e.g., liquid or lyophilized storage stable compositions) and methods include, leukemia, such as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML). Accordingly, the subject lyophilized storage stable compositions and methods find use in providing a therapeutically effective treatment for neoplastic conditions, such as a cancer, including leukemia, such as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML).

[0165] The lyophilized storage stable compositions and methods (not claimed) of the present disclosure find use in treating subjects of any age. In some cases, the subject compositions (e.g., liquid or lyophilized storage stable compositions) and methods find use in treating an adult. For example a human adult subject may be 18 years or older. In other cases, the compositions (e.g., liquid or lyophilized storage stable compositions) and methods find use in treating a juvenile. For example a human juvenile subject may be less than 18 years old.

[0166] The compositions and methods of the present disclosure find use in applications where a storage stable composition is desired. For example, the compositions and methods of the present disclosure find use in providing a storage stable composition that is stable (e.g., does not significantly degrade and/or retains substantially all its activity) over an extended period of time. For instance, the compositions and methods of the present disclosure find use in providing a storage stable composition that is stable for an extended period of time, such as 1 week or more, or 2 weeks or more, or 3 weeks or more, or 1 month or more, or 2 months or more, or 3 months or more, or 4 months or more, or 6 months or more, or 9 months or more, or 1 year or more, or 1.5 years (e.g., 18 months) or more, or 2 years or more, or 2.5 years (e.g., 30 months) or more, or 3 years or more, or 3.5 years (e.g., 42 months) or more, or 4 years or more, or 4.5 years (e.g., 54 months) or more, or 5 years or more. In some cases, the compositions and methods of the present disclosure find use in providing a storage stable composition that is stable for 9 months or more. In some cases, the compositions and methods of the present disclosure find use in providing a storage stable composition that is stable for 1 year (e.g., 12 months) or more. In some cases, the compositions and methods of the present disclosure find use in providing a storage stable composition that is stable for 1.5 years (e.g., 18 months) or more. In some cases, the compositions and methods of the present disclosure find use in providing a storage stable composition that is stable for 2 years (e.g., 24 months) or more. In certain embodiments, the compositions and methods of the present disclosure find use in providing a storage stable composition that increases the shelf life of the composition by up to 1 week, or 2 weeks, or 3 weeks, or 1 month, or 2 months, or 3 months, or 4

months, or 6 months, or 9 months, or 1 year, or 1.5 years (e.g., 18 months), or 2 years, or 2.5 years (e.g., 30 months), or 3 years, or 3.5 years (e.g., 42 months), or 4 years or more, or 4.5 years (e.g., 54 months), or 5 years. In certain embodiments, the compositions and methods of the present disclosure find use in providing a storage stable composition that increases the shelf life of the composition by 1 month to 5 years, or 6 months to 4 years, or 9 months to 3 years, or 1 year to 2 years.

[0167] In certain embodiments, dosages of the present disclosure can be administered prior to, concurrent with, or subsequent to other one or more other neoplastic condition therapies for treating related or unrelated conditions. If provided at the same time as other neoplastic condition therapies, dosages of the present disclosure can be provided in the same or in a different formulation. For example, concurrent therapy may be achieved by administering a dosage and a pharmaceutical composition having at least one other active agent, such as a chemotherapeutic agent, which in combination provide a therapeutically effective dose, according to a particular treatment regimen. Administration of separate pharmaceutical compositions or treatments can be performed simultaneously or at different times (e.g., sequentially, in either order, on the same day, or on different days), as long as a therapeutically effective effect of the combination of these substances is caused in the subject undergoing therapy. Accordingly, methods and compositions of the present disclosure find use in treating a subject using a combination therapy that includes administering a polyalkylene oxide- asparaginase of the present disclosure in combination with one or more additional active agent(s) and/or therapies (e.g., radiation, chemotherapy, immunotherapy, etc.).

[0168] Unless indicated otherwise, parts are parts by weight, molecular weight is weight average molecular weight, temperature is in degrees Celsius, and pressure is at or near atmospheric.

[0169] The following examples are offered for illustrative purposes only, and are not intended to limit the scope of the embodiments of the present disclosure in any way. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), but some experimental error and deviation should, of course, be allowed for.

EXAMPLES

Example 1

[0170] A concentrated bulk composition that included a polyethylene glycol-asparaginase having an SS-PEG linker was produced according to the following protocol. Following production of the concentrated bulk composition, a lyophilized composition was produced from the concentrated bulk composition according to the protocol described below. FIG. 1 shows a process flow diagram for a method of making a lyophilized storage stable composition according to embodiments of the present disclosure.

L-Asparaginase Solution Preparation

[0171] The amount of L-asparaginase required for processing was calculated, weighed into a 6 L stainless steel beaker, and mixed for 5 to 10 minutes. The amount of phosphate buffer needed to dilute the L-asparaginase to a target concentration of 5 mg/mL was calculated and weighed. The L-asparaginase was then added to the phosphate buffer and mixed in a 7 gallon stainless steel pressure vessel for 10 to 15 minutes. Samples were taken and submitted for protein and specific activity testing.

PEGylation

[0172] The amount of SS-PEG required for this step was calculated and weighed. The 7 gallon stainless steel pressure vessel containing the diluted L-asparaginase solution was heated to 29 to 31 °C under gentle agitation. Once the L-asparaginase solution reached the appropriate temperature range, the mixer speed was increased, and the titration pump was started. Once the pH was adjusted to 7.7-7.9 with 0.5 N NaOH, the SS-PEG was added to the 7 gallon stainless steel pressure vessel. After 30 minutes, the titration pump was stopped and the temperature jacket was disconnected.

Clarification

[0173] The process material was then filtered through a 0.45 µm filter (Millipore, Billerica, Massachusetts) into another 7 gallon stainless steel pressure vessel using a diafiltration peristaltic pump. After clarification, phosphate buffer was added to the original 7 gallon stainless steel pressure vessel and pumped through the 0.45 µm filter into the 7 gallon stainless steel pressure vessel as a rinse.

Diafiltration/Concentration

[0174] The amount of PBS required for 15X diafiltration was calculated and the diafiltration system was prepared. The 7 gallon stainless steel pressure vessel was placed on a scale. A Millipore Pellicon®-2 diafiltration system was set up with membranes of 100,000 Da nominal molecular weight limits, which were pre-conditioned using a diafiltration peristaltic pump and 5 L of PBS. The level control system, including a buffer peristaltic pump, was then set up and the 7-gallon stainless steel pressure vessel placed on top of a scale. The Pellicon®-2 system was filled with polyethylene glycol-asparaginase for conditioning and recirculated for 5 minutes. Following conditioning, the permeate waste line was opened and diafiltration was started. After 15 and 30 minutes, a sample was obtained from the permeate waste line into a vial and submitted for activity and protein testing. Material intended for lyophilization was diafiltered then concentrated to 18.0 mg/mL or more and a potency of 1,850 IU/mL or more. When diafiltration was complete, the volume of in-process material in the 7 gallon stainless steel pressure vessel was adjusted to reach the target concentration (18.0 mg/mL or more for the process for lyophilized formulation) by removing the appropriate amount of permeate. PBS was then pumped through the system into the 7 gallon stainless steel pressure vessel as a rinse.

[0175] Quality control assays of the product after diafiltration were performed, including a determination of the impurity profile of the product. Permeate Enzyme Enzymatic Activity (EEA) was measured after 15 minutes and 30 minutes to ensure that product was retained by the diafiltration membrane. Free PEG and N-Hydroxysuccinimide (NHS) were components of the process related impurity profile measured in the final product. Formal in-process controls for the diafiltration unit operation are presented in Table 1 below.

[0176] The NHS and Free-PEG data generated from three drug substance compositions (e.g., concentrated bulk drug substance compositions) intended for lyophilization are shown in Table 2 below. Data generated demonstrated that small changes to diafiltration/concentration process did not affect the quality of the product.

Table 1: Specifications for Bulk Drug Substance Compositions Intended for Lyophilization

Test	Acceptance Criteria for Drug Substance Compositions for Lyophilization
N-Hydroxysuccinimide (NHS)	≤ 6.0 ppm
Modification by 2,4,6-Trinitrobenzenesulfonic acid (TNBS)	69-82 moles PEG/mole protein
Endotoxin	≤ 35 EU/mL

Test	Acceptance Criteria for Drug Substance Compositions for Lyophilization
Bioburden	≤ 2 CFU/20 mL
Sterility (performed after sterile filtration)	Complies

Table 2: Concentrated Bulk Drug Substance Composition Batch Analysis

Test	Acceptance Criteria	Lot 1	Lot 2	Lot 3
Protein concentration	19.0 to 21.0 mg/mL	20.94	19.65*	18.37
Potency (activity)	≥ 1850 IU/mL	2305	2360*	2091
Appearance	Colorless solution	Complies	Complies	Complies
Clarity	Clear, no visible particles	Complies	Complies	Complies
pH	7.2 to 7.4	7.2	7.2	7.2
Specific activity	≥ 85 IU/mg of protein	110	116	114
Purity by GF-HPLC	≥ 95% Active components; ≤ 8% Aggregates	98.30 5.07	98.26 5.23	97.80 0.70
Total free PEG by RP-HPLC	≤ 6.0 mg/mL	< 0.07	< 0.07	0.74
Free 10K PEG by RP-HPLC	≤ 0.6 mg/mL	< 0.07	< 0.07	< 0.07
N-Hydroxysuccinimide (NHS)	≤ 6.0 ppm	Not tested	1.87	0.65
Modification by 2,4,6-Trinitrobenzenesulfonic acid (TNBS)	69-82 moles PEG/mole protein	Not tested	76	73
Endotoxin	≤ 35 EU/mL	<5	< 5	<5
Bioburden	≤ 2 CFU/20 mL	0	0	0
Sterility (performed after sterile filtration)	Passes USP	Not tested	Not tested	Complies

* values taken from testing of samples post-diafiltration/pre-dilution

Dilution

[0177] The in-process material was mixed in the 7 gallon stainless steel pressure vessel before samples were pulled for activity and protein testing. The volume of in-process material was then diluted with PBS to bring the protein concentration to a target value of ≥ 18.0 mg/mL (target 20.0 mg/mL), (≥ 1850 IU/mL activity) for the drug substance intended for the lyophilized composition. The diluted in-process material was then mixed before samples were removed for quality assurance testing (see Table 1).

Sterile Filtration

[0178] The concentrated solution for lyophilization was filtered at 0.2 µm into a disposable 20 L sterile bag for storage until lyophilization was performed. A sample was collected and submitted for sterility testing. The bulk drug substance composition that included the polyethylene glycol-asparaginase for lyophilization may be held in the 20 L bag at 2-8 °C for up to 2 months prior to lyophilization.

Container Closure

[0179] The bulk drug substance composition that included the polyethylene glycol-asparaginase for lyophilization was processed into lyophilized composition following the 0.2 µm filtration step and delivery into a disposable pre-sterilized 20 L bioprocess bag. The material of construction of the bag included of layers of low-density polyethylene (LDPE), linear low-density polyethylene (LLDPE), nylon, and ethylene vinyl alcohol (EVOH). The direct product contact surface (inner layer) was LDPE. Each bag had two openings with attached tubing that was fixed to the bag and was crimped closed with clamps until it was ready to receive the bulk drug substance composition that included the polyethylene glycol-asparaginase for lyophilization. The bags were irradiated and released based on exposure of 25- 40 kGy, and underwent Limulus Amebocyte Lysate (LAL) endotoxin testing, 100% visual seal and air leak testing, as well as a 100% visual inspection following assembly. The results of qualification testing showed that the inner layer of the bag passed biological reactivity tests, including USP <88> Class IV plastics testing, USP <87> cytotoxicity testing, and USP <661> testing of physiochemical attributes. In addition, the bags complied with USP <788> for particulate matter in injections and all extractable testing conformed to the manufacturer's requirements.

Drug Substance Stability Hold times

[0180] The concentrated bulk drug substance material was monitored at 0, 2, 4, 6, 8, and 12 weeks at 2-8°C. Stability samples were maintained in 250 mL sample bags with product contact surface of polyethylene. Data from the testing plan is presented in Table 3 for Lot 1, Table 4 for Lot 2, and Table 5 for Lot 3.

[0181] The stability data for the concentrated bulk drug substance intended for lyophilized compositions met the acceptance criteria throughout the 12 week testing plan and indicated that a 2 month hold time between concentrated bulk drug substance production and the production of the lyophilized composition was acceptable.

Table 3: Stability Data for Lot 1 Stored at 2-8 °C

Test	Acceptance Criteria	Time (Weeks)					
		Initial	2	4	6	8	12
Protein concentration	≥ 18.0 mg/mL	20.94	21.31	21.31	21.18	21.15	21.34
Potency (activity)	≥ 1850 IU/mL	2305	2413	2448	2432	2498	2538
Appearance	Colorless solution	Complies	Complies	Complies	Complies	Complies	Complies
Clarity	Clear, no visible particles	Complies	Complies	Complies	Complies	Complies	Complies
pH	7.2 to 7.4	7.2	7.2	7.2	7.2	7.2	7.3
Specific activity	≥ 85 IU/mg of protein	110	113	115	115	118	119
Purity by GF-HPLC	≥ 95% Active components; ≤ 8% Aggregates	98.30, 5.07	97.83, 4.48	98.99, 4.38	99.24, 4.39	98.14, 4.43	97.34, 3.36
Free 10K PEG by RP-HPLC	≤ 0.6 mg/mL	< 0.07	< 0.07	< 0.07	0.24	0.24	0.33
Total free PEG by RP-HPLC	≤ 6.0 mg/mL	0.07	3.03	2.41	3.07	3.11	4.19

Test	Acceptance Criteria	Time (Weeks)					
		Initial	2	4	6	8	12
N-Hydroxysuccinimide (NHS)	≤ 6.0 mg/mL	Not tested	2.23	2.31	2.31	2.32	2.34
Modification by TNBS	69-82 moles PEG/mole protein	Not tested	76	75	76	74	73

Table 4: Stability Data for Lot 2 Stored at 2-8 °C

Test	Acceptance Criteria	Time (Weeks)					
		Initial	2	4	6	8	12
Protein concentration	≥ 18.0 mg/mL	19.65*	20.28	20.11	19.82	20.25	20.09
Potency (activity)	≥ 1850 IU/mL	2279*	2248	2263	2344	2360	2426
Appearance	Colorless solution	Complies	Complies	Complies	Complies	Complies	Complies
Clarity	Clear, no visible particles	Complies	Complies	Complies	Complies	Complies	Complies
pH	7.2 to 7.4	7.2	7.2	7.2	7.3	7.2	7.2
Specific activity	≥ 85 IU/mg of protein	116	111	113	118	117	128
Purity by GF-HPLC	≥ 95% Active components; ≤ 8% Aggregates	98.26, 5.23	98.17, 5.19	98.16, 4.71	98.27, 4.79	97.19, 4.21	98.24, 4.30
Free 10K PEG by RP-HPLC	≤ 0.6 mg/mL	<0.07	0.27	0.33	0.37	0.44	0.47
Total free PEG by RP-HPLC	≤ 6.0 mg/mL	< 0.07	1.25	2.05	2.75	4.15	4.50
N-Hydroxysuccinimide (NHS)	6.0 mg/mL	1.87	2.55	2.76	2.79	2.82	2.83
Modification by TNBS	69-82 moles PEG/mole protein	76	74	78	75	75	76

*values taken from testing of samples post-diafiltration/pre-dilution

Table 5: Stability Data for Lot 3 Stored at 2-8 °C.

Test	Acceptance Criteria	Time (Weeks)					
		Initial	2	4	6	8	12
Clarity	Clear, no visible particles	Complies	Complies	Complies	Complies	Complies	Complies
pH	7.2 to 7.4	7.2	7.3	7.2	7.3	7.3	7.3
Specific activity	≥ 85 IU/mg of protein	114	124	124	121	118	124
Purity by GF-HPLC	≥ 95% Active components; ≤ 8% Aggregates	97.80, 0.7	98.00, 0.65	97.61, 0	97.76, 0	97.24, 0.55	97.94, 0
Free 10K PEG by RP-HPLC	≤ 0.6 mg/mL	< 0.07	< 0.07	< 0.07	< 0.07	0.07	< 0.07
Total free PEG by RP-HPLC	≤ 6.0 mg/mL	< 0.07	2.23	2.00	3.00	3.98	5.00
N-Hydroxysuccinimide (NHS)	6.0 mg/mL	0.65	0.70	0.70	0.70	0.68	0.64
Modification by TNBS	69-82 moles PEG/mole protein	73	Not tested	70	70	74	76

Lyophilized Composition

[0182] The lyophilized composition powder for injection was produced in a single-use vial containing 3,750 IU of active PEGylated L-asparaginase (750 IU/mL after reconstitution with 5.2 mL of WFI). The components of the lyophilized composition included 4.5% sucrose, dibasic sodium phosphate, monobasic sodium phosphate, and sodium chloride after reconstitution. The composition of the lyophilized composition is provided in Table 6. In addition, the lyophilized composition was provided in a treated glass vials container (Nipro Type 1) having a 20 mm aluminum flip-off seal.

Table 6: Components of the Polyethylene Glycol-Asparaginase Composition

Component	Grade	Amount per g*
Polyethylene glycol-asparaginase	n/a	750 IU
Dibasic sodium phosphate	USP	2.79 mg
Monobasic sodium phosphate	USP	0.60 mg
Sodium Chloride	USP	4.25 mg
Sucrose	National Formulary (NF)	45 mg
Water for injection (WFI)	USP	QS to 1.0 g

* values are post reconstituted with WFI

Formulation Development of Lyophilized Polyethylene Glycol-Asparaginase

[0183] The objective of developing a lyophilized polyethylene glycol-asparaginase formulation was to attain a stable lyophilized composition that was suitable for 2-8°C or 25°C storage for at least 18 months.

[0184] Initial experiments to assess the feasibility of a lyophilized composition of polyethylene glycol-asparaginase were performed. Five variations of lyophilized compositions were investigated. Each formulation contained ~5 mg/mL of polyethylene glycol-asparaginase in 50 mM phosphate buffer, pH 6.5 and 5% w/v of one of five different cryoprotectants (mannitol, maltose, sucrose, trehalose, and/or β -HPCD). In addition, polyethylene glycol-asparaginase without a cryoprotectant was also subjected to lyophilization. These six lyophilized compositions were compared to a lot of polyethylene glycol-asparaginase in liquid formulation (Oncaspar®) that was used for preparation of these different formulations. SEC-Purity (GF-HPLC) method was used for assessing the quality of the polyethylene glycol-asparaginase compositions. The results of the study are presented in Table 7. As seen from Table 7, sucrose was found to be most effective at preserving purity of polyethylene glycol-asparaginase during lyophilization. Purity (83.0%) of the lyophilized composition with 5% sucrose was comparable to purity (83.8%) of the liquid polyethylene glycol-asparaginase formulation that was used for the preparation of the six formulations for the subsequent lyophilization.

Table 7: Results of Feasibility Study for Lyophilizing Polyethylene Glycol-Asparaginase

Composition ¹	% Purity (SEC-HPLC; RT-minutes)				
	10.0	10.2	10.5	11.2 ²	12.0
Oncaspar (Control, liquid composition)	-	-	3.0	83.8	13.2
5% Mannitol	-	0.9	1.4	74.7	23.1
5% Maltose	-	0.9	2.3	78.8	17.9
5% Sucrose	-	-	3.1	83.0	14.0
5% Trehalose	-	-	3.2	79.5	17.3
5% β -HPCD	-	-	2.9	78.9	18.3
lyophilized, no preservative	0.4	0.8	9.4	65.7	23.7

All formulations also contained ~5 mL Oncaspar in 5 mM phosphate buffer, pH 6.5 ² expected retention time of Oncaspar

[0185] Several different excipients (e.g., sucrose, trehalose, mannitol, polysorbate 80) were evaluated as potential stabilizing agents to include in the lyophilized composition. Four experiments, each including four different compositions, were performed. Small pilot scale lyophilized polyethylene glycol-asparaginase batches were prepared with the different excipients and evaluated for stability. A list of formulations that were tested is shown in Table 8.

Table 8: Polyethylene Glycol-Asparaginase Compositions Tested

Lot	Composition
1A	5% Sucrose, 12.5mg/mL PEG-asparaginase, Phosphate Buffer
1B	2.5% Sucrose, 2.5% Mannitol, 12.5mg/mL PEG-asparaginase, Phosphate Buffer
1C	2.5% Sucrose, 2.5% Mannitol, 0.01% Polysorbate-80, 12.5mg/mL PEG-asparaginase, Phosphate Buffer
ID	5% Sucrose, 0.01% Polysorbate-80, 12.5 mg/mL PEG-asparaginase, Phosphate Buffer
2A	5% Trehalose, 12.5mg/mL PEG-asparaginase, Phosphate Buffer
2B	2.5% Trehalose, 2.5% Mannitol, 12.5mg/mL PEG-asparaginase, Phosphate Buffer

Lot	Composition
2C	2.5% Trehalose, 2.5% Mannitol, 0.01% Polysorbate-80, 12.5mg/mL PEG-asparginase, Phosphate Buffer
2D	5% Trehalose, 0.01% Polysorbate-80, 12.5 mg/mL -asparginase, Phosphate Buffer
3A	5% Sucrose, 6.5mg/mL PEG-asparginase, Phosphate Buffer
3B	2.5% Sucrose, 2.5% Mannitol, 6.5mg/mL L-Aspariginase, Phosphate Buffer
3C	2.5% Sucrose, 2.5% Mannitol, 0.01% Polysorbate-80, 6.5mg/mL LAspariginase, Phosphate Buffer
3D	5% Sucrose, 0.01% Polysorbate-80, 6.5 mg/mL L-Aspariginase, Phosphate Buffer
4A	5% Trehalose, 6.5mg/mL L-asparginase, Phosphate Buffer
4B	2.5% Trehalose, 2.5% Mannitol, 6.5mg/mL L-Aspariginase, Phosphate Buffer
4C	2.5% Trehalose, 2.5% Mannitol, 0.01% Polysorbate-80, 6.5mg/mL L-Aspariginase, Phosphate Buffer
4D	5% Trehalose, 0.01% Polysorbate-80, 6.5 mg/mL L-Aspariginase, Phosphate Buffer

[0186] All of the lots described in Table 8 were evaluated in stability tests at 5°C, 25°C and 40°C, and evaluated with a panel of tests (Activity, Specific Activity, Protein, pH, Purity (GF-HPLC), Aggregates (GF-HPLC), and Particulates), that assessed the primary quality attributes of polyethylene glycol-asparaginase at release and on stability. Based these analyses of the stability data collected from the 16 different formulations described in Table 8, sucrose was identified as a suitable cryoprotectant (e.g., stabilizing agent).

[0187] Various sucrose concentrations were tested to evaluate the concentration suitable for a more robust (i.e., less impactful lyophilization protocol) and a more stable product. Additional pilot scale batches were prepared containing different concentrations of sucrose, as summarized in Table 9. The sucrose and PEG-asparaginase concentrations shown in Table 9 show the amounts present in the concentrated bulk drug substance. During the lyophilization process, vials were filled at 2.5 mL prior to initiating lyophilization. These lyophilized vials were reconstituted with 5.0 mL, resulting in final sucrose and PEG-asparaginase concentrations that were approximately half those shown in the table. This study demonstrated that the increase in sugar content allowed for higher lyophilization temperatures, which was less stressful for the lyophilized product, and also reduced the overall lyophilization cycle time and resulted in a drier (more stable) lyophilized product.

Table 9: Sucrose Compositions Tested

Lot	Phosphate Buffer (M)	NaCl (%)	Sucrose (mg/mL) ¹	PEG-Asparaginase (mg/mL) ¹
5A	0.1	0.85	10 (1%)	12.5
5B	0.1	0.85	25 (2.5%)	12.5
5C	0.1	0.85	50 (5%)	12.5
5D	0.1	0.85	75 (7.5%)	12.5
5E	0.1	0.85	100(10%)	12.5

Concentration during lyophilization in 2.5 mL/vial. The concentration decreased in half after the reconstitution of the final product with 5mL/vial of WFI.

[0188] The five lots described in Table 9 were also evaluated in stability tests at 5°C, 25°C and 40°C. Quality attributes such as Activity, Specific Activity, Protein, pH, Purity (GF-HPLC), Aggregates (GF-HPLC), and Particulates were evaluated during this stability study. Purity and Potency results from accelerated (25°C) and stressed (40°C) stability studies for these lots are shown in FIGS. 2-5. These stability data indicated that the formulation containing 10% sucrose (5% sucrose after the reconstitution of the final product with 5 mL/vial of WFI) provided a product with the best stability in regards to purity and potency. Other quality attributes were less affected by different formulations, and also were stable in the lot with 10% sucrose. FIG. 2 shows a graph of purity (%) vs. time (weeks) at 40 °C for lyophilized PEG-asparaginase compositions of Lots 5A, 5B, 5C, 5D, 5E and 1A. FIG. 3 shows a graph of potency (IU/mL) vs. time (weeks) at 40 °C for lyophilized PEG-asparaginase compositions of Lots 5C, 5D, 5E and 1A. FIG. 4 shows a graph of purity (%) vs. time (weeks) at 25 °C for lyophilized PEG-asparaginase compositions of Lots 5A, 5B, 5C, 5D, 5E and 1A. FIG. 5 shows a graph of potency (IU/mL) vs. time (weeks) at 25 °C for lyophilized PEG-asparaginase compositions of Lots 5C, 5D, 5E and 1A.

Lyophilization

[0189] A buffer was prepared that included water for injection (WFI), dibasic sodium phosphate, monobasic sodium phosphate, sodium chloride, and sucrose. The buffer was used for dilution of the concentrated bulk drug substance.

[0190] WFI was added to a beaker at 90% of the target weight required to produce the buffer solution. Sodium phosphate monobasic, sodium phosphate dibasic, and sodium chloride were then individually weighed and added to the WFI and mixed until dissolved. The required quantity of sucrose was weighed and added to the mixing buffer solution and mixed until dissolved. The pH of the solution was then measured and adjusted to 7.3 ± 0.1 with slow addition of NaOH. WFI was added to the buffer solution as needed, and the density of the concentrated bulk solution was used to weigh the required volume of concentrated bulk solution needed for the batch size. A sample of the buffer was collected for a sucrose assay. The concentrated bulk solution was added to the buffer solution and the final solution was mixed for not less than (NLT) 10 minutes. Upon completion of mixing, confirmatory pH measurements (7.3 ± 0.1) were obtained from the top, middle, and bottom of the vessel, and samples were collected for protein, density, sucrose, and pre-filtration bioburden in-process testing.

[0191] Following final formulation the solution underwent sterile filtration. Previously sterilized filtration tubing assembly was placed in the formulated bulk vessel and the bulk was then filtered through two 0.22 µm filters located on the filtration tubing assembly into a pre-sterilized 10 L bioprocess bag in preparation for filling. Once the entire product was transferred to the 10 L bioprocess bag, the filtration tubing assembly was disconnected from the bioprocess bag and the filters were tested for integrity. One 20 mL pre-lyophilization sample was collected from the filter upstream (unfiltered) and tested per finished drug product specifications.

[0192] A flow diagram illustrating the final formulation and sterile filtration process step is shown in FIG. 6.

Aseptic Filling and Lyophilization

[0193] Following the completion of sterile filtration, the 10 L biobag containing the bulk API solution was connected to the fill tubing assembly and the product vials were then filled at a target fill weight of 2.5 g/vial and partially stoppered using the Flexicon FMB210 filler. Fill weights were monitored by performing a minimum of one weight check (1 vial) for every tray filled (action limit: 2.43-2.57 g, alert limit: 2.38-2.62 g) during the filling operation. When the filling operation was complete, 20 pre-lyophilized vials were tested and all remaining filled vials were transferred into stainless steel lyophilization trays and subsequently loaded into a prechilled (5 °C)

270 ft² Hull freeze-drying system for lyophilization. The lyophilization process included the phases shown in Table 10.

Table 10: Lyophilization Cycle - Process Parameters

Thermal Treatment Phase				
Step	Temp. (°C)	Ramp Time (minutes)	Soak Time (minutes)	
1	5	0	30	
2	-45	100	120	
Freeze Condenser and Evacuate Phase				
Condenser S.P.			-45 °C	
Evacuate S.P.			60 mT	
Primary Dry Phase				
Step	Temp. (°C)	Ramp Time (minutes)	Soak Time (minutes)	Vac. Cont. S.P. (mT)
1	-45	0	30	50
2	-28	60	3860	50
Secondary Dry Phase				
Step	Temp. (°C)	Ramp Time (minutes)	Soak Time (minutes)	Vac. Cont. S.P. (mT)
1	35	630	1920	50

[0194] After the lyophilization cycle was complete, the evacuated chamber was backfilled with nitrogen gas and the vials were fully stoppered. A flow diagram illustrating the aseptic filling and lyophilization process step is shown in FIG. 7. The fully stoppered vials were then packaged into cartons (90 vials/carton) and then stored and/or shipped.

Lyophilized Composition Specifications

[0195] The product specifications for the lyophilized composition are shown in Table 11.

Table 11: Specifications for Lyophilized Composition

Test	Acceptance Criteria	
	Method	Lyophilized Composition ¹
Appearance	ACM-1504	White to off white cake (pre-reconstitution); Colorless solution
		after reconstitution
Clarity		Clear, no visible particles after reconstitution
Fill volume		To deliver 5.0 mL (USP)
pH		7.2-7.4
Potency (activity)	RDM-10004	600-900 IU/mL
Specific activity	ACM-1510	≥ 85 IU/mg protein
Purity by GF-HPLC	ACM-1517	≥ 95% active components
	RDM-10006	≤ 8% aggregates
Total free PEG by RP-HPLC	ACM-1509	≤ 2.0 mg/mL
Free 10K PEG by RP-HPLC	RDM-10007	≤ 0.2 mg/mL

Test	Acceptance Criteria	
	Method	Lyophilized Composition ¹
N-Hydroxysuccinimide (NHS)	ACM-1505	≤ 2.0 ppm
Modification by TNBS	ACM-1507 RDM-10015	69-82 moles PEG/mole protein
Protein concentration	ACM-1506 RDM-10005	4.5-8.5 mg/mL
Sterility	USP <71>	Pass USP sterility test
General safety	USP <88>	Pass USP test in Guinea Pig
	21 CFR610.11	Pass USP test in mice
Endotoxin by LAL	ACM-1511	≤ 35 EU/mL
Particulate matter	ACM-0070	≥ 2µm NMT 27,000 Particles/Container ¹
		≥ 10µm NMT 6000 Particles/Container
		≥ 25µm NMT 600 Particles/Container
Identity test	ACM-1805	Deaminates asparagine
Content uniformity	RDM-10004	Complies with USP
Reconstitution time	LSNE SOP CQC032 ¹	NMT 3 minutes
Water (KF)	LSNE SOP CQC0320	NMT 3.0%

¹ With the exception of pre-reconstitution appearance testing, all testing was performed post-reconstitution with WFI;

Lot Analyses

[0196] Lot analyses for lyophilized composition product lots are provided in Table 12 below. Results for all three lots were within release specifications.

Table 12: Lot Analyses for Lyophilized Compositions

Test	Acceptance Criteria	Lot 1	Lot 2	Lot 3
Appearance	White to off white cake	Complies	Complies	Complies
Appearance after reconstitution	Colorless solution	Complies	Complies	Complies
Clarity after reconstitution	Clear, no visible particles after reconstitution	Complies	Complies	Complies
Fill volume	To deliver 5.0 mL (USP)	5.5	5.4	5.2
pH	7.2-7.4	7.4	7.4	7.4
Potency (activity)	600-900 IU/mL	805	718	741
Specific activity	≥ 85 IU/mg protein	114	111	113
Purity by GF-HPLC	≥ 95% active components	97	97	97
	≤ 8% aggregates	5	4	1
Total free PEG by RP-HPLC	≤ 2.0 mg/mL	0.9	1.3	0.5

Test	Acceptance Criteria	Lot 1	Lot 2	Lot 3
Free 10K PEG by RP-HPLC	≤ 0.2 mg/mL	0.1	0.2	0.1
N-Hydroxysuccinimide (NHS)	≤ 2.0 ppm	0.1	0.9	0.2
Modification by TNBS	69-82 moles PEG/mole protein	77	77	75
Protein concentration	4.5-8.5 mg/mL	7.1	6.5	6.6
Sterility	Pass USP sterility test	n/a	Complies	Complies
General safety	Pass USP test in Guinea Pig Pass USP test in mice	Conforms	Conforms	Conforms
Endotoxin by LAL	≤ 35 EU/mL	<4	<4	<4
Particulate matter	≥ 2 μ m NMT 27,000 Particles/Container	1835	530	5834
	≥ 10 μ m NMT 6000 Particles/Container	116	12	96
	≥ 25 μ m NMT 600 Particles/Container	1	1	2
Identity test	Deaminates asparagine	n/a	n/a	n/a
Content uniformity	Complies with USP	Complies	Complies	Complies
Reconstitution time	NMT 3 minutes	< 1	< 1	< 1
Water (KF)	NMT 3 .0%	0.1	0.2	0.1

Stability Studies

[0197] Lyophilized drug product Lots 1, 2, and 3 were placed in long-term (2-8°C) and accelerated (25 ± 3°C; 60% ± 5% RH) stability tests. These lots were also placed in Heat Stress stability test (40 ± 2°C; 75% ± 5% RH) to assess the product's heat-induced degradation profile.

Long-Term Stability (2-8°C)

[0198] Stability data generated for lyophilized drug product lots stored under long-term (2-8°C) conditions are provided in Tables 13-16. Long-term stability data indicated that lyophilized drug product stored at 5 ± 3°C remained well within the acceptance criteria for all stability time points. Water Content (KF) data ranged from 0.96%-1.35% (specification = NMT 3.0%) at the 2-8°C storage condition through 12 weeks. Unlike commercial liquid drug product, which demonstrated an increase in activity and a decrease in purity over time, this trend was not observed for lyophilized compositions. Stability graphs for the purity (FIG. 8) and potency (FIG. 9), as well as aggregates (FIG. 10), at 2-8 °C shown in the accompanying figures.

Table 13: Lot 1 Long Term Stability Data

Test	Acceptance Criteria	Time (months)			
		Initial	3	6	9
Appearance	White to off white cake; Colorless solution after reconstitution	Conforms	Conforms	Conforms	-
Clarity	Clear, no visible particles after reconstitution	Conforms	Conforms	Conforms	-

Test	Acceptance Criteria	Time (months)			
		Initial	3	6	9
pH	7.2-7.4	7.4	7.4	7.4	-
Potency (activity)	600-900 IU/mL	805	750	801	-
Specific activity	≥ 85 IU/mg protein	114	107	111	
Purity by GF-HPLC	≥ 85% active components; ≤ 8% aggregates	97.07 4.73	96.53 3.82	97.68 5.05	-
Total free PEG by RP-HPLC	≤ 6.0 mg/mL	0.86	0.86	1.13	-
Total 10K PEG by RP-HPLC	≤ 0.6 mg/mL	0.13	0.13	0.14	-
Protein concentration	4.5-8.5 mg/mL	7.06	7.01	7.20	-
Particulate matter	≥ 2µm NMT 27,000 Particles/Container ≥ 10µm NMT 6000 Particles/Container ≥ 25µm NMT 600 Particles/Container	1835 116 1	- 21 0	- 126 2	204 ¹
Reconstitution time	NMT 3 minutes	0.99	0.99	0.99	-
Water (KF)	NMT 3.0%	-	-	-	-

¹Test was performed at 9 months using MilliQ water for reconstitution of the drug product.

Table 14: Lot 2 Long Term Stability Data

Test	Acceptance Criteria	Time (months)			
		Initial	3	6	9
Appearance	White to off white cake; Colorless solution after reconstitution	Conforms	Conforms	Conforms	-
Clarity	Clear, no visible particles after reconstitution	Conforms	Conforms	Conforms	-
pH	7.2-7.4	7.4	7.4	7.4	-
Potency (activity)	600-900 IU/mL	718	738	741	-
Specific activity	≥ 85 IU/mg protein	111	115	115	-
Purity by GF-HPLC	≥ 85% active components; ≤ 8% aggregates	97.16 4.35	96.94 3.85	96.99 0.79	-
Total free PEG by RP-HPLC	≤ 6.0 mg/mL	1.31	1.11	0.88	-
Total 10K PEG by RP-HPLC	≤ 0.6 mg/mL	0.15	0.13	0.069	-
Protein concentration	4.5-8.5 mg/mL	6.48	6.44	6.44	-

Test	Acceptance Criteria	Time (months)			
		Initial	3	6	9
Particulate matter	≥ 2µm NMT 27,000 Particles/Container	530	-	-	207 ¹
	≥ 10µm NMT 6000 Particles/Container	12	55	69	-
	≥ 25µm NMT 600 Particles/Container	1	0	0	-
Reconstitution time	NMT 3 minutes	0.99	0.99	0.99	-
Water (KF)	NMT 3.0%	0.2%	-	-	-

¹Test was performed at 9 months using MilliQ water for reconstitution of the drug product.

Table 15: Lot 3 (upright) Long Term Stability Data

Test	Acceptance Criteria	Time (months)			
		Initial	3	6	9
Appearance	White to off white cake; Colorless solution after reconstitution	Conforms	Conforms	-	-
Clarity	Clear, no visible particles after reconstitution	Conforms	Conforms	-	-
pH	7.2-7.4	7.4	7.4	-	-
Potency (activity)	600-900 IU/mL	741	733	-	-
Specific activity	≥ 85 IU/mg protein	113	117	-	-
Purity by GF-HPLC	≥ 85% active components; ≤ 8% aggregates	97.05 0.55	98.87 0.65	-	-
Total free PEG by RP-HPLC	≤ 6.0 mg/mL	0.45	1.20	-	-
Total 10K PEG by RP-HPLC	≤ 0.6 mg/mL	0.11	0.069	-	-
Protein concentration	4.5-8.5 mg/mL	6.55	6.25	-	-
Particulate matter	≥ 2µm NMT 27,000 Particles/Container	5834	-	165 ¹	-
	≥ 10µm NMT 6000 Particles/Container	96	90	-	-
	≥ 25µm NMT 600 Particles/Container	2	0	-	-
Reconstitution time	NMT 3 minutes	0.99	0.99	-	-
Water (KF)	NMT 3.0%	0.1%	-	-	-

¹Test was performed at 9 months using MilliQ water for reconstitution of the drug product.

Table 16: Lot 3 (inverted) Long Term Stability Data

Test	Acceptance Criteria	Time (months)			
		Initial	3	6	9
Appearance	White to off white cake;	Conforms	Conforms	-	-
	Colorless solution after reconstitution				
Clarity	Clear, no visible particles after reconstitution	Conforms	Conforms	-	-
pH	7.2-7.4	7.4	7.4	-	-
Potency (activity)	600-900 IU/mL	741	745	-	-
Specific activity	≥ 85 IU/mg protein	113	118	-	-

Test	Acceptance Criteria	Time (months)			
		Initial	3	6	9
Purity by GF-HPLC	≥ 85% active components; ≤ 8% aggregates	97.05 0.55	98.90 0.63	-	-
Total free PEG by RP-HPLC	≤ 6.0 mg/mL	0.45	1.18	-	-
Total 10K PEG by RP-HPLC	≤ 0.6 mg/mL	0.11	< 0.07	-	-
Protein concentration	4.5-8.5 mg/mL	6.55	6.29	-	-
Particulate matter	≥ 2 μ m NMT 27,000 Particles/Container	5834	-	-	-
	≥ 10 μ m NMT 6000 Particles/Container	96	50	-	-
	≥ 25 μ m NMT 600 Particles/Container	2	0	-	-
Reconstitution time	NMT 3 minutes	0.99	0.99	-	-
Water (KF)	NMT 3.0%	0.1%	-	-	-

Accelerated Stability (25 ± 3°C; 60% ± 5%RH)

[0199] Stability data for lyophilized drug product lots stored under accelerated (25 ± 3°C; 60% ± 5% RH) conditions are provided in Tables 17-20. Stability data indicates that lyophilized drug product stored at the accelerated condition remained well within the acceptance criteria for all stability time points. Water Content (KF) ranged from 1.12%-1.23% (specification = NMT 3.0%) at the 25°C storage condition through 4 weeks. Stability charts for the quality attributes purity (FIG. 11) and potency (FIG. 12), as well as aggregates (FIG. 13), at 25 ± 3 °C are provided in the accompanying figures.

Table 17: Lot 1 Accelerated Stability Data

Test	Acceptance Criteria	Time (months)				
		Initial	1	2	3	6
Appearance	White to off white cake; Colorless solution after reconstitution	Conforms	Conforms	Conforms	Conforms	Conforms
Clarity	Clear, no visible particles after reconstitution	Conforms	Conforms	Conforms	Conforms	Conforms
pH	7.2-7.4	7.4	7.4	7.4	7.4	7.4
Potency (activity)	600-900 IU/mL	805	782	809	778	805
Specific activity	≥ 85 IU/mg protein	114	111	112	111	-
Purity by GF-HPLC	≥ 85% active components;	97.07	96.43	96.58	96.29	96.88
	≤ 8% aggregates	4.73	-	4.6	4.11	5.9
Total free PEG by RP-HPLC	≤ 6.0 mg/mL	0.86	0.99	1.12	0.74	0.88
Total 10K PEG by RP-	≤ 0.6 mg/mL	0.13	0.14	0.17	0.12	0.13

Test	Acceptance Criteria	Time (months)				
		Initial	1	2	3	6
HPLC						
Protein concentration	4.5-8.5 mg/mL	7.06	7.03	7.2	7.02	7.13
Particulate matter	≥ 2µm NMT 27,000 Particles/Container	1835	-	-	11,753	12,096
	≥ 10µm NMT 6000 Particles/Container	116	-	-	70	116
	≥ 25µm NMT 600 Particles/Container	1	-	-	1	1
Reconstitution time	NMT 3 minutes	< 1	< 1	< 1	< 1	< 1
Water (KF)	NMT 3.0%	-	-	-	-	-

Table 18: Lot 2 Accelerated Stability Data

Test	Acceptance Criteria	Time (months)				
		Initial	1	2	3	6
Appearance	White to off white cake; Colorless solution after reconstitution	Conforms	Conforms	Conforms	Conforms	-
Clarity	Clear, no visible particles after reconstitution	Conforms	Conforms	Conforms	Conforms	-
pH	7.2-7.4	7.4	7.4	7.4	7.4	-
Potency (activity)	600-900 IU/mL,	718	748	733	720	-
Specific activity	≥ 85 IU/mg protein	111	115	113	116	-
Purity by GF-HPLC	≥ 85% active components; ≤ 8% aggregates	97.16 4.35	96.69 4.01	96.52 3.76	96.79 4.31	-
Total free PEG by RP-HPLC	≤ 6.0 mg/mL	1.31	1.48	1.12	1.16	-
Total 10K PEG by RP-HPLC	≤ 0.6 mg/mL	0.15	0.18	0.16	0.14	-
Protein concentration	4.5-8.5 mg/mL	6.48	6.51	6.46	6.21	-
Particulate matter	≥ 2µm NMT 27,000 Particles/Container	530	-	-	10,051	-
	≥ 10µm NMT 6000 Particles/Container	12	-	-	121	-
	≥ 25µm NMT 600 Particles/Container	1	-	-	6	-
Reconstitution time	NMT 3 minutes	< 1	< 1	< 1	< 1	-
Water (KF)	NMT 3.0%	0.2%	-	-	-	-

Table 19: Lot 3 (upright) Accelerated Stability Data

Test	Acceptance Criteria	Time (months)				
		Initial	1	2	3	6
Appearance	White to off white cake; Colorless solution after reconstitution	Conforms	Conforms	Conforms	Conforms	-
Clarity	Clear, no visible particles after reconstitution	Conforms	Conforms	Conforms	Conforms	-
pH	7.2-7.4	7.4	7.4	7.4	7.4	-
Potency (activity)	600-900 IU/mL	741	700	750	718	-
Specific activity	≥ 85 IU/mg protein	113	111	113	-	-
Purity by GF-HPLC	≥ 85% active components; ≤ 8% aggregates	97.05 0.55	96.88 0.62	97.25 0.75	96.98 0.89	-
Total free PEG by RP-HPLC	≤ 6.0 mg/mL	0.45	0.95	1.06	0.87	-
Total 10K PEG by RP-HPLC	≤ 0.6 mg/mL	0.11	< 0.07	< 0.07	< 0.07	-
Protein concentration	4.5-8.5 mg/mL	6.55	6.28	6.63	6.34	-
Particulate matter	≥ 2µm NMT 27,000 Particles/Container	5834	-	-	8000	-
	≥ 10µm NMT 6000 Particles/Container	96	-	-	83	-
	≥ 25µm NMT 600 Particles/Container	2	-	-	2	-
Reconstitution time	NMT 3 minutes	< 1	< 1	< 1	< 1	-
Water (KF)	NMT 3.0%	0.1%	-	-	-	-

Table 20: Lot 3 (inverted) Accelerated Stability Data

Test	Acceptance Criteria	Time (months)				
		Initial	1	2	3	6
Appearance	White to off white cake; Colorless solution after reconstitution	Conforms	Conforms	Conforms	Conforms	-
Clarity	Clear, no visible particles after reconstitution	Conforms	Conforms	Conforms	Conforms	-
pH	7.2-7.4	7.4	7.4	7.4	7.4	-
Potency (activity)	600-900 IU/mL	741	719	733	721	-
Specific activity	≥ 85 IU/mg protein	113	113	113	113	-
Purity by GF-HPLC	≥ 85% active components; ≤ 8% aggregates	97.05 0.55	96.76 0.63	97.31 0.72	97.02 0.74	-
Total free PEG by RP-HPLC	≤ 6.0 mg/mL	0.45	0.92	1.04	1.22	-

Test	Acceptance Criteria	Time (months)				
		Initial	1	2	3	6
Total 10K PEG by RP-HPLC	≤ 0.6 mg/mL	0.11	< 0.07	< 0.07	0.14	
Protein concentration	4.5-8.5 mg/mL	6.55	6.37	6.49	6.38	-
Particulate matter	≥ 2 μ m NMT 27,000 Particles/Container	5834	-	-	10,277	-
	≥ 10 μ m NMT 6000 Particles/Container	96	-	-	113	-
	≥ 25 μ m NMT 600 Particles/Container	2	-	-	1	-
Reconstitution time	NMT 3 minutes	< 1	< 1	< 1	< 1	-
Water (KF)	NMT 3.0%	0.1%	-	-	-	-

Heat Stress Stability (40 ± 2°C; 75% ± 5%RH)

[0200] Stability data for lyophilized drug product lots stored under stress (40 ± 2°C; 75% ± 5% RH) conditions are provided in Tables 21-24. Stability data indicated that lyophilized drug product stored at stress conditions remained well within the acceptance criteria for the duration of the study. Water Content (KF) ranged from 1.16%-1.45% (specification = NMT 3.0%) at the 40°C storage condition through 4 weeks. Stability charts for the potency (FIG. 14) and purity (FIG. 15), as well as aggregates (FIG. 16), at 40 ± 2°C are provided in the accompanying figures.

Table 21: Lot 1 Heat Stress Stability Data

Test	Acceptance Criteria	Time (months)				
		Initial	1	2	3	6
Appearance	White to off white cake; Colorless solution after reconstitution	Conforms	Conforms	Conforms	Conforms	Conforms
Clarity	Clear, no visible particles after reconstitution	Conforms	Conforms	Conforms	Conforms	Conforms
pH	7.2-7.4	7.4	7.4	7.4	7.4	7.4
Potency (activity)	600-900 IU/mL	805	757	747	759	746
Specific activity	≥ 85 IU/mg protein	114	109	107	107	-
Purity by GF-HPLC	≥ 85% active components; ≤ 8% aggregates	97.07	95.02	94.52	93.64	92.64
		4.73	-	4.74	4.31	6.01
Total free PEG by RP-HPLC	≤ 6.0 mg/mL	0.86	1.07	1.15	0.86	1.07
Total 10K PEG by RP-HPLC	≤ 0.6 mg/mL	0.13	0.15	0.16	0.13	0.14

Test	Acceptance Criteria	Time (months)				
		Initial	1	2	3	6
Protein concentration	4.5-8.5 mg/mL	7.06	6.94	7.01	7.09	7.08
	≥ 2µm NMT 27,000 Particles/Container	1835	-	-	-	12,025
Particulate matter	≥ 10µm NMT 6000 Particles/Container	116	-	-	-	53
	≥ 25µm NMT 600 Particles/Container	1	-	-	-	1
Reconstitution time	NMT 3 minutes	< 1	< 1	< 1	< 1	-
Water (KF)	NMT 3.0%	-	-	-	-	-

Table 22: Lot 2 Heat Stress Stability Data

Test	Acceptance Criteria	Time (months)				
		Initial	1	2	3	6
Appearance	White to off white cake; Colorless solution after reconstitution	Conforms	Conforms	Conforms	Conforms	-
Clarity	Clear, no visible particles after reconstitution	Conforms	Conforms	Conforms	Conforms	-
pH	7.2-7.4	7.4	7.4	7.4	7.4	-
Potency (activity)	600-900 IU/mL	718	738	690	694	-
Specific activity	≥ 85 IU/mg protein	114	109	107	107	-
Purity by GF-HPLC	≥ 85% active components; ≤ 8% aggregates	97.16 4.35	93.91 3.99	93.92 3.71	93.70 4.33	-
Total free PEG by RP-HPLC	≤ 6.0 mg/mL	1.31	1.45	1.15	1.26	-
Total 10K PEG by RP-HPLC	≤ 0.6 mg/mL	0.15	0.17	0.16	0.14	-
Protein concentration	4.5-8.5 mg/mL	6.48	6.42	6.4	6.3	-
Particulate matter	≥ 2µm NMT 27,000 Particles/Container	530	-	-	-	-
	≥ 10µm NMT 6000 Particles/Container	12	-	-	-	-
	≥ 25µm NMT 600 Particles/Container	1	-	-	-	-
Reconstitution time	NMT 3 minutes	< 1	< 1	< 1	< 1	-
Water (KF)	NMT 3.0%	0.2%	-	-	-	-

Table 23: Lot 3 (upright) Heat Stress Stability Data

Test	Acceptance Criteria	Time (months)				
		Initial	1	2	3	6
Appearance	White to off white cake; Colorless solution after reconstitution	Conforms	Conforms	Conforms	Conforms	-
Clarity	Clear, no visible particles after reconstitution	Conforms	Conforms	Conforms	Conforms	-
pH	7.2-7.4	7.4	7.4	7.4	7.4	-
Potency (activity)	600-900 IU/mL	741	722	691	681	-
Specific activity	≥ 85 IU/mg protein	113	112	111	109	-
Purity by GF-HPLC	≥ 85% active components; ≤ 8% aggregates	97.05 0.55	96.11 0.98	95.4 2.58	93.1 2.88	-
Total free PEG by RP-HPLC	≤ 6.0 mg/mL	0.45	1.1	1.25	0.64	-
Total 10KPEG by RP-HPLC	≤ 0.6 mg/mL	0.11	< 0.07	< 0.07	< 0.07	-
Protein concentration	4.5-8.5 mg/mL	6.55	6.43	6.23	6.25	-
Particulate matter	≥ 2µm NMT 27,000 Particles/Container	5834	-	-	8989	-
	≥ 10µm NMT 6000 Particles/Container	96	-	-	116	-
	≥ 25µm NMT 600 Particles/Container	2	-	-	2	-
Reconstitution time	NMT 3 minutes	< 1	< 1	< 1	< 1	-
Water (KF)	NMT 3.0%	0.1%	-	-	-	-

Table 24: Lot 3 (inverted) Heat Stress Stability Data

Test	Acceptance Criteria	Time (months)				
		Initial	1	2	3	6
Appearance	White to off white cake; Colorless solution after reconstitution	Conforms	Conforms	Conforms	Conforms	-
Clarity	Clear, no visible particles after reconstitution	Conforms	Conforms	Conforms	Conforms	-
pH	7.2-7.4	7.4	7.4	7.4	7.4	-
Potency (activity)	600-900 IU/mL	741	719	668	663	-
Specific activity	≥ 85 IU/mg protein	113	113	107	106	-
Purity by GF-HPLC	≥ 85% active components; ≤ 8% aggregates	97.05 0.55	96.12 1.02	95.31 1.01	96.45 2.74	-
Total free PEG by RP-HPLC	≤ 6.0 mg/mL	0.45	1.08	1.25	0.62	-

Test	Acceptance Criteria	Time (months)				
		Initial	1	2	3	6
Total 10K PEG by RP-HPLC	≤ 0.6 mg/mL	0.11	< 0.07	< 0.07	< 0.07	-
Protein concentration	4.5-8.5 mg/mL	6.55	6.38	6.23	6.25	-
Particulate matter	≥ 2µm NMT 27,000 Particles/Container	5834	-	-	9963	-
	≥ 10µm NMT 6000 Particles/Container	96	-	-	157	-
	≥ 25µm NMT 600 Particles/Container	2	-	-	3	-
Reconstitution time	NMT 3 minutes	< 1	< 1	< 1	< 1	-
Water (KF)	NMT 3.0%	0.1%	-	-	-	-

Example 2

[0201] A composition that included a polyethylene glycol-asparaginase having an SC-PEG linker (i.e., succinimidyl carbonate linker) was produced - calaspargase pegol (succinimidyl carbonate-polyethylene glycol [SC-PEG] E. coli L-asparaginase). The composition of the composition is provided in Table 25.

Table 25: Components of the Calaspargase Pegol Composition

Component	Grade	Amount per g*
Calaspargase Pegol	n/a	750 IU
Dibasic sodium phosphate	USP	5.58 mg
Monobasic sodium phosphate	USP	1.29 mg
Sodium Chloride	USP	8.50 mg
Water for injection (WFI)	USP	QS to 1.0 g

Example 3

[0202] Following production of the concentrated bulk composition, a lyophilized composition of calaspargase pegol can be produced from the concentrated bulk composition. FIG. 1 shows an example of a process flow diagram that can be used for making a lyophilized storage stable composition according to embodiments of the present disclosure. The lyophilized composition powder for injection can be produced in a single-use vial containing 3,750 IU of active calaspargase pegol (750 IU/mL after reconstitution with 5.2 mL of WFI). The components of the lyophilized composition can include 4.5% sucrose, dibasic sodium phosphate, monobasic sodium phosphate, and sodium chloride after reconstitution. The composition of the lyophilized composition is provided in Table 26.

Table 26: Components of the Calaspargase Pegol Composition

Component	Grade	Amount per g*
Calaspargase Pegol	n/a	750 IU

Component	Grade	Amount per g*
Dibasic sodium phosphate	USP	2.79 mg
Monobasic sodium phosphate	USP	0.60 mg
Sodium Chloride	USP	4.25 mg
Sucrose	National Formulary (NF)	45 mg
Water for injection (WFI)	USP	QS to 1.0 g

* values are post reconstituted with WFI

Example 4

[0203] The purpose of this study was to provide comparative pharmacokinetic (PK), pharmacodynamics (PD) and immunogenicity information for liquid pegaspargase (PEG-L-asparaginase; Oncaspar®) and lyophilized pegaspargase, when administered intravenously, via slow bolus injection, to beagle dogs once (Day 1) or once weekly for 4 weeks (Days 1, 15, 22, 29 and 36). Because the reconstituted lyophilized pegaspargase will be administered intravenously to humans, the same route of administration was used in this study. A single-dose and repeat-dose PK/PD study was necessary to determine and compare the pharmacokinetics and pharmacodynamics of liquid and reconstituted lyophilized versions at an equivalent dose.

[0204] Beagle dogs (nominally 5/sex/group) were administered 500 IU/kg liquid pegaspargase or reconstituted lyophilized pegaspargase by intravenous injection at a dose volume of 0.667 mL/kg (see Table 27). The beagles were approximately 6 months old with males 7.2 kg to 10.7 kg and females 5.6 kg to 8.2 kg.

[0205] Liquid pegaspargase (5mL PBS buffer with 50 mM phosphate and 0.85% saline at pH 7.2-7.4) was used as supplied and no preparation was needed. Lyophilized pegaspargase (see example 1) was prepared for administration by (using a 21 gauge syringe) reconstituting the contents of a vial with 5.2 mL water for injection (WFI) using aseptic techniques to achieve a 750 IU/mL concentration. The contents of the vial were gently swirled until completely dissolved. The mixture was visually inspected for particulate matter, cloudiness or discolorations prior to administration. Fresh formulations were prepared for each day of dose administration, maintained at room temperature and used within 2 hours of preparation.

Table 27: Protocol and Dosing Regimen

Group	Treatment	Dose (IU/kg)	Concentration (IU/mL)	Volume dose (mL/kg)	Male Dogs	Female Dogs
1	Liquid pegaspargase - Single-Dose	500	750	0.667	5	6
2	Liquid pegaspargase - Repeat-Dose	500	750	0.667	5	5
3	Lyophilized pegaspargase - Single-Dose	500	750	0.667	5	5
4	Lyophilized pegaspargase - Repeat-Dose	500	750	0.667	6	5

[0206] Animals in Groups 1 and 3 received a single dose of liquid pegaspargase or lyophilized pegaspargase, respectively on Day 1. Animals in Groups 2 and 4 were given repeated doses of liquid pegaspargase or

lyophilized pegaspargase, respectively. Slow bolus (over approximately 2 minutes) intravenous injection within 2 hours of test article preparation were administered. An indwelling catheter (non-butterfly catheter) was used, followed by a saline flush to clear the catheter cap of any remaining dose volume. A straight needle was inserted into the catheter cap to guarantee the needle placement would remain consistent over the 2 minute duration.

[0207] Blood samples were obtained from all animals on Days 1 and 36 for pharmacokinetic and pharmacodynamics analysis. Approximately 1.0 mL of whole blood was obtained at each time point. Animals were unanesthetized and non-fasted prior to blood collection. Blood was collected into tubes containing sodium heparin anticoagulant and placed on wet ice in an upright position. Centrifugation for 5 minutes (at approximately 3000 rpm, at approximately 4°C) of the blood sample to obtain plasma began within 5 minutes of collection of the blood sample.

[0208] PD: One aliquot of 125 µL of plasma was pipetted into a cryotube pre-filled with 125 µL of SeraPrep for asparagine determination. The tube was inverted 3 times to mix the SeraPrep and flash frozen immediately with liquid nitrogen or methanol/dry ice within 15 minutes from collection of the blood sample. All aliquots containing SeraPrep were analyzed for asparagine determination by High Performance Liquid Chromatography (HPLC) with mass spectrometric detection (LC-MS/MS).

[0209] PK: The remainder of the plasma was split into two cryotubes for asparaginase activity determination and flash frozen within 30 minutes from collection of the blood sample. All aliquots not containing SeraPrep were analyzed for asparaginase activity by a colorimetric mixed enzyme reaction.

Results

[0210] Analyses conducted during the treatment period for the lyophilized pegaspargase confirmed that dose formulations of appropriate concentration (expected protein concentration of 6.6 mg/mL and activity of 741 IU/mL, per Batch Analysis) were administered (Table 28).

Table 28: Analytical Chemistry

Interval	Protein (mg/mL)		Activity (IU/mL)	
	Male	Female	Male	Female
Injection Day 1	6.36	6.30	738	722
Injection Day 22	6.55	6.54	794	785
Injection Day 36	6.30	6.44	722	741

[0211] Pooled group mean plasma concentrations (C_{max}) of asparaginase and the pooled group mean areas under the plasma asparaginase concentration time curves estimated up to 552 hours postdose (AUC₀₋₅₅₂) on Day 1 and following repeated dosing on Day 36 are summarized for each group (combined sexes) in Table 29.

Table 29: Bioequivalence: Pooled group mean data (combined sexes)

Formulation (500 IU/kg)		Group mean C _{max} (mIU/mL)		Group mean AUC ₀₋₅₅₂ (mIU.h/mL)	
		Day 1	Day 36	Day 1	Day 36
Liquid	Geomean	9947	19440	2929202	4514287
	Mean	10018	19580	2953000	4561000
	SD	1300	2404	405245	648322
	CV%	13.0	12.3	13.7	14.2
Lyophilized	Geomean	9393	17416	2603255	4258048

Formulation (500 IU/kg)	Group mean C _{max} (mIU/mL)		Group mean AUC ₀₋₅₅₂ (mIU.h/mL)	
	Day 1	Day 36	Day 1	Day 36
Mean	9416	17480	2611000	4350000
SD	688	1555	214758	797663
CV%	7.3	8.9	8.2	18.3

[0212] The study was designed as a parallel group design and the data were analyzed statistically using analysis of variance techniques. C_{max} and AUC₀₋₅₅₂ data from both days were analyzed using an ANOVA model with formulation, time, sex and their interactions as factors.

[0213] The two pegaspargase formulations were analyzed with respect to C_{max} and AUC₀₋₅₅₂ and the corresponding two-sided 90% CIs for the ratio of geometric means are summarized in Table 30.

Table 30: Pharmacokinetic Data

Parameter	Table of Formulation means (back-transformed - mIU/mL)		90% Confidence interval of mean ratio (Lyophilized/Liquid)		
	Lyophilized	Liquid	Lower	Ratio	Upper
C _{max}	12790	13943	0.867	0.917	0.970
AU C ₀₋₅₅₂	3329382	3636380	0.841	0.916	0.996

[0214] For C_{max} there was evidence of bioequivalence as the confidence interval (0.867 to 0.970) was contained in the critical region. For AUC₀₋₅₅₂ there was evidence of bioequivalence as the confidence interval (0.841 to 0.996) was contained in the critical region.

[0215] Mean maximum plasma concentrations (C_{max}) of pegaspargase and the mean areas under the plasma pegaspargase concentration time curves estimated up to 552 hours postdose (AUC₀₋₅₅₂) on Day 1 and following repeated dosing on Day 36 are summarized below (by sex) with standard deviations in parentheses in Table 31.

Table 31: Plasma Concentration-Time Profiles

Formulation (500 IU/kg)	C _{max} (mIU/mL)				AUC ₀₋₅₅₂ (mIU.h/mL)			
	Day 1		Day 36		Day 1		Day 36	
	Males	Females	Males	Females	Males	Females	Males	Females
Liquid	10700	9450	20200	19000	3250000	2660000	4660000	4470000
	(1600)	(610)	(2700)	(2200)	(370000)	(140000)	(690000)	(670000)
Lyophilized	9580	9250	17800	17200	2700000	2520000	4170000	4530000
	(540)	(840)	(1400)	(1800)	(190000)	(220000)	(1120000)	(320000)

[0216] The relationships between mean maximum plasma concentrations (C_{max}) of asparaginase, mean areas under the plasma asparaginase concentration time curves (AUC₀₋₅₅₂) and dose level for the lyophilized formulation are expressed as a ratio compared to the liquid formulation and presented in Table 32.

Table 32: Relationship between Mean C_{max}, Mean AUC, and Dose Level

Formulation (500 IU/kg)	Dose level ratio	C _{max} ratio				AUC ₀₋₅₅₂ ratio			
		Day 1		Day 36		Day 1		Day 36	
		Males	Females	Males	Females	Males	Females	Males	Females
Liquid	1	1	1	1	1	1	1	1	1
Lyophilized	1	0.90	0.98	0.88	0.91	0.83	0.95	0.89	1.0

[0217] The C_{max} and AUC₀₋₅₅₂ values of systemic exposure of dogs to asparaginase were similar following administration of reconstituted lyophilized pegaspargase, compared to the liquid formulation, on Day 1 and following repeated administrations on Day 36. There was no evidence of a significant difference between the formulations for AUC₀₋₅₅₂, but there was some evidence of a difference between the C_{max} values of the different formulations where C_{max} following administration of the lyophilized product was slightly lower (8%) than when dosed as the liquid formulation.

[0218] The C_{max} and AUC₀₋₅₅₂ values of systemic exposure of female dogs to asparaginase were generally similar to those indices of exposure in males and there was no evidence for any statistically significant sex related differences in systemic exposure for C_{max} or AUC₀₋₁₅₂.

[0219] Other parameters evaluated during the study were: viability, clinical observations, body weight, food consumption, breathing rates, body temperature, hematology, coagulation and blood chemistry; no test article-related adverse effects were seen for these.

[0220] After repeated intravenous doses (Day 36) the C_{max} values and extent (AUC₀₋₅₅₂) of systemic exposure of dogs to asparaginase were higher than those values after a single dose (Day 1) and these differences were statistically significant ($p<0.001$). The mean accumulation ratios, calculated based on AUC₀₋₅₅₂ values (note that different animals provided the data on each day), were greater than one indicating that accumulation of asparaginase occurred after repeated intravenous administration of liquid pegaspargase.

[0221] Overall, the two pegaspargase formulations were shown to be equivalent with respect to C_{max} and AUC₀₋₅₅₂, as the corresponding two-sided 90% CIs for the ratio of geometric means fell completely within the conventional margins of bioequivalence ranging from 0.8 to 1.25. There was no significant difference between the two formulations for AUC₀₋₅₅₂. Systemic exposure to asparaginase was similar with the two products and some accumulation occurred in both sexes with repeated dosing. Asparagine was completely suppressed for up to 336 hours in all animals and up to 552 hours in the majority of them.

[0222] In summary, there were no notable differences between doses of 500 IU/kg with either the liquid pegaspargase or reconstituted lyophilized pegaspargase and they had comparable pharmacokinetic, pharmacodynamics and immunogenic profiles.

REFERENCES CITED IN THE DESCRIPTION

Cited references

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or

omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- [CN102138909B \[0004\]](#)
- [US20160060613A1 \[0004\]](#)
- [EP0893439B \[0004\]](#)
- [US4179337A \[0004\]](#)
- [US20150224207A1 \[0004\]](#)
- [US20100143324A1 \[0004\]](#)
- [US5122614A \[0037\]](#)
- [US5324844A \[0037\]](#)
- [US5612460A \[0037\]](#)
- [WO9633212A \[0127\]](#)
- [WO9614856A \[0127\]](#)
- [US6323315B \[0127\]](#)
- [EP1391213A \[0127\]](#)
- [WO9407882A \[0134\]](#)
- [WO9407881A \[0134\]](#)
- [WO9407880A \[0134\]](#)
- [WO9407876A \[0134\]](#)
- [WO9323555A \[0134\]](#)
- [WO9319076A \[0134\]](#)
- [US5294637A \[0134\]](#)
- [US5283253A \[0134\]](#)
- [US5279949A \[0134\]](#)
- [US5274137A \[0134\]](#)
- [US5202448A \[0134\]](#)
- [US5200534A \[0134\]](#)
- [US5229529A \[0134\]](#)
- [EP590267A \[0134\]](#)
- [WO9918113A \[0134\]](#)
- [WO9914209A \[0134\]](#)
- [WO9909021A \[0134\]](#)
- [WO9822451A \[0134\]](#)
- [US58669680A \[0134\]](#)
- [WO9828288A \[0134\]](#)
- [US5821263A \[0134\]](#)
- [US54115869A \[0134\]](#)
- [WO9858927A \[0134\]](#)
- [WO9813059A \[0134\]](#)
- [US5824701A \[0134\]](#)

Non-patent literature cited in the description

- **ANGIOLILLO, AL. et al.** Pharmacokinetic (PK) and pharmacodynamics (PD) properties of SC-PEG E.

coli 1-asparaginase (EZN-2285) in the treatment of patients with acute lymphoblastic leukemia (ALL): Results from Children's Oncology Group (COG) study AALL07P4American Society of Clinical Oncology (ASCO) Annual Meeting, 2012, [0035]

- **ANGIOLILLO, AL. et al.** Pharmacokinetic and Pharmacodynamic Properties of Calaspargase Pegol Escherichia coli L-Asparaginase in the Treatment of Patients With Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Study AALL07P4J Clin. Oncology, 2014, vol. 32, 343874-3882 [0035]
- Remington: The Science & Practice of PharmacyWilliams & Williams20120000 [0077]
- Physician's Desk ReferencePDR Network20150000 [0077]
- **ROWE, RC.** Handbook of Pharmaceutical Excipients20120000 [0077]
- **LIU et al.** Proc. Natl. Acad. Sci. USA, 1996, vol. 93, 8618-8623 [0127]

Patentkrav**1. Rekonstitueret lyofiliseret sammensætning omfattende:**

en polyalkylenoxid-asparaginase i en koncentration på 100 til 5.000 IU per ml af nævnte sammensætning;

5 dibasisk natriumphosphat i en koncentration på 0,1 til 0,8 vægt-%;

monobasisk natriumphosphat i en koncentration på 0,01 til 0,5 vægt-%;

et salt i en koncentration på 0,05 til 1 vægt-%; og

et sukker i en koncentration på 0,1 til 25 vægt-%,

hvor polyalkylenoxid-asparaginasen omfatter en asparaginase kovalent
10 bundet til en polyalkylenoxidgruppe.

2. Sammensætningen ifølge krav 1, hvor:

a. koncentrationen af dibasisk natriumphosphat er fra 0,1 til 0,5 vægt-%,
eller 0,2 til 0,3 vægt-%; og

15 b. koncentrationen af monobasisk natriumphosphat er fra 0,01 til 0,1 vægt-% eller 0,05-0,07 vægt-%.

**3. Sammensætningen ifølge et hvilket som helst af de foregående krav, hvor
koncentrationen af sukker er fra 0,5 til 20 vægt-%, 1 til 10 vægt-%, eller 4 til 5
20 vægt-%.**

**4. Sammensætningen ifølge et hvilket som helst af de foregående krav, hvor
saltet er natriumchlorid, kaliumchlorid, calciumchlorid, magnesiumchlorid eller en
kombination deraf, eventuelt hvor saltet er natriumchlorid.**

25

**5. Sammensætningen ifølge et hvilket som helst af de foregående krav, hvor
sukkeret er et monosaccharid, et disaccharid eller et polysaccharid; eventuelt hvor
sukkeret et saccharose, mannitol, maltose, trehalose, 2-hydroxypropyl-beta-
cyclodextrin (β -HPCD), lactose, glucose, fructose, galactose, glucosamin eller
30 kombinationer deraf, yderligere eventuelt hvor sukkeret er saccharose.**

**6. Sammensætningen ifølge et hvilket som helst af de foregående krav, hvor
koncentrationen af polyalkylenoxid-asparaginasen er:**

a. 500 til 1.000 IU per ml af nævnte sammensætning;

- b. 700 til 800 IU per ml af nævnte sammensætning; eller
- c. 750 IU per ml af nævnte sammensætning.

7. Sammensætningen ifølge et hvilket som helst af de foregående krav, hvor

5 polyalkylenoxidgruppen omfatter en polyethylenglycolgruppe, eventuelt hvor

- a. polyethylenglycolgruppen har en molekylevægt i området fra 2.000 til 10.000 dalton; eller
- b. polyethylenglycolgruppen har en molekylevægt på 5.000 dalton.

10 **8.** Sammensætningen ifølge et hvilket som helst af de foregående krav, hvor linkeren er en urethan- eller succinatlinker.

9. Sammensætningen ifølge et hvilket som helst af kravene 1-8, hvor sammensætningen yderligere omfatter natriumhydroxid eller saltsyre.

15

10. Lyofiliseret lagerstabil sammensætning omfattende:

- en polyalkylenoxid-asparaginase;
- en buffer som omfatter dibasisk natriumphosphat og monobasisk natriumphosphat;

20 et salt; og

- et sukker,

hvor den lyofiliserede lagerstabile sammensætning er i stand til at danne sammensætningen ifølge et hvilket som helst af kravene 1-9 ved rekonstituering af den lyofiliserede lagerstabile sammensætning med vand

25 til injektion (WFI).

11. Fremgangsmåde til fremstilling af en lyofiliseret polyalkylenoxid-asparaginase-sammensætning, hvor fremgangsmåden omfatter lyofilisering af en vandig koncentratsammensætning omfattende:

30 (i) en polyalkylenoxid-asparaginas omfattende en polyalkylenoxidgruppe kovalent bundet via en linker til en asparaginase;

(ii) en buffer, som omfatter dibasisk natriumphosphat og monobasisk natriumphosphat;

(iii) et salt; og

35 (iv) et sukker

på en måde som er tilstrækkelig til at fremstille en lyofiliseret lagerstabil polyalkylenoxid-asparaginasesammensætning ifølge krav 10,

eventuelt hvor fremgangsmåden yderligere omfatter indførsel af en vandig koncentratsammensætning i en enhedsdosisbeholder og lyofilisering af den

5 vandige koncentratsammensætning i enhedsdosisbeholderen, eventuelt hvor enhedsdosisbeholderen er et hætteglas, såsom et forseglet hætteglas.

12. Sammensætning ifølge et hvilket som helst af kravene 1-10 til anvendelse i en fremgangsmåde til behandling af et individ for en neoplastisk tilstand.

10

13. Sammensætningen til anvendelse ifølge krav 12, hvor den neoplastiske tilstand er en kræftform, eventuelt hvor kræftformen er leukæmi, eventuelt hvor leukæmien er:

15 (i) akut lymfatisk leukæmi (ALL), eller

(ii) akut myeloid leukæmi (AML).

14. Sammensætningen til anvendelse ifølge krav 12 eller krav 13, hvor individet er blevet ordineret en behandlingsplan, som inkluderer en induktionsfase, en konsolideringsfase og en vedligeholdelsesfase,

20 eventuelt hvor fremgangsmåden omfatter indgivelse af en enkelt dosisenhed til individet i induktionsfasen og flerdosisenheder under vedligeholdelsesfasen,
yderligere eventuelt hvor flerdosisenhederne indgives til individet ved indgivelse af en dosisenhed til individet hver 3. uge eller hver 2. uge.

25

15. Sammensætningen til anvendelse ifølge et hvilket som helst af kravene 12-14, hvor:

- a. individet er et ungt menneske; eller
- b. individet er en voksen.

30

16. Kit omfattende en eller flere enhedsdosisbeholdere, som hver indeholder en lyofiliseret lagerstabil sammensætning ifølge krav 10.

DRAWINGS




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10




FIG. 11




FIG. 12




FIG. 13




FIG. 14




FIG. 15




FIG. 16